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Preface
The study of the structure and behavior of cardiomyocyte is fundamental to the
education of all cardiologists because it is the bridge leading from basic science to
clinical cardiology. The marked diversity of cells constituting the tissues and organs
of the human body is known. There are more than 200 morphologically distinct
adult cell types and this large number reflects the diversity of their function. 
However, despite this diversity of structure and function, there is a small range
of structural subunits and organelles that comprise these cell types. A cell with a
particular function will have a predictable constellation of organelles relating to
that specialization. So, understanding the structure and function of normal heart
cells lays the foundation for developing studies designed to explore the pathogenesis
of diseased myocardium. Knowledge of the pathological basis of disease, with
particular reference to causation, pathogenesis, and possible natural histories, is
essential if the clinical manifestations of disease are to be interpreted and treated in
a rational way.
Many pathological states can be represented as expression of disturbances in a
normal dynamic equilibrium. Myocardial ischemia may represent a condition if the
blood supply to the myocardium does not meet the demand. The energy require-
ments of heart muscle are high. If this disturbance in the normal equilibrium
persists, it triggers a cascade of cellular, inflammatory, and biochemical events, 
leading to the death of cardiomyocytes. Contraction of cardiomyocytes and the
maintenance of their membrane integrity require large amounts of energy. Heart
muscle is poorly supplied with endogenous fuel stores, is well vascularized, and is
highly aerobic in its metabolism. Interruptions to the blood supply of the myocar-
dium, even for comparatively shorts periods, produce catastrophic results.
Generation, reception, and transduction of signals at an appropriate level are
intrinsic to normal cell behavior. Serious functional disturbances may arise when
the cells cannot generate or transport an appropriate signal or lack the appropriate
receptors to receive an important signal. Intercellular communication is funda-
mental for normal cardiac function. Synchronization of mechanical and electrical 
activity is essential to transform the work of individual myocytes into the pumping 
function of the organ. Desmosome is a specialized adhesive junction that interacts
with the cytoskeleton and creates interactions with gap and adherens junctions. 
Mutations in components of the desmosome lead to a variety of disorders such as
arrhythmogenic cardiomyopathy, a disease that bridges the gap between inherited 
arrhythmia syndromes and heart muscle disorders.
In the introductory chapter, the author discusses the importance of understand-
ing the molecular and cellular basis of cardiovascular disease. Knowledge of the
pathological basis of disease with the integration of multilevel biological data
and the connection with the clinical practice reveal the potential of personalized 
medicine, with future implications for prognosis, diagnosis, and management of
cardiovascular diseases.
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XIV
The authors of the second chapter investigate the molecular adaptation of right 
ventricular (RV) in response to left ventricular (LV) infarction. RV failure is 
common in patients with acute ST-segment elevated myocardial infarction and 
animal models of remodeling post-myocardial infarction. However, a systematic 
analysis of chamber-specific changes in the expression of genes linked to cardiac 
function, apoptosis, fibrosis, receptor responsiveness, and inflammation is lacking. 
The underlying reason for biventricular failure due to myocardial infarction and/
or transient ischemic events is not clear but may be a consequence of hemodynamic 
changes during infarction and ischemic events in the RV as well. Nevertheless, RV 
failure is a severe complication during the subsequent post-infarct period and a 
limitation to further prognosis.
Human physiological activity and condition during illness are under the control of 
the circadian rhythm. It is well known that many cardiovascular processes show 
daily variations depending on the circadian rhythm (blood pressure, heart rate), 
and the gene expression of the cardiomyocyte circadian clock influences myocardial 
contractile function, metabolism, and other gene expressions. The authors present 
a review of the latest knowledge on the impact of circadian rhythm and circadian 
rhythm genes on myocardial infarction.
The authors of the next chapter discuss the importance of human-induced pluripo-
tent stem cell-derived cardiomyocytes (hiPSC-CMs) to investigate the mutation-
specific mechanism. While animal models fail to recapitulate human cardiac disease 
phenotype properly, hiPSC-CMs have been successful in recapitulating crucial 
phenotypes of many genetic cardiac diseases in terms of morphology, contractil-
ity, Ca2+ handling, ion channel biophysics, cell signaling, and metabolism. Most 
strikingly, hiPSC-CMs provide the patient-specific platform to study the disease 
mechanism and drug response individually, which the traditional disease modeling 
technique would never offer. In addition, cardiac subtype-specific arrhythmias and 
drug screening could be performed with the help of an unlimited supply of hiPSC-
CMs, thus chamber-specific treatment modalities could be identified. Certainly, 
by improving the current weaknesses of hiPSC-CMs, and incorporating with new 
gene-editing techniques, complex cardiac disease mechanisms could be deciphered 
and novel effective treatment therapies could be identified to improve the life of 
cardiac patients.
In the last decades, major advances have been made in the understanding of 
molecular and genetic issues, as well as in the pathophysiology and clinical assess-
ment of cardiomyopathies. Especially, understanding the genetic basis of dilated 
cardiomyopathy (DCM) has improved considerably with the availability of genetic 
analysis. To further improve the prognosis of patients, it is important to regularly 
gather knowledge about the current state of DCM and adapt the appropriate diag-
nostic workups. Therefore, this chapter provides the reader with a comprehensive 
overview of the current state of DCM from definition over etiology, including the 
genetic aspects to management for cardiovascular specialists.
The following chapter is a review of myocardial changes associated with obesity. 
It is recognized that obesity contributes to cardiovascular and metabolic disorders 
through alterations in the levels of adipocyte-derived cytokines called adipokines. 
The authors conclude that, “our understanding of adipokine biology and obesity-
induced adiposopathy increases, and the major challenge will reside in translating 
this information into new prognostic and therapeutic approaches to limit cardiovas-
cular risk in obese individuals.”
V
Higher intakes of industrially produced trans-fatty acids (IP-TFAs) and of saturated 
fatty acids are associated with increased risk for congenital heart disease (CHD), 
and higher intakes of both the ω6 (n-6) polyunsaturated fatty acids (PUFAs) and 
the omega-3 PUFAs are associated with a lower risk of CHD. Since estimation of
dietary intakes of fatty acids (FAs) using questionnaires is challenging (because of
out-of-date databases, reliance on memory, poor estimation of portion sizes, etc.), 
many researchers have begun to measure plasma/blood levels of FAs as more objec-
tive biomarkers of exposure. The two general classes of FAs for which biomarkers
are most strongly linked with intakes are PUFAs (especially the omega-3 class) and 
IP-TFAs. Because risk for CHD is much lower in Japan than in the USA, the authors
undertook this study to compare the FA profiles in Japanese and American men over
the age of 50.
I wish to thank the authors who have contributed so generously to this book. They
are all experts in their fields of interest, but have taken time to write on their
subjects to make this work as comprehensive as possible.
Angelos Tsipis, MD, PhD, MSc
Department of Cardiology,
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Cardiomyocyte - Fundamental 
Unit of Heart Life and Disease
Angelos Tsipis
1. Introduction
In the field of cardiology, some of the most dramatic advances in recent years 
have come from understanding the molecular and cellular basis of cardiovascular 
disease. The knowledge of the pathological basis of disease in some cases allows 
the development of new strategies for prevention and treatment. This book was 
planned not only to convey the new facts of cardiovascular diseases but also to boost 
the excitement and challenges of research in the dynamic area of modern molecular 
and cellular biology of cardiology.
2. Cardiomyocyte: structure and function
Cells are the fundamental unit of life, and the large number of them reflects 
the diversity of their function. The myocardium is composed principally of spe-
cialized muscle cells called cardiomyocytes. The major components of cardiac 
myocytes, cell membrane (sarcolemma) and T-tubules, necessary in excitation-
contraction coupling, thereby facilitate a fast and synchronous contraction across 
the entire cell volume, sarcoplasmic reticulum, nucleus, and contractile elements. 
Cardiomyocytes contain many more mitochondria than skeletal muscle cells reflect-
ing the dependence of cardiac muscle cell on aerobic metabolism. The functional 
intracellular contractile unit of cardiac muscle is the sarcomere that contains the 
contractile proteins myosin and actin. Sarcomeres also contain the regulatory pro-
teins troponin and tropomyosin. Functional integration of myocytes is mediated by 
intercalated disks, which join individual cells and within which specialized intercel-
lular junctions permit mechanical and electrical coupling. Intercalated disk contains 
various junctional complexes including the zonula adherens, desmosomes, and gap 
junctions. One of the most important types of adhesive interactions required for 
the formation and maintenance of tissues is that mediated by the cadherin family. 
The expression and distribution of many of these junctional components are often 
perturbed in cardiovascular disease [1–4]. One of the components of intercalated 
disks is gap junctions which facilitate synchronous myocyte contraction by provid-
ing electrical coupling. Deregulation of gap junction in cardiovascular disease may 
contribute to electromechanical dysfunction and arrhythmias. In addition, the 
cardiac conduction system consists of specialized myocardial fibers that conduct 
electrical impulses more readily than surrounding myocardial fibers and regulate 
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3. Cardiomyocyte: the basis of life and cardiac disease
The etiology of heart failure involves the interaction of multiple parameters, such 
as genetic predisposition, environment factors, and chance. Research advances and 
clinical investigations recognized familial transmission for many cardiomyopathies 
and confirmed the hypothesis that cardiomyopathies are characterized as genetic 
disorders. Numerous theories regarding the cause of idiopathic dilatative cardiomy-
opathy have been proposed such as viral myocarditis, autoimmune response against 
myocardial epitopes, and genetic factors that appear to be more important than 
previously believed. Nowadays, studies based on a more careful evaluation of disease 
inheritance and on prospective systematic family screening revealed a high fre-
quency of genetic transmission of the disease in different populations. However, the 
true frequency is probably still underestimated due to the absence of early markers 
of the disease and reduced penetrance. Mutations in several known genes including 
those encoding dystrophin, δ-sarcoglycan, troponin T, β-myosin heavy chain, actin, 
lamin A/C, and desmin have been identified as a cause of a phenotype [3, 5, 6].
Cells are poised between survival and apoptosis, and their fate rests on a balance 
of powerful intracellular and extracellular forces, whose signals constantly act upon 
and counteract each other. In many circumstances, apoptosis is a self-protective 
programmed mechanism that leads to the suicide of a cell when its survival is 
deemed detrimental to the organism. In other instances, apoptosis is a pathological 
process that contributes to many disorders. Although increasing experiment data 
suggest that necrosis and apoptosis occur in heart failure, the relation between 
the two conditions and the relevant pathophysiological mechanism are less clear. 
Significant progress has been made in demonstrating the role of apoptosis in 
various heart diseases and in elucidating the molecular mechanisms of cardiac 
apoptosis. The progressive loss of cardiac myocytes is one of the most important 
pathogenic components of the heart failure. Even though the rate of apoptosis 
in heart failure is relatively low in absolute numbers, it is significantly higher 
than that in the normal heart, which has essentially negligible baseline apoptosis. 
Recently, animal models of heart failure incorporating transgenic technology have 
confirmed that myocyte apoptosis itself is sufficient to induce heart failure. The 
elevated presence of p53, Bax, and Bak-positive cells in dilated cardiomyopathy is 
associated with progressive loss of myocytes in heart failure. On the other hand, 
increased expression of the antiapoptotic protein bcl-2 in the human myocardium 
with dilated cardiomyopathy may be a compensation for the loss of myocytes 
and a possible compensatory antiapoptotic mechanism in the diseased group. 
Furthermore, the elevated expression of proapoptotic proteins is associated with 
the progressive loss of myocytes by apoptosis and may play a role in the evolution 
of the chronic heart failure in patients with old myocardial infarction and chronic 
ischemic disease. Immunohistochemistry of proapoptotic Bax and antiapoptotic 
bcl-2 protein demonstrated higher levels of both of these proteins in the diseased 
group of patients with acute myocardial infarction than normal hearts. A 1.3- and 
twofold increase in Bax and bcl-2 positive samples was observed in diseased group 
with acute myocardial infarction compared with the control group. The increased 
expression of antiapoptotic proteins in acute myocardial infarction represents a 
possible compensatory mechanism of salvaged myocytes. The prevalence of the 
apoptotic mechanism or this compensatory antiapoptotic may influence the evolu-
tion of heart failure in heart diseases. Thus, the pharmacological manipulation of 
apoptosis represents an active frontier of drug development [7].
Cell and molecular biology is a rapidly growing field of research and transfers 
knowledge, from basic cardiology science and preclinical studies, to the clini-
cal cardiology. At the present time, cell priming, bio-nanotechnology, and tissue 
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engineering are coming up as valuable techniques for cell- and tissue-based therapy 
application in clinical cardiology. The integration of multilevel biological data 
and the connection with the clinical practice reveal the potential of personalized 
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Right Heart Adaptation to Left 
Ventricular STEMI in Rats
Rolf Schreckenberg and Klaus-Dieter Schlüter
Abstract
Development of right ventricular (RV) failure in patients after ST-segment 
elevation myocardial infarction (STEMI) is common. However, a systematic 
analysis of chamber-specific changes in the expression of genes linked to cardiac 
function, apoptosis, fibrosis, receptor responsiveness, and inflammation is lacking. 
Postischemic remodeling was analyzed in rats that received STEMI in the closed 
chest mode. Rats were sacrificed at day 1, 3, 7, and 120 after surgery. The mRNA 
expression of genes was quantified by a real-time RT-PCR. Echocardiography 
was performed after 120 days. Organ weights and systemic blood pressure were 
determined in addition. Rats developed left and RV dysfunction within 7 days after 
ischemia/reperfusion and this lasted until the end of the experiments. However, 
adaptation to ischemia/reperfusion differed significantly between both ventricles. 
In the LV, a high expression of MMP12, a neutrophile-specific elastase, indicated a 
significant inflammatory responsiveness that did not occur in RV. A number of dif-
ferentially regulated genes in the RV exceeded that of the LV at day 3. Postinfarction 
RV failure is common in rats with ischemia/reperfusion of the left arterial descend-
ing aorta. It is associated with severe RV remodeling that occurred delayed to that 
of the LV. Changes in RV are independent of the initial inflammation.
Keywords: myocardial infarction, cardiac remodeling, right heart failure, 
inflammation, reperfusion injury
1. Introduction
Right ventricular (RV) failure is common in patients with acute ST-segment 
elevated myocardial infarction (STEMI) and animal models of remodeling post-
myocardial infarction [1–3]. The underlying reason for biventricular failure due 
to myocardial infarction and/or transient ischemic events is not clear but may be a 
consequence of hemodynamic changes during infarction and ischemic events in the 
RV as well. Nevertheless, RV failure is a severe complication during the subsequent 
postinfarct period and a limitation of further prognosis [4]. Therefore, it is impor-
tant to understand the molecular adaptation of the RV in response to LV infarction.
Molecular and cellular mechanisms involved in cardiac remodeling after myo-
cardial infarction are triggered by transcriptional regulation of genes linked to 
apoptosis, fibrosis, inflammation, calcium handling, and receptor responsiveness. 
Some of these adaptive mechanisms occur early after reperfusion and activation 
of the transcription factor AP-1 have been identified as main factors [5]. However, 
steady-state mRNA levels depend also from RNA degradation leading to a decrease 
in the expression of some genes. Thus, steady-state mRNA expression of genes 
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to myocardial infarction and/or transient ischemic events is not clear but may be a 
consequence of hemodynamic changes during infarction and ischemic events in the 
RV as well. Nevertheless, RV failure is a severe complication during the subsequent 
postinfarct period and a limitation of further prognosis [4]. Therefore, it is impor-
tant to understand the molecular adaptation of the RV in response to LV infarction.
Molecular and cellular mechanisms involved in cardiac remodeling after myo-
cardial infarction are triggered by transcriptional regulation of genes linked to 
apoptosis, fibrosis, inflammation, calcium handling, and receptor responsiveness. 
Some of these adaptive mechanisms occur early after reperfusion and activation 
of the transcription factor AP-1 have been identified as main factors [5]. However, 
steady-state mRNA levels depend also from RNA degradation leading to a decrease 
in the expression of some genes. Thus, steady-state mRNA expression of genes 
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involved in cardiac remodeling can be increased or decreased. Real-time RT-PCR 
allows quantification of such molecular and cellular adaptation in tissues and can be 
used to characterize such changes in a time- and organ-specific manner. This study 
was aimed to identify differentially regulated cardiac genes in the LV and RV that 
are involved in cardiac remodeling during postmyocardial infarction.
The left anterior descending coronary artery was occluded in rats for 45 min and 
subsequently reopened. Success of occlusion and reperfusion was monitored by 
ECG recordings. Rats were sacrificed after 1, 3, 7, and 120 days and the left and right 
ventricles were removed and analyzed thereafter. The hemodynamic consequences 
were recorded by echocardiography.
2. Material and methods
2.1 Animal models and animal handling
The investigation conforms to the directive 2010/63/EU of the European 
Parliament. Use of animals was registered at the Justus-Liebig-University (registra-
tion-no.: 417-M). The experimental protocols were approved by the ethics commit-
tee for animal experimentation of the local authorities in Giessen, Germany and 
Szeged, Hungary.
Myocardial infarction and reperfusion was performed in the closed-chest model. 
To achieve this, rats were anesthetized by inhalation of isoflurane (induction: 
5%, maintenance: 2–3%), intubated, and placed on a respirator during surgery to 
maintain ventilation. Before surgery, 0.03 mg/kg nalbuphine (Nalbuphin Orpha, 
AOP Orpha Pharmaceuticals, Vienna, Austria) was injected (i.p.). The adequacy 
of anesthesia was monitored by electrocardiography and pulse rate. A suture was 
placed around the left anterior descending coronary artery (LAD) and remained 
subcutaneously [6]. Two hours after the wound closing, 0.03 mg/kg nalbuphine 
was repeated to alleviate postoperative pain. Seven days later, rats were anesthetized 
as before and the suture was mobilized and the LAD was occluded for 30 min. 
The occlusion was monitored by electrocardiography (ST elevation; see Figure 1). 
Thereafter, the occluder was opened again and the suture was cut and the skin was 
closed in one layer. Sham rats received the same protocol but the occluder was not 
mobilized after 7 days. Please note that this study is a second end-point analysis 
of tissue material also used before to characterize the role of arginase in ischemia/
reperfusion injury [7].
2.2 Ex vivo analysis of cardiac function
In order to analyze the cardiac function ex vivo, rats were anesthetized again 
by isoflurane and killed by cervical dislocation. Thereafter, hearts were rapidly 
excised and the aorta was cannulated for retrograde perfusion with a 16-gauge 
needle connected to a Langendorff perfusion system. Left ventricular function was 
determined by insertion of a water-filled balloon into the left ventricle as described 
before [8]. Hearts were paced during measurements.
2.3 In vivo analysis of cardiac function
Transthoracic echocardiography was performed as described previously [9] 
under isoflurane anesthesia (1.5%) at 120 days after ischemia/reperfusion. Briefly, 
two-dimensional and M-mode echocardiographic examinations were performed 
in accordance with the criteria of the American Society of Echocardiography with 
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a Vivid 7 dimension ultrasound system (General Electric Medical Systems) using a 
phased array 5.5–12 MHz transducer (10S probe). Data of three consecutive heart 
cycles were analyzed (EchoPac Dimension software; General Electric Medical 
Systems) by an experienced investigator in a blinded manner. The mean values of 
three measurements were calculated and used for statistical evaluation. Functional 
parameters including left ventricular ejection fraction (EF) and fractional shorten-
ing (FS) were calculated on four-chamber view images.
2.4 qRT-PCR
After removing the hearts from the Langendorff apparatus, the ventricular 
tissue was carefully isolated and quickly frozen into fluid nitrogen. Tissue samples 
were prepared to analyze the steady-state mRNA levels of proteins of interest 
according to the previously described method [8]. Briefly, total RNA was iso-
lated from the ventricles using peqGoldTriFast (peqlab, Biotechnology GmbH, 
Germany) according to the manufacturer’s protocol. To remove genomic DNA 
contamination, isolated RNA samples were treated with 1 U DNase per mg RNA 
(Invitrogen, Karlsruhe, Germany) for 15 min at 37°C. One microgram of total 
RNA was used in 10 μl reaction to synthesize cDNA using superscript RNaseH 
Figure 1. 
ECG recording during ischemia (A) and after reperfusion (B) indicating ST elevation in these rats  
(red arrow). (C) TTC staining visualizing the location of the infarct.
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Forward Reverse
ANP ATG GGC TCC TTC TCC ATC AC TCT TCG GTA CCG GAA GCT
BNP ATG ATT CTG CTC CTG CTT TTC TCT GCA TCG TGG ATT GTT CTG
MHC-α CAC CCT GGA GGA CCA GAT TA TGG ATC CTG ATG AAC TTC CC
TGF-β1 ATT CCT GGC GTT ACC TTG G CCT GTA TTC CGT CTC CTT GG
Biglycan TGA TTG AGA ATG GGA GCC TGA G CCT TGG TGA TGT TGT TGG AGT G
Decorin GGC AGT CTG GCT AAT GTT C CTT CGG AGA TGT TGT TGT TAT G
Collagen-1 GCG AAC AAG GTG ACA GAG CCA GGA GAA CCA GCA GAG
Collagen-3 TGG AGT CGG AGG AAT G GCC AGA TGG ACC AAT AG
Elastin TGC TAC TGC TTG GTG GAG AAT G CGT GGC TGC TGC TGT CTG
Fibronectin TGG AGC AAG AAG GAC AAC CGG ACA TCT GTG AAG GAG
Laminin CGA GGA TGT CAG CGT TGT TCA CAG CCG TCT CCA GTC
SERCA2a CGA GTT GAA CCT TCC CAC AA AGG AGA TGA GGT AGC GGA TGA A
Phospholamban TAT GTC TGC TGC TGA TAT GC ACT CTT AAA TCG TGA CCC TTC
NCX CGC TAA TCA GCA TTT CAG AG GCC AGG TTC GTC TTC TTA AT
Bax ACT AAA GTG CCC GAG CTG ATC CAC TGT CTG CCA TGT GGG G
Bcl-2 ATC TTC TCC TTC CAG CCT GA TCA GTC ATC CAC AGA GCG AT
ODC GAA GAT GAG TCA AAC GAG CA AGT AGA TGT TTG GCC TCT GG
Arginase-2 TGA GGA GCA GCG TCT CCC GT GCT TCT CGG ATG GCG GCT GG
eNOS AGC CCG GGA CTT CAT CAA TCA G GCC CCA AAC ACC AGC TCA CTC TC
Intermedin TGC CTC AGG GTG GTG GCT CAA CT GTG GGG GCT GCT GGG AT
RAMP-1 AGC ATC CTC TGC CCT TTC ATT GAC CAC CAG GGC AGT CAT G
RAMP-2 GCA GCC TAC CTT CTC CGA TCC TCC TCC ACA CCA CAA GCG TAA C
RAMP-3 CAA CCT GTC GGA GTT CAT CGT TGT CTC CAT CTC CGT GCA GTT
MMP9 CAA TCC TTG CAA TGT GGA TG AAA TCT TCT TGG ACT GCG GA
MMP12 TGC AGC TGT CTT TGA TCC AC GCA TCA ATT TTT GGC CTG AT
iNOS AAG AGA CGC ACA GGC AGA G CAG CAG GCA CAC GCA ATG
Nrf-1 GGC ATC ACT GGC AGA GGC CG GCT GCT GCG GTT TCC CCA GA
PGC-1α AGT GCT CAG CCG AGG ACA CGA TGC CCC TGC CAG TCA CAG GA
SDF-1α CCA AGG TCG TCG CCG TGC TG GGC TCT GGC GAC ATG GCT CT
VEGF TGC CCC TAA TGC GGT GTG CG GGC TCA CAG TGA ACG CTC CAG G
GATA4 CTA TGG CCG CCA ACC ACG GG CGC GGA GTG GGC ACG TAG AC
Mef-2c CAG TTG GGA GAC CGT ACC AC GTG AGT CCA ATG GGG GAG TG
Nkx.2a CAC ACG CCC TCC TCA GTC AA GAG TAG CCG TCC GGC TTG AA
vWF AAG ATG GCA AGA GAG TGG GC CCG TAG GCC TCA CTG GAA AG
VE-cadherin CCA GAA TTT GCC CAG CCC TA GTC CTC GTT CTT CAG GGC AA
B2M GCC GTC GTG CTT GCC ATT C CTG AGG TGG GTG GAA CTG AGA C
HPRT CCA GCG TCG TGA TTA GTG AT CAA GTC TTT CAG TCC TGT CC
Table 1. 
List of primers used in this study.
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reverse transcriptase (200 U/μg; Invitrogen) and oligo dTs (Roche, Mannheim, 
Germany) as primers. Reverse transcriptase reactions were performed for 60 min at 
37°C. Real-time PCR was performed using the Icycler IQ detection system (Bio-
Rad, Munich, Germany) in combination with IQ SYBR Green real-time supermix 
(Bio-Rad). A complete list of all primers used in this study is given in Table 1. Data 
are normalized to hypoxanthine phosphoribosyltransferase (HPRT) expression that 
was used as a house-keeping gene in this study. Preliminary experiments with β2 
microglobulin, which was alternatively considered as house-keeping gene, revealed 
similar results but higher variability. The relative change in expression was quanti-
fied by the ΔΔC method [10].
2.5 Statistics
The results are expressed as means ± S.E.M or median with 25 and 75% quartiles 
as indicated in the legend to the figures. Statistical comparisons were performed 
by two-side T-Test or Mann-Whitney Test. Levene test was used to check the 
normal distribution of the samples. A p value of 0.05 was considered as statistical 
significant.
3. Results
3.1  Weight of organs, left ventricular pressures, and biventricular functions 
analysis over time
Body weight, LV weight, RV weight, lung wet weight, and kidney weight 
increased during the 4-months observation period in sham rats and those undergo-
ing ischemia/reperfusion (Table 2). Mean increase in body weight at day 3 after 
the ischemic event was smaller in the surgery group (+2 g) versus the sham group 
(+13 g) indicating a small impact of the surgery on general behavior. Differences 
between both groups in ventricular weight occurred only for the RV at day 1 (Table 1). 
RV weights of rats in the experimental group normalized thereafter. No differences 
were obtained for lung and kidney weights (Table 2). Necrotic tissue was nearly 
exclusively seen in LV (Figure 1).
LV function was determined in vitro. Immediately after ischemia/reperfusion, 
a significant decline in cardiac function was observed but this was normalized 
thereafter (Table 3). Biventricular function was analyzed after 120 days via echo-
cardiography. RV fractional area change (four-chamber view) and LV ejection 
fraction (longitudinal four-chamber view) were significantly lower in rats of the 
experimental group compared to shams (Table 4).
3.2 Biventricular gene regulation over time
In total, biventricular expression of 36 genes was analyzed by a real-time 
RT-PCR. These genes cover the following area of interest: cardiac hypertrophy 
(ANP, BNP, MHC-α), fibrosis (TGF-β1, biglycan, decorin, collagen-1, collagen-3, 
elastin, fibronectin, laminin, MMP9), intracellular calcium handling (SERCA2a, 
phospholamban, NCX), apoptosis (bax, bcl-2), arginine metabolism  
(ODC, arginase-2, eNOS), receptor coupling (intermedin, RAMP-1, -2, -3), 
inflammation (iNOS, MMP12), cardiac metabolism (Nrf-1, PGC-1α), stem 
cell mobilization (SDF-1α, CXCR4, VEGF), cardiac transcription factors 
(GATA-4, Mef-2c, Nkx.2a), and endothelial markers (von Willebrand factor 
(vWF), VE-cadherin). Figure 2 shows how many of these 36 genes were either 
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(ODC, arginase-2, eNOS), receptor coupling (intermedin, RAMP-1, -2, -3), 
inflammation (iNOS, MMP12), cardiac metabolism (Nrf-1, PGC-1α), stem 
cell mobilization (SDF-1α, CXCR4, VEGF), cardiac transcription factors 
(GATA-4, Mef-2c, Nkx.2a), and endothelial markers (von Willebrand factor 
(vWF), VE-cadherin). Figure 2 shows how many of these 36 genes were either 
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upregulated or downregulated in the two ventricles over the time. In general, 
there was an upregulation of several genes mainly at day 3 postinfarction, whereas a 
downregulation of genes dominated at days 7 and 120. At the first time point (day 1), 
BW LV/BW RV/BW Lung/BW Kidney/BW
(g) (mg/g) (mg/g) (mg/g) (mg/g)
Day 1
Sham 208 ± 28 2.76 ± 0.37 0.48 ± 0.10 8.38 ± 2.06 5.87 ± 0.65
I/R 209 ± 16 2.87 ± 0.16 0.66 ± 0.07 8.90 ± 3.01 6.94 ± 2.11
P value 0.958 0.317 0.003 0.711 0.222
Day 3
Sham 222 ± 17 2.64 ± 0.11 0.57 ± 0.06 8.14 ± 2.00 6.05 ± 0.39
I/R 211 ± 21 2.69 ± 0.22 0.64 ± 0.10 7.28 ± 0.77 5.77 ± 0.25
P value 0.292 0.550 0.135 0.674 0.133
Day 7
Sham 222 ± 20 2.69 ± 0.15 0.51 ± 0.08 7.47 ± 0.95 5.80 ± 0.36
I/R 225 ± 22 2.93 ± 0.25 0.51 ± 0.07 7.81 ± 1.43 6.03 ± 0.61
P value 0.775 0.054 1.000 0.613 0.389
Day 120
Sham 255 ± 16 2.69 ± 0.13 0.53 ± 0.06 8.84 ± 1.81 5.85 ± 0.34
I/R 256 ± 21 2.74 ± 0.52 0.55 ± 0.12 9.89 ± 1.08 6.32 ± 0.73
P value 0.908 0.736 0.666 0.211 0.210
Data are means ± S.D. from n = 8–9 rats. Data are given for body weight (BW), left ventricular weight (LV), right 
ventricular weight (RV), lung weight, and kidney weight. Data for LV, RV, lung, and kidney were normalized to body 
weight.
Table 2. 
Body weight and organ weight.
Sham I/R Δ P value
Day 1 157.5 ± 20.9 mmHg 122.9 ± 21.7 mmHg Δ = −34.6 mmHg 0.006
Day 3 155.0 ± 23.8 mmHg 132.0 ± 30.1 mmHg Δ = −23.0 mmHg 0.113
Day 7 188.2 ± 31.4 mmHg 162.1 ± 15.4 mmHg Δ = −26.1 mmHg 0.054
Day 120 144.4 ± 10.4 mmHg 137.9 ± 22.3 mmHg Δ = −6.5 mmHg 0.442
Data are means ± S.D. from n = 8–9 hearts.
Table 3. 
Left ventricular developed pressure (LVDP).
Sham I/R Δ P value
LV EF 65.0 ± 5.8 51.3 ± 8.1 Δ = −13.7% 0.000
RV FAC 55.8 ± 7.2 45.5 ± 7.2 Δ = −10.3% 0.004
Data are means ± S.D. from n = 9–13 rats. LV EF = left ventricular ejection fraction (determined by four-chamber 
longitudinal view); RV FAC = right ventricular fractional area change (determined by four-chamber view).
Table 4. 
Biventricular function determined by echocardiography.
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there were significant differences in the expression between both ventricles. In 
the LV, four genes were significantly downregulated: GATA4, VEGF, eNOS, and 
MHC-α. VEGF, eNOS, and MHC-α genes contain a GATA4 promoter region. As 
expected, GATA4 expression correlated significantly with that of VEGF, eNOS, 
and MHC-α (Figure 3). Only two genes were upregulated (MMP12, Mef2c) at that 
time point. As MMP12 is a neutrophil-specific elastase, its strong expression in LV 
may indicate leukocyte infiltration into the LV during initial tissue repair. In the 
RV, only one gene was significantly affected by myocardial ischemia/reperfusion 
at that time (NCX). Figure 4 shows the relative expression of all genes including 
those that were either up- or downregulated but without reaching the level of sig-
nificance. At day 1, there is more variability and, therefore, more transcriptional 
adaptation in LV compared to RV. In the LV, the strongest downregulation that was 
not yet significant (>0.05) was found for laminin (again correlated with GATA4; 
Figure 3). The strongest upregulation that was not yet significant was found for 
MMP9. However, lack of statistical significance for laminin and MMP9 indicates a 
high interindividual variability. In the RV, ANP and Nkx.2a were strongly upregu-
lated and collagen-3 was strongly downregulated but yet not significant.
Figure 2. 
Time-dependent induction gene regulation in both ventricles. Note that the number of genes differentially 
regulated (cutoff p < 0.05) is increased in RV after 3 days.
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At day 3, there were many genes significantly upregulated in both ventricles such 
as BNP, MHC-α, SERCA2a, phospholamban, NCX, and VEGF. ANP and PGC-1α 
were also significantly upregulated but in both ventricles. However, the individual 
variability in RV was strong for these genes so that the level of induction did not 
reach the level of significance. An exception from the coregulation of genes between 
both ventricles is the transcription factor Nkx.2a. Nkx2a was upregulated in the LV 
but beyond the level of detection in the RV. At day 3, only two genes were downregu-
lated in the LV. These are RAMP-2, that was similarly downregulated in the RV and 
vWF that was slightly reduced in the RV. In addition to the aforementioned genes, six 
genes were specifically upregulated in the RV that were not induced in the LV. These 
were decorin, collagen-3, eNOS, RAMP-3, MMP12, and Nrf-1. The increased expres-
sion of most of these genes is indicated in the plot shown in Figure 4.
At day 7, the expression of most genes induced at early time points was normal-
ized again. However, at that time point, many genes were significantly downregu-
lated. In the LV, this holds for NCX, intermedin, PGC-1α, vWF, and VE-cadherin. 
Only VE-cadherin and intermedin were also downregulated in the RV; although 
due to the high individual variability of the RV, this does not reach the level of 
significance. Only biglycan was induced in the LV at this time point. The gene 
expression profile of the RV differed significantly from that of the LV at this time 
point. SERCA2a and NCX were still strongly induced. TGF-β1, bax, bcl-2, RAMP-1, 
RAMP-2, iNOS, Nrf-1, and CXCR4 were all significantly downregulated. The level 
of regulation strongly increased the level of regulation of these genes in the left 
ventricle. Figure 4 summarizes the expression of all genes at that time point.
Figure 3. 
Correlation between GATA4 expression and that of GATA4-dependent regulated genes.
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At day 120, 6 out of 36 genes under investigation were downregulated in the 
LV. These were decorin, RAMP-1, MMP9, MMP12, GATA4, and vWF. Among 
them, only GATA4 and vWF were not similarly downregulated in the RV. Elastin, 
fibronectin, bax, and Nkx.2a were specifically downregulated in the RV. Except 
for Nkx.2a, similar changes (although not significant) were also seen in the 
LV. The expression of SERCA2a was induced in the RV at that time but not in 
the LV. Overall, a stronger transcription adaptation is seen in the RV at that time 
(Figure 4).
Figure 4. 
Profile of gene expression at days 1, 3, 7, and 120 in both ventricles. Upregulated genes are on the right side. 
Above the horizontal bar differences are below p < 0.05.
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4. Discussion
This study investigated transcriptional adaptation in LV and RV following 
ischemia/reperfusion in vivo up to 120 days. A higher gene expression level has 
been attributed to better postinfarct adaptation in female versus male mice [11]. 
Here, differences were found between both ventricles in the very early phase 
after ischemia/reperfusion. A significant downregulation of the transcription 
factor GATA-4 was found specifically in the LV 24 h after reperfusion confirming 
similar findings after 2 h [11]. According to this observation, the expressions of 
GATA4-dependent genes (MHC-α, eNOS, and VEGF) were also downregulated. 
GATA-4 can exert cell survival signaling in cardiac myocytes and delivery of 
GATA-4 locally to the infarct border zone induces multiple local effects resulting 
in beneficial remodeling [12, 13]. Regardless of these initial differences, similar 
changes, mainly induction of gene expression, were found in both ventricles after 
3 days. In both ventricles, repression of cardiac gene expression was more promi-
nent rather than induction at later time points, specifically after 4 months. At that 
time point, the expression profile significantly differed between both ventricles 
with a more adaptive phenotype in the RV. Again, at this later time point, reduced 
expression of GATA4 seems to account for some of the differentially downregu-
lated genes in the LV. In summary, this study highlights the differential expression 
of GATA4 in LV and RV after successful reperfusion and correlates the expression 
of GATA4 with main differences in molecular adaptation between both ventricles. 
Regardless of the different molecular adaptation, LV and RV developed a drop of 
function although the infarct area and inflammation was specifically located at 
the left ventricle.
The cardiac ventricle is able to respond to ischemic stress with changes in 
steady-state mRNA levels within 24 h. In principle, steady-state levels of mRNA are 
the sum of mRNA formation and degradation and the quantification of steady-state 
levels does not necessarily identify mechanisms that cause these changes. However, 
in the current study, the main changes in ventricular expression that occurred 
within 24 h in the LV corresponded to genes that are known to obtain a GATA-4 
promoter responsive element. Please note that only the LV is exposed to ischemia/
reperfusion. Moreover, GATA-4 itself was also downregulated. It should be noted 
that within the first few hours after the ischemic event, transcriptional changes 
were mainly present in the LV.
The response of the heart to LV ischemia and reperfusion significantly differed at 
day 3. At that time, strong molecular adaptations were obtained in both ventricles. In 
most cases, these were linked to an upregulation of genes indicating an active adapta-
tion to the postischemic stress. Interestingly, most genes that were upregulated in the 
LV were also regulated in the RV. An exception to this rule was Nkx.2a. This cardiac-
specific transcription factor was below the level of detection in the RV but induced in 
the LV, probably indicating an active regenerative process. This may indicate cardiac 
differentiation of cells infiltrated into the infarct-affected ventricle (possibly circulat-
ing stem cells), or a cardiac differentiation of cells that were located in the LV and that 
still have a potential to differentiate (cardiac progenitor cells). Alternatively, it may 
indicate an active repair process of terminally differentiated cardiomyocytes (hyper-
trophy). However, the more important finding was the observation that a couple of 
genes were specifically upregulated in the RV that are not induced in the LV. As such 
decorin, an endogen inhibitor of the profibrotic cytokine TGF-β1, eNOS, increasing 
the bioavailability of nitric oxide, and Nrf-1, improving mitochondrial biogenesis, 
were identified. Each of these factors is a marker of compensatory hypertrophy.
One week after the ischemic event, the initial activation of gene transcrip-
tion is normalized and replaced by downregulation of many genes in LV and 
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RV. Interestingly among them are endothelial cell markers and genes linked to 
cardiac metabolism. Thus, the molecular adaptation switches into a profile of 
maladaptation. In concert with this view, biglycan, a factor that favors fibrosis, was 
induced in the LV. In the RV, the expression of profibrotic genes was downregulated 
as well as the expression of inflammatory markers. Again, the molecular adaptation 
of the RV seems to be more favorable than that of the LV.
Four months after the ischemic event, the cardiac function was reduced in both 
ventricles. At that time, decorin was downregulated in both ventricles. Moreover, 
the RV was characterized by downregulation of elastin and fibronectin. Both 
molecules are required for a proper cardiac function. In summary, although the 
molecular adaptation of the RV to LV myocardial infarction differs from that of  
the LV, the corresponding molecular adaptation of the RV leads to dysfunction of 
the RV as well.
In this study, we analyzed also the expression of intermedin and the receptor 
activation modifier proteins (RAMP). They have been analyzed with respect to 
cardiac regulation in the context of pressure-induced hypertrophy but data on the 
expression in ischemia and reperfusion are lacking. Intermedin (=adrenomedul-
lin-2) potentially stabilized cardiac function by binding to CGRP receptors that 
are linked to RAMP-1, -2, or -3. This study shows a downregulation of intermedin 
in the RV at day 3 and in the LV at day 7. Thus, it is differentially regulated during 
the subsequent molecular adaptation after ischemia/reperfusion but not as a direct 
response to the ischemic event itself. Significant downregulation of RAMP-2 and 
RAMP-1 days after myocardial infarction in both ventricles (RAMP-2) and specifi-
cally in the RV (RAMP-1) suggests an impairment of receptor signaling during 
CGRP-receptors during the subsequent remodeling process. As the development 
of cardiac dysfunction occurred in both ventricles within 4 months, this observa-
tion requires future work because this may be a likely candidate for the subsequent 
development of heart failure.
Finally, it should be mentioned that this study has of course some limitations. 
Firstly, data are restricted to genes which mRNA steady-state levels are different 
between sham and ischemia/reperfusion at a p value of 0.05. This does not exclude 
the possibility that genes that are strongly regulated but below a p value of 0.05 
due to a higher individual variation are not relevant for the molecular adaptation. 
Secondly, the level of significance is a variable of the n number of animals that are 
investigated. Here, we used eight rats per group. A lower n reduces the number of 
genes identified as significantly regulated. However, these limitations are counter-
balanced by the quantitative real-time RT-PCR protocol and even more important 
by the high number of genes under investigation and the analysis of groups of genes 
linked to specific adaptations (i.e., linked to fibrosis, apoptosis, etc.). This allows a 
more general view on the adaptation process.
In conclusion, the study identifies a time-dependent difference in the response 
of LV and RV to STEMI. In the early phase of LV remodeling, GATA-4-dependent 
downregulation was dominant. The novel and important finding from this study 
is, however, that a delayed but significant molecular adaptation of the RV. This RV 
adaptation in the absence of necrosis seems to be more adaptive but still not suffi-
cient to preserve the function. The regulation of RAMP-2 in both ventricles may be 
one candidate for future research.
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the RV was characterized by downregulation of elastin and fibronectin. Both 
molecules are required for a proper cardiac function. In summary, although the 
molecular adaptation of the RV to LV myocardial infarction differs from that of  
the LV, the corresponding molecular adaptation of the RV leads to dysfunction of 
the RV as well.
In this study, we analyzed also the expression of intermedin and the receptor 
activation modifier proteins (RAMP). They have been analyzed with respect to 
cardiac regulation in the context of pressure-induced hypertrophy but data on the 
expression in ischemia and reperfusion are lacking. Intermedin (=adrenomedul-
lin-2) potentially stabilized cardiac function by binding to CGRP receptors that 
are linked to RAMP-1, -2, or -3. This study shows a downregulation of intermedin 
in the RV at day 3 and in the LV at day 7. Thus, it is differentially regulated during 
the subsequent molecular adaptation after ischemia/reperfusion but not as a direct 
response to the ischemic event itself. Significant downregulation of RAMP-2 and 
RAMP-1 days after myocardial infarction in both ventricles (RAMP-2) and specifi-
cally in the RV (RAMP-1) suggests an impairment of receptor signaling during 
CGRP-receptors during the subsequent remodeling process. As the development 
of cardiac dysfunction occurred in both ventricles within 4 months, this observa-
tion requires future work because this may be a likely candidate for the subsequent 
development of heart failure.
Finally, it should be mentioned that this study has of course some limitations. 
Firstly, data are restricted to genes which mRNA steady-state levels are different 
between sham and ischemia/reperfusion at a p value of 0.05. This does not exclude 
the possibility that genes that are strongly regulated but below a p value of 0.05 
due to a higher individual variation are not relevant for the molecular adaptation. 
Secondly, the level of significance is a variable of the n number of animals that are 
investigated. Here, we used eight rats per group. A lower n reduces the number of 
genes identified as significantly regulated. However, these limitations are counter-
balanced by the quantitative real-time RT-PCR protocol and even more important 
by the high number of genes under investigation and the analysis of groups of genes 
linked to specific adaptations (i.e., linked to fibrosis, apoptosis, etc.). This allows a 
more general view on the adaptation process.
In conclusion, the study identifies a time-dependent difference in the response 
of LV and RV to STEMI. In the early phase of LV remodeling, GATA-4-dependent 
downregulation was dominant. The novel and important finding from this study 
is, however, that a delayed but significant molecular adaptation of the RV. This RV 
adaptation in the absence of necrosis seems to be more adaptive but still not suffi-
cient to preserve the function. The regulation of RAMP-2 in both ventricles may be 
one candidate for future research.
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Myocardial Infarction and 
Circadian Rhythm
Ivana Škrlec, Svjetlana Marić and Aleksandar Včev
Abstract
Human physiological activity and condition during illness are under the control 
of the circadian rhythm. Circadian rhythms handle a wide diversity of physiological 
and metabolic functions, and the interruption of these rhythms has been linked to 
obesity, sleep disorders, metabolic and psychological disorders, and cardiovascular 
events such as myocardial infarction (MI), stroke, and vascular death. Disruption 
of circadian rhythms increases the risk of developing myocardial infarction, 
indicating that circadian genes might play an essential role in determining disease 
susceptibility. It is well known that many cardiovascular processes show daily varia-
tions depending on the circadian rhythm (blood pressure, heart rate), and the gene 
expression of the cardiomyocyte circadian clock influences myocardial contractile 
function, metabolism, and other gene expressions. We present a review of the 
latest knowledge on the impact of circadian rhythm and circadian rhythm genes on 
myocardial infarction. Today, in a time of personalized medicine, it is essential to 
know each person’s circadian rhythm for its treatment and possible inclusion in the 
diagnostic procedures.
Keywords: cardiomyocytes, circadian rhythm, myocardial infarction
1. Introduction
Everyday life is organized according to three different clocks: the solar clock 
which gives us light and temperature during the day, the social clock which deter-
mines the working day, and the biological clock which we notice during shift work 
or when we adjust to a reduced amount of daylight. In real life, the circadian clock is 
synchronized within 24 hours of the solar clock [1, 2].
It is known that almost all cardiovascular events occur in a circadian manner 
with a higher frequency in the morning after waking [3]. In the peripheral clocks of 
the cardiovascular tissues or cells, there is daily expression of the clock-controlled 
genes (CCG) synchronized and regulated by central clock [4, 5]. Disturbances of 
circadian rhythm can lead to cardiovascular disease.
Today we are facing a global epidemic of cardiovascular disease. In 2015 car-
diovascular disease was the cause of 17.7 million deaths worldwide or 31% of total 
mortality. Of these 7.4 million deaths were caused by ischemic heart disease and 
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1. Introduction
Everyday life is organized according to three different clocks: the solar clock 
which gives us light and temperature during the day, the social clock which deter-
mines the working day, and the biological clock which we notice during shift work 
or when we adjust to a reduced amount of daylight. In real life, the circadian clock is 
synchronized within 24 hours of the solar clock [1, 2].
It is known that almost all cardiovascular events occur in a circadian manner 
with a higher frequency in the morning after waking [3]. In the peripheral clocks of 
the cardiovascular tissues or cells, there is daily expression of the clock-controlled 
genes (CCG) synchronized and regulated by central clock [4, 5]. Disturbances of 
circadian rhythm can lead to cardiovascular disease.
Today we are facing a global epidemic of cardiovascular disease. In 2015 car-
diovascular disease was the cause of 17.7 million deaths worldwide or 31% of total 
mortality. Of these 7.4 million deaths were caused by ischemic heart disease and 
6.7 million by cerebrovascular diseases, according to World Health Organization 
(WHO) [6].
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2. Circadian rhythm
Circadian rhythm is controlled by a molecular clock located in almost every cell. 
A hierarchical system organizes molecular clocks—the master clock is located in 
the suprachiasmatic nucleus (SCN) in the hypothalamus [2, 7], while the peripheral 
clocks are located in each organ or cell. The central clock regulates physiological 
functions via the autonomic nervous system, humoral mediators, and other still 
unknown factors [7, 8]. In the maintenance and generation of circadian or biologi-
cal rhythm in humans, a whole series of anatomical (suprachiasmatic nucleus), 
neurological (retinohypothalamic paths) and neuroendocrine (melatonin) systems 
are involved, indicating that the biology of the circadian rhythm of humans is 
similar to that of animals [9].
The master clock in the SCN consists of about 100,000 neurons in humans. It 
is the only molecular clock that receives light as an input signal from the retina. 
Internal clocks are synchronized with light depending on the time of day. SCN 
receives a direct light signal from the retina via the optic nerve from the photore-
ceptor called the intrinsically photoreceptive retinal ganglion cell (ipRGC), which 
expresses the circadian photopigment, melanopsin [10]. The signal is further 
transmitted to peripheral clocks via the endocrine system [11, 12]. The central clock 
synchronizes each of the peripheral clocks in the body, and the primary circadian 
hormone is melatonin [13]. The pineal gland secretes melatonin during the night. 
Melatonin plays an essential role in maintaining the circadian rhythm depending 
on the period of light or darkness. The main difference between the master and 
peripheral clocks is in their degree of intercellular interaction. Peripheral clocks 
are under the influence of the master clock from the SCN via hormones, chemical 
signals and other metabolites (such as food), as well as by changes in the body, such 
as body temperature [11, 12].
On the other hand, due to the high degree of neuron connection the master 
clock in the SCN is not under the influence of internal signals but only under 
the influence of light [14]. Peripheral tissues integrate central clock signals with 
environmental factors (including sleepiness, physical activity, and feeding) and 
their autonomic rhythms which regulate the metabolism in a circadian manner 
[10]. The rhythm of the peripheral clocks in humans is measured by direct mea-
surement of physiological changes, or by determining the expression of the clock 
genes. Central and peripheral clocks together control the daily circadian rhythm of 
the metabolism [15].
Feeding time is one of the key triggers or external factors that sets the phases 
of the peripheral clocks [15]. Complex feedback loops connect the circadian clock 
with metabolic pathways and integrate these systems independently of light [10]. 
It is believed that the central clock regulates the metabolism by hormones (primar-
ily cortisol and melatonin) and synaptic signaling (via the autonomic nervous 
system) [10]. Feeding is a circadian event that serves not only as the output of the 
central clock, but also as an input signal for peripheral clocks because peripheral 
tissues communicate with the brain through ghrelin, leptin, glucose, and insulin. 
Circadian feeding contributes to the interworking of the clock and metabolism, 
which is crucial for metabolic homeostasis [16]. The central clock rhythm is 
primarily related to light, whereas peripheral tissue rhythms derive from the input 
of signals from the central clock, external factors (light, physical activity, feeding, 
and sleepiness) and the availability of numerous metabolites [15]. All these signals 
affect the molecular clock, creating a complex correlation between the circadian 
clock and physiological processes [10]. SCN coordinates all cellular circadian clocks 
in the organs and tissues through its rhythmic outcomes, to adapt physiology to 
Earth’s rotation [17].
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The two clock systems become desynchronized when their drivers or stimuli do 
not coincide because different stimuli affect the phases of the central and periph-
eral clocks. This mismatch disrupts the metabolism because the two clock systems 
coordinate interlinked metabolic pathways. Circadian rhythm mismatch increases 
the risk of developing metabolic diseases [15].
The central clock is primarily triggered by light, and its rhythm is often mea-
sured by determining the concentrations of melatonin, cortisol or body tempera-
ture [15]. The expression of the clock genes is disrupted in pathological conditions. 
Such a change may result in different tissue response to external signals and acceler-
ate tissue damage. The loss of synchronization can lead to various diseases, includ-
ing an increased incidence of cardiovascular disease [18].
3. Molecular basis of circadian rhythm
The central clock genes are expressed in a circadian manner in the SCN, and 
light is one of the main initiators (so-called zeitgeber) and can reset the phase of 
the rhythm. The first circadian rhythm gene discovered was the Per gene in the 
fruit fly in 1971 [19, 20], while the first circadian rhythm gene discovered in the 
vertebrae was the CLOCK gene [21]. There are about 10 circadian rhythm genes 
known to regulate cyclic expression of mRNA and protein, via transcription 
and translation feedback loops [22]. In the SCN there are four essential proteins: 
ARNTL (Aryl Hydrocarbon Receptor Nuclear Translocator-Like) and CLOCK 
(Circadian Locomotor Output Cycles Caps) are activators, while PER (Period) and 
CRY (Cryptochrome) are transcription inhibitors. The feedback of the circadian 
rhythm gene maintains circadian oscillations in one cell at the transcriptional and 
posttranscriptional levels, and the transition from light to dark triggers these oscil-
lations. The whole process of activation and repression of gene expression within 
the loop lasts for about 24 hours. These transcriptional factors trigger numerous 
physiological changes by acting on the expression of the same genes, and other 
clock-controlled genes [23, 24].
ARNTL and CLOCK heterodimers bind to regulatory elements of the promoters 
and enhancers (E-box) of the PER and CRY genes and stimulate their expression 
and the expression of other clock-controlled genes. Overnight the amount of 
PER and CRY proteins gradually increases, and heterodimers are created in the 
cytoplasm. The phosphorylated PER-CRY heterodimers are translocated into the 
nucleus where they inhibit the ARNTL-CLOCK protein complex. Therefore, during 
the day, transcription of PER and CRY genes is reduced, while the levels of PER 
and CRY protein decrease due to their degradation by ubiquitin. The PER-CRY 
heterodimers directly bind to the ARNTL-CLOCK complex, and as PER2 contains 
histone deacetylase, the chromatin structure changes, resulting in transcription 
termination. Also, the PER-CRY heterodimer is in interaction with RNA-binding 
proteins and helicase that are important in stopping transcription independently of 
the interaction with the ARNTL-CLOCK complex. Additionally, PER-CRY het-
erodimers regulate the transcription of various nucleic hormone receptors [25–28].
During the day a new cycle begins by the termination of the ARNTL-CLOCK 
heterodimer inhibition. Casein kinase 1 (CK1) controls the amount of phosphoryla-
tion or degradation of PER-CRY heterodimers and thereby determines the amount 
of PER-CRY heterodimer entering the nucleus and inhibiting the ARNTL-CLOCK 
complex. CK1 phosphorylates the proteins and thus regulates their activity [29].
The additional negative loop is REV-ERBα that binds to the REV-ERB/ROR 
response element (RRE) of the ARNTL and CLOCK genes, and prevents their 
transcription. Also, RORα (Retinoic Acid Receptor-related Orphan Receptor) binds 
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heterodimer inhibition. Casein kinase 1 (CK1) controls the amount of phosphoryla-
tion or degradation of PER-CRY heterodimers and thereby determines the amount 
of PER-CRY heterodimer entering the nucleus and inhibiting the ARNTL-CLOCK 
complex. CK1 phosphorylates the proteins and thus regulates their activity [29].
The additional negative loop is REV-ERBα that binds to the REV-ERB/ROR 
response element (RRE) of the ARNTL and CLOCK genes, and prevents their 
transcription. Also, RORα (Retinoic Acid Receptor-related Orphan Receptor) binds 
Visions of Cardiomyocyte - Fundamental Concepts of Heart Life and Disease
24
to the same regulatory elements of the ARNTL gene as well as REV-ERBα. With 
REV-ERBα degradation overnight, RORα promotes transcription of the ARNTL 
gene [30]. The second regulatory loop consists of ARNTL-CLOCK heterodimers 
which promote the transcription of the nucleic receptors REV-ERBα and RORα [31] 
(Figure 1).
Circadian clock genes have an essential role in many physiological processes. 
Thus, animal models demonstrate that the ARNTL gene plays an essential role in 
lipid metabolism because it induces the expression of genes involved in lipogenesis 
in adipose tissue in a circadian manner [32]. Pancreatic beta cells have a circadian 
clock dependent on ARNTL and CLOCK protein oscillations, which regulate insulin 
secretion depending on the stage of alertness. Abnormalities of the pancreas clock 
may trigger the onset of diabetes [33]. It was found that CLOCK polymorphisms 
are associated with body weight, the risk for metabolic syndrome and insomnia in 
humans [9, 32], and polymorphisms of the PER2 and PER3 genes are associated 
with sleep disorders [34, 35]. Some variants of CRY1 and CRY2 genes are associated 
with metabolic syndrome, particularly hypertension and increased triglyceride 
levels in the blood [36]. Many variants of the circadian rhythm genes are associated 
with the risk factors for the development of cardiovascular diseases such as blood 
pressure, glucose concentration [23, 37]. An overview of the essential circadian 
rhythm genes with their roles is shown in Table 1 [38, 39].
Figure 1. 
The molecular mechanism of circadian rhythm in humans. ARNTL and CLOCK activate transcription 
of CRY and PER, nuclear receptors (REV-ERBα and RORα) and other clock-controlled genes. CRY and 
PER heterodimerize and phosphorylate by casein kinases and translate into the nucleus where they prevent 
binding of the ARNTL-CLOCK to the regulatory regions of target genes. In the second feedback loop, REV-
ERBα prevents the transcription of ARNTL because it binds to the RRE element, while overnight the same 
regulatory elements bind RORα and activate transcription of ARNTL. Also, ARNT-CLOCK heterodimers 
activate transcription of the REV-ERBα and RORα proteins. ARNTL—aryl hydrocarbon receptor nuclear 
translocator-like, CLOCK—circadian locomotor output cycles kaput, CRY—cryptochrome, PER—period, 
P—phosphate, RORα—retinoic-related orphan receptor alpha, RRE element—REV-ERB/ROR response 
element, Ub—ubiquitin.
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Numerous studies on animal models, as well as human populations, have 
confirmed the association of the circadian clock gene with metabolic syndrome and 
cardiovascular diseases [15, 40, 41].
4. Cardiovascular diseases
The WHO data for 2017 show that cardiovascular diseases were the cause of 
19.9 million deaths worldwide, and about 80% of deaths from cardiovascular 
diseases were due to myocardial infarction and stroke [42]. It is estimated that by 
2030, 23.6 million people will die annually due to cardiovascular diseases [43].
Cardiovascular diseases are the primary cause of death in developed countries 
of the world, and in less developed parts of the world, this mortality is rising and 
overtaking mortality rates for infectious diseases [44].
There are variable and constant risk factors for cardiovascular disease. The 
variable risk factors are those that can be affected by therapy and lifestyle change, 
such as smoking, hyperlipoproteinemia, hypertension, and to some extent diabetes 
and homocysteinemia. The constant risk factors cannot be affected, namely age, 
genetic predisposition, gender, and menopause. The general risk factors which can 
be altered most are smoking, hypertension and hyperlipidemia, and obesity and 
diabetes whose prevalence has risen in the last few decades. However, some recent 
risk factors (fibrinogen, lipoprotein (a), homocysteine) should not be ignored. All 
of these contribute to total cardiovascular risk [45].
Cardiometabolic risk factors are determined by a cluster of metabolic and 
cardiovascular changes. Diabetes and obesity are also associated with reduced 
quality of life and increased economic burden on the person and society [46, 47]. 
Cardiovascular diseases and type 2 diabetes share common pathophysiological 
Gene Function
ARNTL (Aryl hydrocarbon 
Receptor Nuclear 
Translocator-Like)
Rhythmically expressed. Physically associates with CLOCK. Promotes 
transcription of PER and CRY. It is involved in the risk for hypertension, 
adipogenesis, and glucose metabolism.
CK1ε (Casein kinase 1 ε) Physically associates with and phosphorylates PER. Affects PER stability 
and nuclear localization.
CLOCK (Circadian Locomotor 
Output Cycles Kaput)
Constitutively expressed. Physically associates with ARNTL. Promotes 
transcription of PER and CRY. It is involved in the platelet rhythmic 









Physically associates with CRY. Positive regulator of ARNTL. They are 
involved in the aortic endothelial function.
REV-ERBα (nuclear receptor 
subfamily 1 group D member 1)
Associates with regulatory elements and negative regulator of the 
ARNTL and CLOCK transcription. It is involved in triglyceride and lipid 
metabolism, and circadian activity of PAI-1.
RORα (Retinoic-related orphan 
receptor alpha)
Associates with regulatory elements and positive regulator of the 
ARNTL. It is involved in lipid metabolism.
TIM (Timeless) Circadian function not known. Physically associates with CRY. Negative 
regulator of PER and CRY transcription in vitro.
Table 1. 
The essential circadian rhythm genes in mammals.
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mechanisms of insulin resistance and risk factors for cardiovascular diseases, such 
as metabolic syndrome. Excessive weight plays a significant role because fatty tissue 
becomes an active endocrine organ that secretes low-level inflammation mediators, 
and these stimulate the development of metabolic syndrome and vascular diseases 
[32, 48, 49].
5. Myocardial infarction
Myocardial infarction is the leading cause of mortality in developed countries 
and developing countries. It can be caused and triggered by different pathophysio-
logical processes. Myocardial infarction is an inflammatory disease due to the death 
of myocardial cells because of complete coronary circulation interruption, which is 
in most cases a consequence of thrombotic occlusion of the coronary artery at the 
site of the activated atherosclerotic plaque. An electrocardiogram (ECG) of the ST 
elevation is only an indirect indicator of the fact that ischemia affects all three layers 
of cardiac muscle (endocardium, myocardium, and epicardium) [50].
ST-elevation myocardial infarction (STEMI) is the most severe form of acute 
coronary syndrome. Myocardial infarction is accompanied by increased cellular 
oxidative stress in the pericardial cavity [51]. The primary cause of infarction is 
platelet aggregation in the coronary artery. The platelet activity is the highest in 
the morning. Also, in the morning hours, mental and physical activity increase due 
to cortisol and catecholamine elevation, which increases cardiac output [45]. The 
biochemical markers of myocardial damage are cardiac troponin T or troponin I in 
serum. These biochemical markers are more reliable than those previously used, 
such as measurement of creatine kinase (CK). The initial increase in troponin in 
peripheral blood in patients with infarction occurs over 3–4 hours with a permanent 
increase for up to 2 weeks after infarction. In order to confirm or exclude myo-
cardial damage, troponin T serum levels are repeated in the first 6–12 hours after 
severe chest pain [52].
The classification of myocardial infarction in five types was introduced in 2007 
and established the clinical criteria for its exact differentiation [50]. Type 1 is related 
to a coronary plaque rupture, fissuring, or dissection with resulting intraluminal 
thrombosis. Type 2 myocardial infarction is secondary to myocardial ischemia 
resulting from increased oxygen demand or decreased supply. Type 3 myocardial 
infarction is linked to unexpected cardiac death when cardiac biomarkers are 
unavailable. Types 4 and 5 myocardial infarction are procedure related [53].
In the study of Saaby et al., [54] it was shown that the most significant number 
of patients with myocardial infarction come under Type 1 (72%). In patients with 
Type 1 myocardial infarction, changes in the ECG are seen either as the elevation or 
depression of the ST segment; the troponin T level also increases in the blood and 
serves as a diagnostic marker. The troponin T level in the blood is higher in patients 
with Type 1 myocardial infarction than Type 2 [55].
For manifestation of infarction, apart from lifestyle, a genetic background of 
myocardial infarction is also essential. A positive family history of myocardial infarc-
tion is a major cardiovascular risk factor [56]. Coronary artery disease and myocar-
dial infarction have a genetic background in 50–60% of cases. Many genes are found 
in the genetic background of myocardial infarction. Whole genome association 
studies have revealed many variants of genes associated with increased risk for myo-
cardial infarction [56]. So far the most frequently explored genes with increased risk 
for myocardial infarction are involved in the metabolic pathways of lipid metabolism 
and development of type 2 diabetes. The relationship between the circadian rhythm 
genes and the onset of myocardial infarction will be discussed below.
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6. Myocardial infarction and circadian rhythm
Many cardiovascular events and diseases have a circadian pattern of appearance. 
The normal circadian blood pressure shows the two highest values during the day, 
around 9 am and 7 pm, while there is a slight decrease around 3 pm. It is considered 
that circadian variations in the tone of coronary vessels and endothelial function 
play an essential role in the onset of myocardial infarction. As myocardial infarction 
is significant medical stress, it causes increased cortisol levels in plasma [3]. In the 
acute phase of myocardial infarction, the phase of the circadian clock in the isch-
emic part of the heart differs from the non-ischemic part of the heart. The arrhyth-
mia may occur because of the difference in the phase of the rhythm, or different 
expressions of the circadian clock genes. The loss of synchronization of the circa-
dian rhythm between organs or tissues occurs more often than we would expect [4]. 
Circadian regulation of physiological processes is regulated locally. Peripheral tissue 
clocks control tissue-specific expression [27].
Homeostatic changes, gene expression changes, and external triggers can cause a 
stressful environment and cause damage to the atherosclerotic plaque in the coro-
nary arteries in the morning, when prothrombin is increased [57]. Many intrinsic 
vasoactive and cardioactive substances, such as angiotensin II, melatonin, plasmino-
gen activator inhibitor 1 (PAI-1), glucocorticoids, epinephrine, norepinephrine, and 
nitrogen oxide, show a specific circadian pattern. The fibrinolytic system, which 
regulates PAI-1, shows a circadian pattern of occurrence in both healthy patients and 
those with ischemic heart disease. The concentration and activity of PAI-1 depend 
on the circadian rhythm and are the highest in the morning [28]. CLIF (Cycle-Like 
Factor) expression in endothelial cells creates heterodimers with CLOCK protein, 
and binds to the E-box of the PAI-1 gene promoter and promotes its expression, 
while PER2 and CRY1 inhibit expression of PAI-1 by blocking heterodimer CLOCK-
CLIF. CLIF controls the circadian rhythm of PAI-1 in endothelial cells, which might 
explain the higher incidence of myocardial infarction in the morning [26, 58]. As a 
result of this, the fibrinolytic system in patients with MI might be a potential goal 
for chronotherapy, to treat acute cardiovascular events. The circadian clock regu-
lates the endothelial response to vascular injury. The main factor that can be affected 
by potential chronotherapy is PAI-1 because it is a crucial fibrinolysis inhibitor [59]. 
Chronotherapy includes the accurate timing of drug taking and can improve the 
therapeutic efficacy of the drug, while limiting its toxicity [41]. That is why many 
studies support chronotherapy for cardiovascular disease by limiting pathogenesis 
and improving treatment after the occurrence of acute cardiovascular events [59].
It is known that melatonin levels decrease during the night in coronary heart 
disease and infarction. Melatonin is an antioxidant that can inhibit the action of 
reactive oxygen radicals during heart ischemia. It also plays a vital role in regulating 
blood pressure, depending on the circadian rhythm. Animal studies have shown 
that animals with the pineal gland removed develop hypertension. Clinical exami-
nations have shown that in patients with hypertension melatonin drugs taken daily 
before bedtime reduced blood pressure [3].
The appearance of myocardial infarction has two peaks during the day. The 
highest incidence of myocardial infarction is during the morning, and the second 
peak occurs late at night [60]. The beta blockers prevent increased sympathetic 
activity, catecholamine concentration, heart rate, blood pressure and lack of oxygen 
in the heart, and these are the physiological reasons for the existence of two peaks 
of myocardial infarction [57, 61].
Ischemia occurs in the morning due to increased oxygen demand, whereas in 
the evening it is due to decreased coronary blood flow. The appearance of myocar-
dial infarction depends on ethnic origin, and the British differ from Asians in the 
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frequency of the infarction [3]. In the Mediterranean, the highest incidence of myo-
cardial infarction is between midday and midnight, while in the UK the highest inci-
dence is between midnight and midday [62]. Numerous factors might affect the later 
occurrence of infarction in the Mediterranean, such as the number of sunlight hours, 
inequality in the prevalence of risk factors for cardiovascular disease, and the habit of 
afternoon rest or ‘siesta’ [63]. It has also been noted that the incidence of myocardial 
infarction is higher in the winter [3]. The specific circadian pattern of infarction 
symptoms has been observed, and the correlation of the circadian rhythm gene with 
the infarction investigated. The role of the molecular circadian clock in myocardial 
activity was initially investigated on animal models. It has been observed that the clock 
gene mutations of the circadian rhythm affect the heart rate, myocardial contractility, 
energy metabolism, which altogether leads to ischemia [64, 65]. In contrast, variants 
of the Per2 gene in mice reduce the severity of the injury after myocardial infarction 
because it does not only reduce inflammatory response, but also reduces apoptosis, 
induces cardiovascular hypertrophy, and thus preserves cardiac function [65].
Different variations of circadian rhythm genes are associated with many risk 
factors for cardiovascular disease. Thus, CLOCK gene variations are associated with 
metabolic syndrome in humans, type 2 diabetes, and some with stroke [64, 66–68], 
while CRY2 and PER2 gene variations are associated with myocardial infarction 
[69]. Expression of CRY1 and PER2 genes in fatty tissue is associated with meta-
bolic syndrome in humans [64, 70]. Metabolic syndrome is a significant risk factor 
for cardiovascular disease and contributes to the common pathophysiological 
processes leading to the development of diabetes and cardiovascular diseases [48]. 
Atherosclerotic changes in blood vessels in patients with diabetes are more severe 
than those with normal glucose concentration [71]. It has been shown that the risk 
of cardiovascular disease in diabetic patients is two to three times higher than in 
healthy subjects [72]. Patients with diabetes usually have a higher heart rate in sleep 
and lower heart rate variability over the day than people without diabetes, which 
causes unnecessary oxygen consumption in the myocardium, with reduced nutri-
tional blood supply. Biological and epidemiological studies suggest a direct link 
between lifestyle and metabolic disorders [12], although the genetic and biochemi-
cal linkage of human circadian rhythm with metabolic disorders has not been fully 
explored. Accordingly, the importance of the circadian rhythm in maintaining 
‘energy’ homeostasis and metabolism is evident.
6.1 Cardiomyocyte circadian clock
A peripheral clock is also found in cardiomyocytes, and the internal molecular 
mechanism of cardiomyocytes, such as the circadian clock, might contribute to 
cardiovascular disease [73]. Similar to SCN, cardiomyocytes have a circadian 
expression of clock genes in response to serum shock or norepinephrine. Several 
genes are associated with intracellular metabolism or physiological activity that has 
a circadian expression in cardiomyocytes [74]. After development, cardiomyocytes 
do not replicate, although they possess a meager and permanent rate of renewal. 
Cardiomyocytes renew cellular structure with their new proteins and membrane 
lipids every few weeks [75]. The ischemic precondition is an adaptation of cardio-
myocytes to hypoxia, and once the heart has suffered an ischemic insult, cardio-
myocytes become more resistant to MI because of PER2 and hypoxia inducible 
factor (HIF)-1a [74]. Circadian genes regulate a group of genes encoding for cardiac 
metabolic enzymes, and it is considered that a significant role of circadian genes in 
the heart is to synchronize cardiomyocyte metabolic activity with the availability 
of nutrients in the blood (i.e., feeding time) [29]. It is known that PER2 plays an 
essential role in carbohydrate metabolism during myocardial ischemia [76].
29
© 2019 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms 
of the Creative Commons Attribution License (http://creativecommons.org/licenses/
by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, 
provided the original work is properly cited. 
Myocardial Infarction and Circadian Rhythm
DOI: http://dx.doi.org/10.5772/intechopen.83393
Author details
Ivana Škrlec*, Svjetlana Marić and Aleksandar Včev
Faculty of Dental Medicine and Health, J. J. Strossmayer University of Osijek, 
Croatia
*Address all correspondence to: iskrlec@fdmz.hr
The cardiomyocyte circadian clock affects the daily variations in the heart. 
Studies show that the cardiomyocyte circadian clock affects myocardial contrac-
tions, the metabolism and gene expression. This clock is vital since impairment 
of the cardiomyocyte circadian clock might significantly alter cardiac function, 
cardiovascular disease pathogenesis, and treatment strategies for cardiovascular 
diseases (e.g., chronopharmacology) [77]. Desynchronization between different 
cell types (e.g., cardiomyocytes, vascular smooth muscle cells, endothelial cells) 
could occur within the organs (e.g. the heart) during certain physiological or 
pathological conditions [78]. The cardiomyocyte circadian clock allows the heart 
to predict circadian rhythm by extracellular stimuli, allowing rapid and temporally 
response [77]. The cardiomyocyte circadian clock has a crucial role in mediating 
the daily rhythm in myocardial metabolism and affects the cardiovascular function 
[79]. The cardiomyocyte circadian clock changes during illness, and this molecular 
mechanism might affect the etiology of cardiovascular disease [78].
7. Conclusions
Circadian rhythm adjusts the physiological functions of an individual on a daily 
basis. Daily variations of physiological parameters in the cardiovascular system 
maintain cardiovascular function according to the needs of different activities 
during the day. This information suggests that we need to know not only how, but 
also when to treat heart disease, and also to treat pathological changes not only 
symptomatically but to treat non-symptomatic but potentially harmful changes in 
the circadian rhythm.
Understanding the pathophysiological processes involved in the onset of myo-
cardial infarction requires additional studies to assess the crucial elements of the 
circadian rhythm. In today’s personalized medicine, knowledge of the circadian 
rhythm (i.e., the genetic background) of an individual can be significant for treat-
ment and should be included as an essential part of the diagnostic process.
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frequency of the infarction [3]. In the Mediterranean, the highest incidence of myo-
cardial infarction is between midday and midnight, while in the UK the highest inci-
dence is between midnight and midday [62]. Numerous factors might affect the later 
occurrence of infarction in the Mediterranean, such as the number of sunlight hours, 
inequality in the prevalence of risk factors for cardiovascular disease, and the habit of 
afternoon rest or ‘siesta’ [63]. It has also been noted that the incidence of myocardial 
infarction is higher in the winter [3]. The specific circadian pattern of infarction 
symptoms has been observed, and the correlation of the circadian rhythm gene with 
the infarction investigated. The role of the molecular circadian clock in myocardial 
activity was initially investigated on animal models. It has been observed that the clock 
gene mutations of the circadian rhythm affect the heart rate, myocardial contractility, 
energy metabolism, which altogether leads to ischemia [64, 65]. In contrast, variants 
of the Per2 gene in mice reduce the severity of the injury after myocardial infarction 
because it does not only reduce inflammatory response, but also reduces apoptosis, 
induces cardiovascular hypertrophy, and thus preserves cardiac function [65].
Different variations of circadian rhythm genes are associated with many risk 
factors for cardiovascular disease. Thus, CLOCK gene variations are associated with 
metabolic syndrome in humans, type 2 diabetes, and some with stroke [64, 66–68], 
while CRY2 and PER2 gene variations are associated with myocardial infarction 
[69]. Expression of CRY1 and PER2 genes in fatty tissue is associated with meta-
bolic syndrome in humans [64, 70]. Metabolic syndrome is a significant risk factor 
for cardiovascular disease and contributes to the common pathophysiological 
processes leading to the development of diabetes and cardiovascular diseases [48]. 
Atherosclerotic changes in blood vessels in patients with diabetes are more severe 
than those with normal glucose concentration [71]. It has been shown that the risk 
of cardiovascular disease in diabetic patients is two to three times higher than in 
healthy subjects [72]. Patients with diabetes usually have a higher heart rate in sleep 
and lower heart rate variability over the day than people without diabetes, which 
causes unnecessary oxygen consumption in the myocardium, with reduced nutri-
tional blood supply. Biological and epidemiological studies suggest a direct link 
between lifestyle and metabolic disorders [12], although the genetic and biochemi-
cal linkage of human circadian rhythm with metabolic disorders has not been fully 
explored. Accordingly, the importance of the circadian rhythm in maintaining 
‘energy’ homeostasis and metabolism is evident.
6.1 Cardiomyocyte circadian clock
A peripheral clock is also found in cardiomyocytes, and the internal molecular 
mechanism of cardiomyocytes, such as the circadian clock, might contribute to 
cardiovascular disease [73]. Similar to SCN, cardiomyocytes have a circadian 
expression of clock genes in response to serum shock or norepinephrine. Several 
genes are associated with intracellular metabolism or physiological activity that has 
a circadian expression in cardiomyocytes [74]. After development, cardiomyocytes 
do not replicate, although they possess a meager and permanent rate of renewal. 
Cardiomyocytes renew cellular structure with their new proteins and membrane 
lipids every few weeks [75]. The ischemic precondition is an adaptation of cardio-
myocytes to hypoxia, and once the heart has suffered an ischemic insult, cardio-
myocytes become more resistant to MI because of PER2 and hypoxia inducible 
factor (HIF)-1a [74]. Circadian genes regulate a group of genes encoding for cardiac 
metabolic enzymes, and it is considered that a significant role of circadian genes in 
the heart is to synchronize cardiomyocyte metabolic activity with the availability 
of nutrients in the blood (i.e., feeding time) [29]. It is known that PER2 plays an 
essential role in carbohydrate metabolism during myocardial ischemia [76].
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The cardiomyocyte circadian clock affects the daily variations in the heart. 
Studies show that the cardiomyocyte circadian clock affects myocardial contrac-
tions, the metabolism and gene expression. This clock is vital since impairment 
of the cardiomyocyte circadian clock might significantly alter cardiac function, 
cardiovascular disease pathogenesis, and treatment strategies for cardiovascular 
diseases (e.g., chronopharmacology) [77]. Desynchronization between different 
cell types (e.g., cardiomyocytes, vascular smooth muscle cells, endothelial cells) 
could occur within the organs (e.g. the heart) during certain physiological or 
pathological conditions [78]. The cardiomyocyte circadian clock allows the heart 
to predict circadian rhythm by extracellular stimuli, allowing rapid and temporally 
response [77]. The cardiomyocyte circadian clock has a crucial role in mediating 
the daily rhythm in myocardial metabolism and affects the cardiovascular function 
[79]. The cardiomyocyte circadian clock changes during illness, and this molecular 
mechanism might affect the etiology of cardiovascular disease [78].
7. Conclusions
Circadian rhythm adjusts the physiological functions of an individual on a daily 
basis. Daily variations of physiological parameters in the cardiovascular system 
maintain cardiovascular function according to the needs of different activities 
during the day. This information suggests that we need to know not only how, but 
also when to treat heart disease, and also to treat pathological changes not only 
symptomatically but to treat non-symptomatic but potentially harmful changes in 
the circadian rhythm.
Understanding the pathophysiological processes involved in the onset of myo-
cardial infarction requires additional studies to assess the crucial elements of the 
circadian rhythm. In today’s personalized medicine, knowledge of the circadian 
rhythm (i.e., the genetic background) of an individual can be significant for treat-
ment and should be included as an essential part of the diagnostic process.
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and Genetic Aspects of Dilated 
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Abstract
Dilated cardiomyopathy is the most common form of cardiomyopathy and the 
second leading cause of left ventricular dysfunction with highly variable clinical 
presentation and prognosis. The clinical courses vary and are strongly heteroge-
neous, ranging from asymptomatic patients to those suffering from intractable 
heart failure or sudden cardiac death due to arrhythmias. Previous studies have 
reported a 10 years cardiovascular mortality up to 40% in developed countries, 
due to advanced heart failure or sudden cardiac death. However, the prognosis of 
dilated cardiomyopathy patients is variable and depends on multiple risk factors. 
This chapter provides a review of dilated cardiomyopathy with specific focus on the 
pathophysiological aspects and genetic etiology of the disease.
Keywords: dilated cardiomyopathy, pathophysiology, etiology, diagnostics, therapy
1. Introduction
Dilated cardiomyopathy (DCM) is one of the most common cardiomyopathies 
causing heart failure (HF) worldwide. Although it is less common than coronary 
artery disease (CAD), it affects mainly young adults and presents the most frequent 
reason for cardiac transplantation in young age [1, 2]. According to the European 
Society of Cardiology (ESC), the current definition of DCM includes the presence 
of a dilated and poorly functioning left ventricle or of both ventricles [3]. A het-
erogeneous group of myocardial and systemic conditions may cause left ventricular 
dilatation in combination with dysfunction. In fact, identifying the etiology of 
DCM can be very challenging, which often leads to the common terminology of 
idiopathic dilated cardiomyopathy (IDC). Furthermore, DCM has a highly variable 
clinical presentation. While signs and symptoms of HF are most common, some 
patients are incidentally, for instance, by diagnosing cardiomegaly in chest X-ray. 
Other symptoms include arrhythmias, conduction disturbances, thromboembolic 
complications, or sudden cardiac death (SCD). In the last decades, major advances 
have been made in the understanding of molecular and genetic issues, as well as 
in the pathophysiology and clinical assessment of cardiomyopathies. Especially, 
understanding the genetic basis of DCM has improved considerably with the 
availability of genetic analysis. In addition, other important diagnostic approaches, 
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1. Introduction
Dilated cardiomyopathy (DCM) is one of the most common cardiomyopathies 
causing heart failure (HF) worldwide. Although it is less common than coronary 
artery disease (CAD), it affects mainly young adults and presents the most frequent 
reason for cardiac transplantation in young age [1, 2]. According to the European 
Society of Cardiology (ESC), the current definition of DCM includes the presence 
of a dilated and poorly functioning left ventricle or of both ventricles [3]. A het-
erogeneous group of myocardial and systemic conditions may cause left ventricular 
dilatation in combination with dysfunction. In fact, identifying the etiology of 
DCM can be very challenging, which often leads to the common terminology of 
idiopathic dilated cardiomyopathy (IDC). Furthermore, DCM has a highly variable 
clinical presentation. While signs and symptoms of HF are most common, some 
patients are incidentally, for instance, by diagnosing cardiomegaly in chest X-ray. 
Other symptoms include arrhythmias, conduction disturbances, thromboembolic 
complications, or sudden cardiac death (SCD). In the last decades, major advances 
have been made in the understanding of molecular and genetic issues, as well as 
in the pathophysiology and clinical assessment of cardiomyopathies. Especially, 
understanding the genetic basis of DCM has improved considerably with the 
availability of genetic analysis. In addition, other important diagnostic approaches, 
particularly imaging methods are more widely available. This allows early diagnosis 
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and the initiation of adequate therapy, which already has led to an improvement of 
the prognosis in the last years. Data have shown that approximately 25% of DCM 
patients with recent onset of HF (<6 months) have ameliorated in symptoms or 
even have complete cardiac function recovery [4, 5]. However, the overall prognosis 
in patients with symptomatic HF and DCM is still poor. In order to further improve 
the prognosis of our patients, it is important to regularly gather the knowledge 
about the current state of DCM and adapt the appropriate diagnostic workups. 
Therefore, this chapter provides the reader with a comprehensive overview of the 
current state of DCM from definition over etiology including the genetics aspects to 
management for cardiovascular specialists.
2. Dilated cardiomyopathy: a frequent cardiac disease
2.1 Definition
In 1980, the World Health Organization (WHO) defined cardiomyopathies as 
“heart muscle diseases of unknown cause” [6]. The definition was established to 
distinguish cardiomyopathies from cardiac diseases with known entities such as 
hypertension, ischemic, or valvular heart disease. About 15 years later, the WHO/
International Society and Federation of Cardiology (ISFC) Task Force classified 
cardiomyopathies according to anatomy and physiology into dilated cardiomyopa-
thy (DCM), hypertrophic cardiomyopathy (HCM), restrictive cardiomyopathy 
(RCM), arrhythmogenic right ventricular cardiomyopathy/dysplasia (ARVC/D) 
and unclassified cardiomyopathies. The definitions and classifications of cardiomy-
opathies changed over the years. The American Heart Association (AHA) presented 
a new scheme in 2006 that combined genetic and clinical criteria [7]. In contrast to 
that, the ESC defined in 2008 cardiomyopathies in a more clinically oriented classi-
fication system according to the WHO scheme as myocardial disorders with struc-
turally and functionally abnormities of the heart muscle in the absence of coronary 
artery disease, hypertension, valvular disease, or congenital heart disease [3]. As 
mentioned above, right ventricular dilatation and dysfunction may be present but 
are not necessary for the diagnosis. Further, DCM is classified into familial/genetic 
and nonfamilial/nongenetic forms [3]. Recently, a revised definition of DCM was 
presented by the ESC working group on myocardial and pericardial diseases [8]. 
This position paper did not modify the above-mentioned definition, it rather added 
the important value of diverse etiologies and clinical manifestations with an intro-
duction of a novel concept of a continuous phenotypic DCM spectrum, ranging 
from the subclinical mutation carriers to fully expressed DCM phenotypes.
2.2 Prevalence
The prevalence of DCM in the general population is unknown. The reported 
numbers considerably vary due to inhomogeneous study methodologies, which are 
mainly related to inconsistent definitions and classifications of DCM. In addition, 
the prevalence of DCM varies according to geographic and ethnic differences. 
One of the first reports was derived from an epidemiological study conducted in 
Olmsted County, Minnesota, from 1975 to 1984. For the diagnosis of DCM, the 
authors implemented echocardiography, angiography, and autopsy cases [9]. They 
presented a prevalence of 36.5/100,000 individuals or 1 in 2700 with a male to 
female ratio of 3:4 in a European-American population. A much higher prevalence 
with 1:250 was reported recently by a study from Hershberger et al. The authors 
estimated the DCM prevalence based on the known ratio of idiopathic DCM to 
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HCM of ≈2:1. In addition, clinical data of HF patients and left ventricular dysfunc-
tion were used as a surrogate for DCM [10]. In Western countries, 25–40% of DCM 
patients have been described with evidence of familial DCM with predominantly 
autosomal dominant inheritance [4, 11–13]. In general, epidemiologic studies 
have stated a rate of 20 up to >50% of familial DCM in patients, who were initially 
diagnosed with IDC [9, 11, 14–18].
2.3 Clinical presentation
The first presentation of patients with DCM is often characterized by signs and 
symptoms of HF, such as dyspnea, ankle swelling, fatigue, elevated jugular venous 
pressure, pulmonary rales, and peripheral edema (Table 1). These result from 
reduced cardiac function with low output and/or elevated intracardiac pressures. 
Other clinical manifestations include chest pain caused by reduced coronary blood 
flow or congestion, palpitations, and syncope or sudden cardiac death (SCD). 
Arrhythmia results from multifactorial reasons, which are present in DCM and 
include structural changes with myocardial fibrosis and left ventricular dilation as 
well as electrophysiological changes [19]. The risk of SCD is highly heterogeneous 
and depends on etiologies and risk factors [20]. Some genetic constellations may 
be associated with arrhythmias out of proportion to the degree of left ventricular 
dysfunction (e.g., pathogenic variants in DES, LMNA, and SCN5A) [21]. This is 
described later in this chapter (see Sections 2.7.3 and 2.8). Furthermore, patients 
might present with pulmonary and systemic thromboembolism [22]. Possible clini-
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and the initiation of adequate therapy, which already has led to an improvement of 
the prognosis in the last years. Data have shown that approximately 25% of DCM 
patients with recent onset of HF (<6 months) have ameliorated in symptoms or 
even have complete cardiac function recovery [4, 5]. However, the overall prognosis 
in patients with symptomatic HF and DCM is still poor. In order to further improve 
the prognosis of our patients, it is important to regularly gather the knowledge 
about the current state of DCM and adapt the appropriate diagnostic workups. 
Therefore, this chapter provides the reader with a comprehensive overview of the 
current state of DCM from definition over etiology including the genetics aspects to 
management for cardiovascular specialists.
2. Dilated cardiomyopathy: a frequent cardiac disease
2.1 Definition
In 1980, the World Health Organization (WHO) defined cardiomyopathies as 
“heart muscle diseases of unknown cause” [6]. The definition was established to 
distinguish cardiomyopathies from cardiac diseases with known entities such as 
hypertension, ischemic, or valvular heart disease. About 15 years later, the WHO/
International Society and Federation of Cardiology (ISFC) Task Force classified 
cardiomyopathies according to anatomy and physiology into dilated cardiomyopa-
thy (DCM), hypertrophic cardiomyopathy (HCM), restrictive cardiomyopathy 
(RCM), arrhythmogenic right ventricular cardiomyopathy/dysplasia (ARVC/D) 
and unclassified cardiomyopathies. The definitions and classifications of cardiomy-
opathies changed over the years. The American Heart Association (AHA) presented 
a new scheme in 2006 that combined genetic and clinical criteria [7]. In contrast to 
that, the ESC defined in 2008 cardiomyopathies in a more clinically oriented classi-
fication system according to the WHO scheme as myocardial disorders with struc-
turally and functionally abnormities of the heart muscle in the absence of coronary 
artery disease, hypertension, valvular disease, or congenital heart disease [3]. As 
mentioned above, right ventricular dilatation and dysfunction may be present but 
are not necessary for the diagnosis. Further, DCM is classified into familial/genetic 
and nonfamilial/nongenetic forms [3]. Recently, a revised definition of DCM was 
presented by the ESC working group on myocardial and pericardial diseases [8]. 
This position paper did not modify the above-mentioned definition, it rather added 
the important value of diverse etiologies and clinical manifestations with an intro-
duction of a novel concept of a continuous phenotypic DCM spectrum, ranging 
from the subclinical mutation carriers to fully expressed DCM phenotypes.
2.2 Prevalence
The prevalence of DCM in the general population is unknown. The reported 
numbers considerably vary due to inhomogeneous study methodologies, which are 
mainly related to inconsistent definitions and classifications of DCM. In addition, 
the prevalence of DCM varies according to geographic and ethnic differences. 
One of the first reports was derived from an epidemiological study conducted in 
Olmsted County, Minnesota, from 1975 to 1984. For the diagnosis of DCM, the 
authors implemented echocardiography, angiography, and autopsy cases [9]. They 
presented a prevalence of 36.5/100,000 individuals or 1 in 2700 with a male to 
female ratio of 3:4 in a European-American population. A much higher prevalence 
with 1:250 was reported recently by a study from Hershberger et al. The authors 
estimated the DCM prevalence based on the known ratio of idiopathic DCM to 
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2.4 Pathophysiological aspects and etiology
As a consequence of the definition, the etiology of left ventricular dilatation 
and dysfunction is heterogeneous. In developed countries, CAD is the most com-
mon cause of left ventricular dilatation and dysfunction, and responsible for 
approximately 50–70% of HF patients. Therefore, potentially reversible myocardial 
ischemia must always be excluded for the diagnosis of DCM. The following section 
describes in detail the possible causes of the DCM (Figure 1). However, the current 
literature underscores that the cause of DCM remains unknown, that is, IDC, in 
half of the patients [23].
2.4.1 Non-genetic causes of DCM
2.4.1.1 Inflammatory cardiomyopathy
DCM can occur after a cardiac infection or inflammation as an early (e.g. giant-
cell myocarditis) or late stage disease. Typically, the active or fulminant myocarditis 
appears with preserved left ventricular size, while in contrast inflammatory DCM 
is defined as the presence of chronic inflammatory cells in association with left 
ventricular dilatation and reduced fraction [3]. The inflammatory myocarditis can 
result from an infection or may be mediated by autoimmune mechanisms. The 
infectious myocarditis is commonly caused by viral pathogens as an acute or chronic 
disease [24]. In the developed countries until the 1990s, the most frequently reported 
viruses were adenoviruses and enteroviruses. Recently, parvovirus B12 and human 
herpes virus-6 are increasingly reported causing DCM [25]. In the acute phase, 
the virus replicates actively within the myocardium. This leads to dysfunction of 
cardiomyocytes and endothelial cells, and thus triggering the immune response [23]. 
Commonly, the innate immune system clears the viral load whereas insufficient 
immune response results in viral persistence and progressive myocyte destruction 
[25]. The secondary effect is triggered by primed T-cells. In addition, some host 
myocardial cellular antigens may share epitopic similarities with viral antigens and 
induce an autoimmune response with further destruction of cardiomyocytes [23]. 
Figure 1. 
Etiologies of the dilated cardiomyopathy.
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Another important viral-related form of DCM is HIV syndrome. DCM in HIV 
patients is called HIV-associated cardiomyopathy. Autopsies demonstrated histologi-
cal evidence of myocarditis in around 50% of patients, who died of AIDS-related 
illness [26]. Bacterial infections such as brucellosis, diphtheria, psittacosis, and 
typhoid fever are also known to cause (peri-) myocarditis [27–30]. In addition, E. coli 
bacteraemia have been described to induce myocarditis [31]. Spirochaetal myocardi-
tis may be encountered in the setting of the Lyme disease (Borrelia burgdorferi), the 
Weil disease (Leptospirosis), and syphilis (Treponema pallidum) [32]. In endemic 
areas, the protozoan parasite Trypanosoma cruzi is a typical cause of DCM due to 
acute cardiac infection (perimyocarditis), as well as chronic myocardial fibrosis 
leading to DCM [33]. There are several proposed mechanisms leading to DCM in 
autoimmune disorders. These include immune-mediated myocarditis, progressive 
fibrosis, apoptosis with resultant restrictive and dilated phenotypes, and progressive 
atherosclerosis with subsequent ischemic cardiomyopathy [26]. Other causes for a 
non-infectious myocarditis are: Kawasaki disease in children with coronary vascu-
litis and systemic lupus erythematosus, which can affect the myocardium without 
involvement of the pericardium. In rare cases, connective tissue diseases such as 
scleroderma, rheumatoid arthritis, and polyarteritis nodosa may lead to DCM [26]. 
The non-infectious etiologies of myocarditis include drug-induced hypersensitivity 
and hypereosinophilic syndromes, as well as giant-cell myocarditis, which is one of 
the most aggressive non-infectious autoimmune disorders with rapid and devastating 
outcome if not treated appropriately [24, 26].
2.4.1.2 Peripartum cardiomyopathy
Peripartum cardiomyopathy (PPCM) affects predisposed teenagers and older 
women during the last month of pregnancy or within 5 months of delivery with 
typical signs and symptoms of HF [34, 35]. Suspected etiological factors include 
inflammatory myocarditis, autoimmunity caused by chimerism of hematopoietic 
lineage cells from the fetus, hemodynamic stress during pregnancy, and toxicity 
caused by an abnormal cleavage product of prolactin [3, 36]. Furthermore, genetic 
predisposition seems to be important [37].
2.4.1.3 Toxic cardiomyopathies
A number of chemical compounds are responsible for DCM. In western and 
developing countries, alcoholic cardiomyopathy (ACM) represents one of the most 
common forms of secondary cardiomyopathies resembling IDC with an estimated 
prevalence of 23–40% [24, 38]. More than women, men are affected by ACM and 
the occurrence correlates with a daily level and the duration of alcohol consump-
tion [39]. However, the prevalence of ACM is variable and the mean daily amount 
of alcohol consumption, duration of regular intake, and patients’ individual 
characteristics, including genetic susceptibility, are all related to the development 
of a respective cardiomyopathy [26]. Alcohol may result in both acute and chronic 
depression of myocardial contractility. Street drugs such as cocaine and metham-
phetamines are potent sympathomimetic drugs that induce inotropic and chrono-
tropic effects. Mechanisms of cardiac toxicity include myocardial ischemia from 
increased oxygen consumption, prothrombotic effects, coronary vasospasms, and 
acceleration of coronary atherosclerosis [24]. Anthracycline-based chemothera-
peutic agents are known to induce cardiac dysfunction. Acute or subacute injury 
can occur immediately after treatment with transient arrhythmias, pericarditis, 
and myocarditis [38]. The time course of chronic development of HF varies from an 
early onset (<1 year) to late onset (>1 year) or chronic progressive cardiomyopathy, 
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which can occur 10–30 years after exposure. Both chronic forms tend to be irre-
versible, are dosage dependent and are associated with ultrastructural changes in 
the cardiac myocytes [40]. Trastuzumab, a monoclonal antibody directed against 
the human epidermal growth factor receptor 2 (HER2), is wildly used and very 
effective for the treatment of HER2-positive breast cancer. HER2 receptors are also 
localized on the cardiomyocyte. The inhibition of the Her2:Her4 signaling process 
in the myocardium is principally responsible for the cardiotoxicity [26]. In addi-
tion, a number of other, non-chemotherapeutical medications are associated with 
DCM, such as cyclophosphamide, phenothiazines, antidepressant drugs, carbon 
monoxide, lead, lithium, pseudoephedrine, ephedrine, cobalt, anabolic steroids, 
hydroxychloroquine, clozapine, and catecholamines [38, 41]. Possible causes of 
toxic cardiomyopathy are summarized in Figure 2.
2.4.1.4 Arrhythmia-induced DCM
Tachycardia-induced cardiomyopathy was described more than 100 years ago 
by Gossage et al. as a reversible form of systolic dysfunction caused by long-lasting 
supraventricular or ventricular arrhythmias [42]. Ongoing rapid atrial or ventricu-
lar pacing may result in systemic changes by neurohormonal activation, character-
ized by reduction in serum sodium, activation of the renin-angiotensin system, 
and an increase of plasma atrial natriuretic peptide, aldosterone, and norepineph-
rine. Abnormal myocardial and cellular remodeling occurs, which may result in 
DCM. Furthermore, epinephrine can also lead to abnormal myocardial and cellular 
remodeling, which further result in biventricular dilatation, decreased contractility, 
and elevation of left and/or biventricular filling pressure [26].
2.4.1.5 Infiltrative diseases
Several, systemic diseases may infiltrate the myocardium and result in 
DCM. Sarcoidosis, iron overload, and amyloidosis represent the most common 
clinical entities. Sarcoidosis is a multisystem inflammatory disease of unknown ori-
gin characterized by non-caseating granulomas in multiple organs. Sarcoidosis can 
progress to a fibrotic stage leading to DCM [26]. In the setting of iron overload, such 
as hereditary hematochromatosis, high blood volume, or parenteral iron infusions, 
Figure 2. 
Reasons for toxic cardiomyopathies.
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DCM may occur due to iron-induced reactive oxygen species with cellular oxidative 
stress and fibrosis [43]. Cardiac amyloidosis is the most common cause of infiltra-
tive cardiomyopathy with poor prognosis. Amyloid is an extracellular tissue deposi-
tion of misfolded amyloid protein-fibrils [44]. Cardiac amyloidosis usually presents 
as a cardiomyopathy with restrictive pathophysiology and can progress to severe 
cardiac dysfunction and to DCM in very advanced stages [26].
2.4.1.6 Endocrine/metabolic disorders
Endocrinologic disorders rarely lead to the phenotype of DCM. Especially thyroid 
hormones have a significant impact on cardiac function and structure via regulation 
and expression of key structural and regulatory genes like myosin heavy chain and 
phospholamban. Therefore, excess or deficiency of triiodothyronine (T3) may lead 
to DCM in a late stage [45]. Growth hormone disorders, pheochromocytoma, and 
Cushing’s disease are also very rare causes of DCM [26, 46]. Furthermore, the litera-
ture names nutritional deficiencies of thiamine (beriberi disease), selenium (Keshan 
disease), and l-carnitine being responsible for DCM [47, 48].
2.4.1.7 Neuromuscular disorders
Neuromuscular disease like Duchenne’s muscular dystrophy, Becker muscular 
dystrophy, and Emery-Dreifuss muscular dystrophy can affect the heart and induce 
DCM. Patients with DCM and muscular dystrophy commonly show X-linked muta-
tions or autosomal recessive inheritance [24]. Further information is summarized in 
the following section on genetic causes of DCM.
2.4.2 Genetic causes of DCM
In up to 30% of the cases, a gene mutation may be identified as the main cause 
of DCM [49]. Thanks to advances in next-generation sequencing technologies more 
than 40 genes have already been identified causing DCM [50]. Most commonly, 
familial DCM is inherited as an autosomal dominant pattern. Autosomal recessive, 
X-linked, and mitochondrial inheritance patterns are less common [24]. Most of 
the genes involved in the development of DCM encode structural elements of the 
cardiomyocytes. Mutations in genes encoding sarcomeric, cytoskeletal, desmo-
somal, nuclear membrane, mitochondrial, and RNA-binding proteins have all been 
linked to DCM [51]. Interestingly, several of the gene mutations linked to autosomal 
dominant DCM encode the same contractile proteins that are also responsible for 
the development of HCM [38]. As well, other affected genes are described in ARVC 
and left ventricular non-compaction cardiomyopathy (NCCM). In the following, we 
will describe the most investigated gene mutations and their consequences on the 
cardiomyocyte functioning.
2.4.2.1 Sarcomere protein location: force generation and transmission
The sarcomere is the contracting unit of the myocyte. The thin filaments of 
the sarcomere emanate from the Z-disc. They consist of filamentous α-actin (gene 
name ACTC 1) and calcium-sensitive troponin-tropomyosin regulatory apparatus 
(encoded by TPM1), which includes the three troponin subunits (encoded by 
TNNT2, TNNC1, and TNNI3) [52, 53]. The thick filament core is formed by the 
β-myosin heavy chain (encoded by MYH7), the molecular motor of the thick fila-
ment, and the myosin-binding protein C (β-MYBPC3) [52, 53]. Titin (encoded by 
TTN), which is the largest human protein, spans the half length of the sarcomere, 
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where it acts as a stretch sensor and myofibril stabilizer. It limits sarcomere stretch 
in early diastole and restores resting sarcomere length after contraction [52, 53]. 
Titin (TTN) mutations are the most prevalent genetic cause of idiopathic DCM 
(15–20%). In fact, DCM patients with TTN mutations have a worse outcome due 
to a higher arrhythmic risk and progressive functional deficits [54]. Mutations in 
human genes encoding protein components of the sarcomere cause either HCM or 
DCM. Deficits of force production and transmission are the two main mechanisms 
that lead to DCM due to sarcomere mutations [55]. Mutations of genes encoding 
myosin proteins (MYH 6, MYH7, and MYBPC3), actin proteins (ACTC 1 and ACTC 
2), and tropomyosin protein (TPM 1) result in alterations of coupling-uncoupling 
mechanisms of actin to myosin [50]. Specifically, TPM1 mutations are associated 
with destabilization of actin interactions and compromise force transmission to 
neighboring sarcomeres. ACTC mutations impair the binding of actin to the Z-disc 
compromising force propagation [55]. Impaired contractile force may also occur 
from troponin mutations. Because troponin molecules modulate calcium-stimu-
lated actomyosin ATPase activity, the mutation causes inefficient ATP hydrolysis 
and decrease contractile strength [55].
2.4.2.2 Cytoskeleton protein location: force transmission and structural integrity
The Z-disc is an electron-dense structure, in which titin and the thin filaments 
anchor. Critical components include α-actinin, which aligns actin and titin from 
neighboring sarcomeres and interacts with muscle LIM protein (MLP encoded by 
CSRP3). Telethonin (encoded by TCAP) is another Z-disc component interacting 
with titin and MLP to support overall sarcomere function. In addition, Cipher/Z-
band alternatively spliced PDZ-motif protein (Cipher/ZASP encoded by LDB3), 
which interacts with α-actinin-2 through a PDZ domain, an abundant protein 
interaction modules that recognize short amino acid motifs of the C-termini of 
target proteins, and couples to protein kinase C (PKC)-mediated signaling via its 
LIM domains [55, 56]. Gene mutations of multiple Z-disc proteins like MLP, car-
diac ankyrin repeat protein (CARP), myopalladin, α-actinin 2, TCAP, and nexilin 
may result in DCM [52]. Cipher/ZASP mutations have been associated to isolated 
left ventricular dilatation or DCM with NCCM phenotype [50]. Metavinculin 
(encoded by VCL) attaches the thin filaments to the plasma membrane and plays 
a key role in force transmission. Gene mutations in metavinculin cause DCM by 
disruption of disc structure and actin-filament organization [55]. The costamere, 
a rib-like structure of the cytoplasmatic and transmembrane proteins, intercon-
nects the cytoskeleton to the plasma membrane and the extracellular matrix. 
Dystrophin and its associated proteins, sacroglycans and dystroglycan, enrich 
at the costamere and protect against contraction-induced injury [52]. The integ-
rity of the dystrophin complex is critical for mechano-transduction and loss of 
function mutations trigger instability of the plasma membrane and myofiber loss. 
This mechanism leads to Duchenne and Becker muscular dystrophy [57]. Desmin, 
another intermediate filament in cardiomyocytes, forms a 3D scaffold that 
extends across the entire diameter of the cardiomyocyte, surrounds the Z-discs 
and interlinks them together and integrates the contractile apparatus with the 
sarcolemma and the nucleus. Desmin helps to sense mechanical stretch and trans-
duces downstream signals from extracellular to the nucleus. In addition, desmin 
plays a crucial role during myogenesis. Inhibition of desmin expression blocks 
myoblast fusion and myotube formation [58]. Mutations in the desmin genes are 
associated with an autosomal dominant skeletal myopathy, cardiac conduction 
block, and DCM [59]. Prevalence of desmin mutations in familial DCM have been 
reported in 1–2% [60].
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2.4.2.3 Desmosomes: cell-cell adhesion and intracellular signaling/mechano-signaling
Desmosomes are organized cell membrane structures that provide functional and 
structural contact between adjacent cells. Mutations in protein components of desmo-
somes like plakoglobin, desmoplakin, and plakophilin-2 can cause syndromic and non-
syndromic ARVC as well as DCM due to disruption of intercellular junction [55, 61].
2.4.2.4 Sarcoplasmic reticulum: calcium homeostasis
Calcium enters the myocyte through voltage-gated L-type Ca2+-channels. This 
triggers the release of calcium from the sarcoplasmic reticulum (SR) via the ryanodine 
receptor 2 (RyR2). At low intracellular calcium concentrations, troponin I and actin 
interactions block actomyosin ATPase activity. With increasing intracellular concen-
tration, calcium binds to troponin C, which releases troponin I inhibition and stimu-
lates contraction. Calcium dissociates from troponin C in cardiac relaxation. Calcium 
concentration decreases by calcium reuptake in the SR through the phospholamban-
regulated cardiac sarcoplasmic reticulum CA2+-ATPase (SERCA2a) [55]. Mutations 
of phospholamban precipitate DCM by altering calcium homeostasis [54]. Specific 
phospholamban mutation R14del is associated with high risk of malignant ventricular 
arrhythmias and end-stage HF. Further, it is described in a phenotype of ARVC [62].
2.4.2.5 Nuclear envelope: maintain structural organization
The nuclear membrane protein complex contains emerin and lamin A/C (LMNA) 
[52, 55]. These two lamina proteins and nesprin-1 are part of the LINC complex that 
links the nucleus to the cytoplasm. Stress signals in the cytoplasm are hypothesized to 
act with the LINC complex, affecting gene expression in the nucleus. The LINC com-
plex is crucial for an appropriate transcriptional response of the cell to mechanical 
stress [52]. Defects in emerin proteins can induce X-linked Emery-Dreifuss muscular 
dystrophy, joint contractures, conduction system disease, and DCM. Dominant 
lamin A/C (encoded by LMNA) mutations exhibit a more cardiac-restricted pheno-
type with fibrofatty degeneration of the myocardium and it is conducting system. 
More than 200 different lamin A/C (LMNA) mutations are associated with inherited 
cardiomyopathy, primarily DCM that may be associated with conduction system 
disease prior to the evidence of ventricular dilatation due to fibrofatty degeneration 
of the myocardium and conducting cells [52, 55]. Other diseases caused by lamin A/C 
mutations are Charcot-Marie-Tooth neuropathy, Dunningan partial familial lipodys-
trophy, progeria and other overlapping syndromes, all known as laminopathies [63].
2.4.2.6 Ion channel
The function of sarcolemmal transmembrane cardiac voltage-gated sodium channel 
is crucial in the generation of cardiac action potentials. Some mutations in the encoding 
gene SCNA5 are implicated in DCM. SCN5A mutations causes high burden of arrhyth-
mias. There are also many allelic variants in SCN5A, including those leading to Brugada 
syndrome, idiopathic ventricular fibrillation (VF), familial atrial fibrillation (AF), left 
ventricular non-compaction cardiomyopathy, and long QT syndrome type III [54, 59, 64].
2.4.2.7 Extracellular matrix-cell-adhesion and signaling
Extracellular matrix proteins such as laminin alpha-4 (LAMA4) and Fukutin 
(FKTN) have been described in relation to DCM. They may lead to DCM phenotype 
by disrupting signaling pathways and modifying cell-surface molecules [50].
The genetic evaluation of DCM is summarized in Table 2.
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(ACTC 1 and ACTC 2)
• α-Tropomyosin 1 (TPM 1)
• Cardiac troponin subtypes
(TNNT2, TNNC1, TNNI3)
• Myosin heavy chains
(MYH 6, MYH7)
• Myosin-binding protein C 
(MYBPC)
• Troponin I-interacting kinase 
(TNNI3K)
• 12–25% of genetic related DCM are associated with titin 
(TTN) mutations
• α-Tropomyosin 1 (TPM 1) mutations are described in 1–2% 
of DCM
• Myosin heavy chain (MYH7)-mutations in 3–4% of DCM
• 3% of DCM are linked to cardiac troponin T (TNNT2) 
mutations
• Gene defects in sarcomere proteins are associated with 
defects in force generation and transmission








• α-Actinin 2 (ACTN 2)
• Muscle LIM protein (MLP)




• PDZ LIM domain protein 3
(PDLIM3)







(SGCA, SGCB, SGCD, and 
SGCG)
• Desmin (DES)
• Metavinculin (CVL) mutations are related to 1% of DCM
• Dystrophin (DMD) mutations are associated with 
Duchenne/Becker muscular dystrophy
• Sacroglycan (SDC) mutations can cause Limb-girdle-
muscular dystrophy
Prevalence of Desmin (DES) mutations in genetic related 
DCM is about 1–2%, the mutations are often related with 






• Desmocollin 2 (DSC2)
• Desmoglein 2 (DSG2)
• Plakophilin-2 (PKP2)
• Mutations in desmosomal genes are frequent in patients 
with advanced DCM undergoing cardiac transplantation
• Desmosomal gene mutations are also linked to ARVC
• Desmoplakin (DSP) causes 2% of genetic related DCM
• Plakoglobin (JUP)-mutations are also associated with 
Naxos syndrome





• Ryanodine receptor 2 (RyR2)
• Phospholamban (PLN)
• SR proteins, Ca-ATPase pump 
(SERCA2a)
• Specific mutations are associated with high risk of malig-
nant ventricular arrhythmias and end-stage heart failure
• Ryanodine receptor 2 (RyR2) correlates with cathecola-
minergic polymorphic ventricular tachycardia and ARVC
• Phospholamban (PLN) mutations can cause ARVC
• Some other genes encoding for sarcoplasmic reticulum and 
cytoplasm related proteins like PTPN11, RAF1 and RIT1 
are also associated with Noonan and Leopard Syndrome
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2.5 Diagnosis
Establishing the etiology is of great importance as it may influence treatment 
and prognosis of patients with DCM. Beside the conventional clinical tools, modern 
imaging and genetic tools are available to elucidate and ensure the correct diagno-
sis. The recently published statement for the diagnostic workup on DCM from the 
ESC working group on myocardial and pericardial diseases recommend the follow-
ing steps: first the diagnostic evaluation should be start with in-depth personal and 
family history, followed by physical examination, an electrocardiogram (ECG), and 
echocardiography [8]. These steps often sufficiently differentiate between acquired 
and familial DCM. If there is no suspicion of an acquired DCM and if ‘red flags’ are 
recognized, the second-level diagnostic work-up should be added. ‘Red flags’ are 
defined as signs and suspicion on a specific etiology. Biochemical analyses, cardiac 
magnetic resonance imaging (CMR), endomyocardial biopsy (EMB), and genetic 
testing are recommended in a second step. However, the patient’s age plays a crucial 
role in the decision-making during the diagnostic procedure and should be rated 
against the potential benefit of dedicated investigations. The detailed diagnostic 
workup and possible red flags are presented in Table 3.
2.6 Screening
In common, DCM is a slowly progressive disease and screening is essential 
for an early diagnosis of asymptomatic family members. Currently, screening all 
first-degree family members of patients with genetic proven or non-genetic forms 










• Lamin A/C (LMNA)
• EMD mutations can lead to X-linked Emery-Dreyfuss 
muscular dystrophy, joint contractures and conduction 
system disease
• Prevalence of genetic-related DCM due to LMNA mutation 
is described in 4–8%
• LMNA-related heart failure is often more resistant to heart 
failure therapy and has a high risk for arrhythmias and 
sudden cardiac death
• Mutations in LMNA can cause a severe and progressive 
DCM and can also lead to Charcot-Marie-Tooth neuropa-
thy, Dunningan partial familial lipodystrophy, Emery-




• Sodium channel, voltage-
gated, type V, alpha subunit 
(SCNA5)
• Potassium channel (KCNQ1)
• SCN5A mutations account for 2–3% of DCM, muta-
tions are associated with Brugada syndrome, Long QT 
syndrome, atrial fibrillation and conduction defects
• KCNQ1 mutations may induce atrial fibrillation, Long QT 




• Laminin alpha-4 (LAMA4)
• Fukutin (FKTN)
• Extracellular matrix protein relation has been described 
to DCM
• FKTN and LAMA2 mutations can also cause congenital 
muscular dystrophy
Table 2. 
Genetic aspects of dilated cardiomyopathy.
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Genetic aspects of dilated cardiomyopathy.
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physical examination, 12-lead ECG and transthoracic echocardiography as well as 
measurement of CK levels. The CK levels may help to identify subclinical skeletal 
muscle abnormalities and to provide supportive evidence for the presence of an 
inherited myopathy. If DCM is suspected in first-degree relatives, the screening 
should be repeated anually. Otherwise, asymptomatic first-degree relatives should 
be rescreened at three- to five-year intervals because of possible late onset of DCM 
phenotype [21].
Diagnostic tool Look for Red flags for specific disorders





Toxin exposition Involvement of other 
organs




Skin abnormities, for example, 
hyperpigmentation and palmoplantar 
keratoderma, butterfly-shaped face rash
Woolly hair
Electrocardiogram Low P-wave amplitude
Atrioventricular block






24 h electrocardiogram Relevant brady- and tachyarrhythmias Relevant tachyarrhythmias









Serum iron, ferritin and 
electrophoresis
Urine chemistry and proteinuria
Serum free light chains
HIV and hepatitis serology
Other specific serology tests in 
accordance symptoms and clinical 
suspicion
High levels of creatine kinase
Myoglobinuria
Increased serum iron & ferritin levels
Leucopenia or neutropenia








Segmental dysfunction with noncoronary 
distribution
Coronary angiography Exclude coronary artery disease





Patchy or inferobasal late gadolinium 
enhancement (LGE) distribution
“Midwall sign” septal wall LGE distribution
EBM Giant cell myocarditis
Genetics Screening familial DCM
Table 3. 
Diagnostic workup and possible red flags in dilated cardiomyopathy.
51
Current Pathophysiological and Genetic Aspects of Dilated Cardiomyopathy
DOI: http://dx.doi.org/10.5772/intechopen.83567
2.7 Therapy
Specific treatment is applicable in syndrome associated DCM, for example, 
infectious etiologies and infiltrative disorders. However, specific treatment is not 
available for most DCM patients. Therefore, the therapy focuses on improvement 
of clinical symptoms as well as on the control of disease progression and potential 
complications such as sudden cardiac arrest.
2.7.1 Heart failure treatment
Guidelines recommend the following treatment for acute HF, not including non-
cardiogenic shock: oxygen, non-invasive ventilation (NIV), intravenous diuretics 
(20–40 mg bolus furosemide at admission), and intravenous nitrates. Intravenous 
nitrates have long been described to improve hemodynamic and dyspnea in HF 
patients by many ways: decrease in systemic blood pressure and left ventricular 
afterload, substantial reduction preload and therefore of in right and left ventricular 
filling pressure, an increase in cardiac output, and little or no change in heart rate 
[65]. Improvement in cardiac output by intravenous nitrates is mostly related to the 
reduction in left ventricular afterload, but is also influenced by a decrease in pulmo-
nary vascular resistance, improvement in myocardial oxygenation, and a reduction 
of mitral regurgitation. Administration of inotropes and/or vasopressors is recom-
mended in patients with signs of low cardiac output [66]. However, application of 
inotropes and/or vasopressors is associated with an increased long-term mortality 
risk [67–69]. Additional treatment includes the optimal dosing of angiotensin-
converting enzyme inhibitors (ACEI) or angiotensin receptor blockers (ARB). ACEI 
have been shown to reduce cardiovascular mortality and prevent rehospitalization 
in patients with HF in two key randomized controlled trails (CONSENSUS and 
SOLVD-Treatment) [70]. Likewise, ARB improve long-term outcome in HF patients 
[71]. Another essential component of HF therapy is spironolactone. The RALES 
study has shown a reduction in mortality after addition of 25 mg of spironolactone 
to the standard treatment in HF patients with an LVEF <35% [72]. The international 
guidelines recommend spironolactone in all patients presenting with moderate to 
severe HF symptoms. In the PARADIGM-HF trial, the use of angiotensin receptor-
neprilysin inhibitor (ARNI) (sacubitril/valsartan) showed a reduction of the com-
posite endpoint of cardiovascular death or HF hospitalization by 20% compared with 
enalapril alone in symptomatic HF patients with reduced LVEF [73]. These study 
results are implemented in the updated ACC/AHA/HFSA guidelines on management 
of HF, which recommend to replace ACEI or ARB by sacubitril/valsartan in patients 
with reduced LVEF and ongoing symptoms [74]. Betablockers reduce mortality in HF 
patients even without reduced ejection fraction as has been demonstrated by multi-
center placebo-controlled studies [75–77]. Because of the negative inotropic effect of 
betablockers, patients should not be treated in the very acute presentation with signs 
or symptoms of decompensation and initial doses should be low. Long-term goal is a 
heart rate below 70 bpm in sinus rhythm. If this is not obtainable with the maximum, 
or maximum tolerated dose of betablockers, the current European heart failure 
guidelines recommend the addition of Ivabradine [66]. In addition to pharmacologi-
cal medication cardiac resynchronization therapy (CRT) has been shown to improve 
cardiac performance, to reduce symptoms, morbidity, and mortality [78, 79].
2.7.2 Anticoagulation
The role of anticoagulation in DCM with sinus rhythm is unclear [80]. The 
prospective randomized trials were either underpowered or with a too short 
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available for most DCM patients. Therefore, the therapy focuses on improvement 
of clinical symptoms as well as on the control of disease progression and potential 
complications such as sudden cardiac arrest.
2.7.1 Heart failure treatment
Guidelines recommend the following treatment for acute HF, not including non-
cardiogenic shock: oxygen, non-invasive ventilation (NIV), intravenous diuretics 
(20–40 mg bolus furosemide at admission), and intravenous nitrates. Intravenous 
nitrates have long been described to improve hemodynamic and dyspnea in HF 
patients by many ways: decrease in systemic blood pressure and left ventricular 
afterload, substantial reduction preload and therefore of in right and left ventricular 
filling pressure, an increase in cardiac output, and little or no change in heart rate 
[65]. Improvement in cardiac output by intravenous nitrates is mostly related to the 
reduction in left ventricular afterload, but is also influenced by a decrease in pulmo-
nary vascular resistance, improvement in myocardial oxygenation, and a reduction 
of mitral regurgitation. Administration of inotropes and/or vasopressors is recom-
mended in patients with signs of low cardiac output [66]. However, application of 
inotropes and/or vasopressors is associated with an increased long-term mortality 
risk [67–69]. Additional treatment includes the optimal dosing of angiotensin-
converting enzyme inhibitors (ACEI) or angiotensin receptor blockers (ARB). ACEI 
have been shown to reduce cardiovascular mortality and prevent rehospitalization 
in patients with HF in two key randomized controlled trails (CONSENSUS and 
SOLVD-Treatment) [70]. Likewise, ARB improve long-term outcome in HF patients 
[71]. Another essential component of HF therapy is spironolactone. The RALES 
study has shown a reduction in mortality after addition of 25 mg of spironolactone 
to the standard treatment in HF patients with an LVEF <35% [72]. The international 
guidelines recommend spironolactone in all patients presenting with moderate to 
severe HF symptoms. In the PARADIGM-HF trial, the use of angiotensin receptor-
neprilysin inhibitor (ARNI) (sacubitril/valsartan) showed a reduction of the com-
posite endpoint of cardiovascular death or HF hospitalization by 20% compared with 
enalapril alone in symptomatic HF patients with reduced LVEF [73]. These study 
results are implemented in the updated ACC/AHA/HFSA guidelines on management 
of HF, which recommend to replace ACEI or ARB by sacubitril/valsartan in patients 
with reduced LVEF and ongoing symptoms [74]. Betablockers reduce mortality in HF 
patients even without reduced ejection fraction as has been demonstrated by multi-
center placebo-controlled studies [75–77]. Because of the negative inotropic effect of 
betablockers, patients should not be treated in the very acute presentation with signs 
or symptoms of decompensation and initial doses should be low. Long-term goal is a 
heart rate below 70 bpm in sinus rhythm. If this is not obtainable with the maximum, 
or maximum tolerated dose of betablockers, the current European heart failure 
guidelines recommend the addition of Ivabradine [66]. In addition to pharmacologi-
cal medication cardiac resynchronization therapy (CRT) has been shown to improve 
cardiac performance, to reduce symptoms, morbidity, and mortality [78, 79].
2.7.2 Anticoagulation
The role of anticoagulation in DCM with sinus rhythm is unclear [80]. The 
prospective randomized trials were either underpowered or with a too short 
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follow-up. At present, there are no trial data to guide anticoagulant treatment 
regime in DCM. Due to two studies (WATCH and WARCEF trial) showing a slight 
advantage of warfarin over aspirin, anticoagulation with warfarin is advised in 
patients with a history of thromboembolism or evidence of intracardiac thrombus 
[81, 82]. Current ACC/AHA HF guidelines do not recommend anticoagulation in 
reduced left ventricular function and sinus rhythm without prior thromboem-
bolic events or known cardioembolic source [83]. Studies testing the non-vitamin 
K antagonist oral anticoagulants (NOACs) in patients with reduced left ventricu-
lar function are currently ongoing. In DCM patients with documented AF, oral 
anticoagulant is recommended with CHA2DS2-VASc score ≥ 2, as a class I indica-
tion and in men with a CHA2DS2-VASc score of 1 as class IIa with level of evidence 
B [66, 77, 83, 84].
2.7.3 Arrhythmias
The most common arrhythmia in DCM is AF, which increases the risk of 
thromboembolic complications, impairs cardiac function and worsening HF 
symptoms. Therefore, evaluation of rate control and anticoagulation in order to 
preserve LV-function and prevent thromboembolic events is crucial. In the acute 
setting betablockers, digoxin and their combination may be used to control ven-
tricular rate. In the chronic stage, rhythm control has been shown to be superior 
to rate control alone in reducing mortality [85]. Because of the commonly reduced 
left ventricular function, the only therapeutic option is type III antiarrhythmic 
drug such as amiodarone. Alternatively, electrical cardioversion can be performed. 
Recently, the CASTLE-AF study demonstrated the superiority of AF catheter 
ablation in certain patients with HF as compared to medical therapy. The ablation 
was associated with a significantly lower rate of death and hospitalization for 
worsening HF [86]. DCM patients may suffer from ventricular arrhythmias (VA), 
which are mainly caused by myocardial damage, fibrosis and/or loss of cell-to-cell 
conjunctions, that are described by three mechanisms: reentry, trigger activity, 
and automatism [87]. Monomorphic ventricular tachycardias (VTs) are frequently 
induced by macro-reentry mechanism, which is best treated by ablation. The 
main trigger mechanisms are electrolyte imbalance, mostly secondary to diuretic 
treatment, antiarrhythmic drugs, and bradycardia. The therapeutic options are a 
combination of antiarrhythmic drugs like betablockers and type III antiarrhyth-
mics and/or implantation of an implantable cardioverter defibrillator (ICD). The 
indications for ICD treatment are described later [4].
2.8 Prognosis and risk stratification
Although there has been a significant improvement in prognosis of DCM 
patients over the last decades, mortality is still high. The prognosis is mainly influ-
enced by HF symptoms and more relevant by the appearance of VTs. Survival data 
of adults with DCM have shown a one-year mortality of 25–30% and a 50% survival 
at 5 years. Sustained VT or VF presents the main cause for SCD, which occurs in up 
to 12% of DCM patients [4, 88]. In general, the prevalence of sustained VT (mono-
morphic or polymorphic) is estimated as less than 5% [89]. Recently, the Pediatric 
Cardiomyopathy Registry presented a 5-year incidence rate of SCD in children with 
DCM of 3% [90]. An age at diagnosis below 14 years, LV dilation, and posterior wall 
thinning were identified as the most important risk factors. In contrast, the mortal-
ity in adults is mostly associated with age and male gender, reduced New York Heart 
Association (NYHA) functional class, impaired LVEF, and the presence of specific 
cardiac biomarkers as well as myocardial fibrosis in CMR [91–94]. Furthermore, 
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genetic aspects play an important role for detection of high-risk patients. Most 
commonly the pathogenic mutation in the lamin A/C (LMNA) gene is associated 
with atrial and ventricular arrhythmias. LMNA mutation has been identified as the 
most malignant and penetrant condition with worse outcomes compared to other 
forms of DCM [95]. Beside risk models such as the Seattle Heart Failure Model for 
the prediction of prognosis in the general population of HF patients, there exist no 
specific risk tools for DCM patients [96]. For the identification of high-risk DCM 
patients, a personalized and precise approach is required (Table 3). This should 
include the personal and familial history, measurement of LVEF, detailed search 
for VA and proof of fibrosis using CMR. Other promising approaches are expected 
to be helpful in decision-making in high-risk DCM patients, determination of 
microvolt T-wave alternans analysis and detection of autonomic dysfunction using 
nuclear imaging. In addition, detection of LMNA gene mutation has been described 
to identify the high-risk DCM population. However, all these approaches need 
further research.
2.9 Prevention of sudden cardiac death
The most effective therapy of malignant VTs and thus prevention of SCD in 
DCM patients is the implantation of an ICD. Current ESC guidelines recommend 
the implantation of a defibrillator in patients who experienced VT or VF (secondary 
prevention of sudden cardiac death), as well as in high risk patients for primary 
prevention. The latter are patients with symptomatic HF NYHA class II–III and 
LVEF ≤35% after ≥3 months of optimal medical therapy who are expected to 
survive for at least 1 year [97]. Similarly, the American College of Cardiology and 
American Heart Association guidelines recommend ICD therapy in patients with 
LVEF ≤35% due to prior myocardial infarction (MI), at least 40 days post-MI, or 
non-ischemic DCM and NYHA class II or III [98]. However, existing guidelines 
lack sensitivity and specificity for the selection of patients with DCM for primary 
prevention ICD implantation. A recently presented meta-analysis by Golwala 
et al. has demonstrated a 23% reduction in all-cause mortality with ICD therapy 
compared with optimal medical therapy alone (HR, 0.77; 95% CI, 0.64–0.91) [99]. 
Although ICD implantation seems to be the best possible option for SCD preven-
tion in DCM, there remain potential complications. Inappropriate shocks, risk of 
infection, device or lead replacement have to be considered and discussed in detail 
before an ICD is implanted.
3. Conclusion
DCM includes a heterogeneous group of myocardial and systemic conditions 
causing left ventricular dilatation and dysfunction. DCM is one of the most 
common cardiomyopathies worldwide. Yet, the real prevalence is unknown. The 
etiology contains non-genetic (e.g. myocarditis, peripartum, toxics, arrhyth-
mia, infiltrative etiologies, endocrine, nutritional, and neuromuscular) and 
genetic causes. Literature on genetic mutations being responsible for DCM has 
increased exponentially. Today, up to 30% of the DCM cases are described to 
be caused by a gene mutation, the majority of which occur in autosomal genes 
that encode for a wide range of proteins of the cardiomyocyte’s structural 
elements. Mutations in genes encoding sarcomeric, cytoskeletal, desmosomal, 
nuclear membrane, mitochondrial, and RNA-binding proteins have all been 
linked to DCM. However, the most common mutations occur in genes encod-
ing sarcomeric proteins and in genes related to the nuclear envelope and the 
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the implantation of a defibrillator in patients who experienced VT or VF (secondary 
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common cardiomyopathies worldwide. Yet, the real prevalence is unknown. The 
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ing sarcomeric proteins and in genes related to the nuclear envelope and the 
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cytoskeleton. Therefore, the diagnostic workup of DCM should involve the 
clinical tools as well as imaging and gen-technologies. Specific treatment is only 
available for syndrome-associated DCM. The majority of the DCM patients are 
treated for HF symptoms, prevention of thromboembolic events, and malign 
arrhythmias. The prognosis of DCM patients is variable and depends on multi-
ple risk factors. Some, for example, LVEF and NYHA functional class are known 
for years as risk factors of SCD, others need further research before they can be 
established in clinical routine.
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Cardiac disease modeling is crucial to improve our understanding of the mecha-
nism of various cardiac diseases and to discover new therapeutic approaches. Several 
modeling methods such as animal and computer simulations have been used to elu-
cidate the cardiac diseases’ mechanism and drug responses. However, each modeling 
technique has its own particular advantages and limitations. Human-based models 
would be particularly useful to investigate human cardiac diseases because humans 
and animals have differing cardiac physiologies and drug tolerability. In addition, 
the phenotype of cardiac diseases and response to therapeutic intervention differ not 
only between mutations but also among patients. Therefore, such diseases strongly 
demand the individualized/personalized strategies. Human-induced pluripotent 
stem cell-derived cardiomyocytes (hiPSC-CMs) offer the striking feature of retain-
ing the same genetic information as donor, which guide us to investigate diseases 
and predict response to drug treatment individually. This feature of hiPSC-CMs is 
superior to the conventional in vitro modeling of cardiac diseases. Thus far, hiPSC-
CMs have been successfully recapitulated many monogenic and also complex genetic 
cardiac diseases. hiPSC-CMs could be differentiated into different types of cardio-
myocytes and non-cardiomyocyte cells, which empower us to understand cardiac 
chamber-specific arrhythmias such as atrial fibrillation and ventricular tachycardia.
Keywords: cardiac disease, modeling, hiPSC-CMs, drug
1. The importance of hiPSC-CMs
Cardiovascular diseases (CVDs) are the major causes of premature death and 
chronic disability worldwide [1]. Among CVD-related deaths, the occurrence of 
inherited lethal arrhythmias is the main reason for sudden cardiac death (SCD) in 
cardiac patients especially at young age [2]. Although many risk factors associated 
with SCD have been identified and understanding of pathogenesis of many cardiac 
diseases is progressing, the considerable number of cardiac patients still suffers SCD 
without warning, and we are still far from disease-specific treatment. Heterogeneous 
and multifactorial natures of genetic cardiac diseases are reasons for these complica-
tions. Furthermore, founder mutations causing cardiac disease have been reported in 
Finland [3], the Netherlands [4], and South Africa [5]. Not only disease phenotypes 
vary among different mutations, but also these vary among individuals carrying the 
same mutation. For example, long QT syndrome (LQTS) patients demonstrate a wide 
range of clinical phenotypes even among family members with the identical muta-
tion [6]. Despite carrying the same gene variant resulting in cardiac disease, patients 
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same mutation. For example, long QT syndrome (LQTS) patients demonstrate a wide 
range of clinical phenotypes even among family members with the identical muta-
tion [6]. Despite carrying the same gene variant resulting in cardiac disease, patients 
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often demonstrate the wide spectrum of clinical outcomes ranging from the absence 
of distinct electrocardiogram (ECG) abnormalities and being lifelong asymptomatic 
to clear abnormalities in ECG (e.g., prolonged QT interval and arrhythmias) and pre-
mature SCD. In addition, SCD could also be the first manifestation of cardiac disease. 
These suggest that the type of genetic mutation cannot always be the sole factor that 
dictates the prognosis of disease and clinical phenotype in all individuals who carry 
it [7]. Thus, genetic cardiac diseases exhibit the incomplete penetrance and differ 
among genetic cardiac diseases. For example, Brugada syndrome (BrS) has a penetra-
tion range from 12.5 to 50%; mean penetrance of LQTS is ~40%, while overall pen-
etrance of catecholaminergic polymorphic ventricular tachycardia (CPVT) is 78% 
[7]. Another convoluting factor that hinders the genotype-phenotype correlation is 
variable expressivity within one phenotype because some mutation carriers display 
all the phenotypic symptoms, whereas some only display part of mutation-specific 
phenotypes [8]. The clinical heterogeneity of genetic cardiac diseases suggests that 
ultimate disease severity (i.e., penetrance and expressivity) does not solely depend 
on one particular gene causing cardiac disease, but instead results from the combina-
tion of many modifying factors such as age, gender, and environmental and lifestyle 
factors, which either exacerbate or protect against disease [9]. In addition, patients 
carrying more than one disease-causing mutations (i.e., not polymorphisms) either 
in the same gene or different genes yield to more severe clinical disease including 
earlier onset of disease, early heart failure, and premature SCD [10]. Besides these, 
some of the cardiac diseases overlap their phenotypes with other cardiac diseases 
(Figure 1). For example, mutations in cardiac sodium (Na+) channel gene, SCN5A, 
are associated with type 3 long QT (LQT3), BrS, cardiac conduction diseases, and 
sinus node dysfunction [11]. These incomplete penetrance, variable expressivity, and 
phenotypic overlap impede the complete understanding of diseases’ mechanism as 
well as disease-specific treatment. Furthermore, the treatment therapies are mainly 
targeted for symptomatic patients to prevent and counteract the symptoms, but 
treatments in asymptomatic individuals are still of concern with variable opinions. 
Nevertheless, pharmacological therapies have been resulted in poor outcomes in the 
Figure 1. 
Heterogeneity of genetic cardiac diseases. (A) Overlapping genes causing channelopathies [27]. Brugada 
syndrome (BrS), long QT syndrome (LQTS), short QT syndrome (SQTS), catecholaminergic polymorphic 
ventricular tachycardia (CPVT) (ref). (B) Overlapping genes causing cardiomyopathies [72]. Arrhythmogenic 
right ventricular cardiomyopathy (ARVC), dilated cardiomyopathy (DCM), hypertrophic cardiomyopathy 
(HCM), restrictive cardiomyopathy (RCM), left ventricular non-compaction cardiomyopathy (LVNC).
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cardiac diseases [12]. So far, implantable cardioverter-defibrillator (ICD) is the only 
proven therapy for preventing detrimental consequences in cardiac patients with high 
risk of SCD [13]. However, ICD implantation is associated with its own complications 
and lower quality of life [14]. There are large groups of asymptomatic cardiac patients 
who do not have risk factors, which shift them into high-risk category as candidate 
for ICD implantation, but suffer SCD. Thus, the management for asymptomatic 
patients carrying pathogenic variant is the most challenging since SCD could be 
the first manifestation of disease [15, 16]. The clinical management of most cardiac 
diseases is suboptimal due to lack of comprehensive knowledge of mutations and 
possible mechanism involved. Thus, the mechanism of how mutation leads to modify 
the normal cardiac physiology and engender lethal arrhythmias should be deciphered 
so that the promising prevention and treatment could be established.
The prior cardiovascular research and drug screening have mostly been performed 
in animal models through knock-in/knock-out approaches. Although animal models 
have provided some fundamental information and led to many discoveries in genetic 
cardiac disease, physiological and pharmacological results cannot directly extrapolate 
from animals to humans because of some fundamental differences that exist between 
animal and human cardiac physiology [17]. For example, the resting heart rate of 
human is 75 bpm, while that of rat is 300 bpm, and the animal (mice and rats) can 
tolerate 6–400-fold higher concentration of some drugs compared to human [18]. 
The animal models become even worse when studying human cardiomyopathies due 
to mutations in contractile proteins, which are not highly expressed in mouse or rat. 
Therefore, it is more complicated to extrapolate physiological and pharmacologi-
cal results from animal to human [17, 18]. Furthermore, most of cardiovascular 
drug screening and toxicology studies were performed in non-cardiac cell lines or 
animals, which do not accurately represent human CMs. Thus, considerable amount 
of cardiovascular drugs were withdrawn from market due to off-target effects [19]. 
Therefore, human tissues are required to study the human cardiac diseases and drug 
Figure 2. 
hiPSC-CM-based modeling of human genetic cardiac diseases. Human-induced pluripotent stem cells (hiPSCs) 
can be differentiated into hiPSC-derived cardiomyocytes (hiPSC-CMs). There are at least three subtypes 
of hiPSC-CMs, namely, ventricular-like, atrial-like, and nodal-like hiPSC-CMs. hiPSC-CMs derived 
from cardiac patients carrying genetic mutation recapitulate calcium and electrical abnormalities (early 
afterdepolarization (EAD) and delayed afterdepolarization (DAD)). Newly emerging gene editing techniques 
were able to mitigate these abnormalities in hiPSC-CMs.
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cardiac diseases [12]. So far, implantable cardioverter-defibrillator (ICD) is the only 
proven therapy for preventing detrimental consequences in cardiac patients with high 
risk of SCD [13]. However, ICD implantation is associated with its own complications 
and lower quality of life [14]. There are large groups of asymptomatic cardiac patients 
who do not have risk factors, which shift them into high-risk category as candidate 
for ICD implantation, but suffer SCD. Thus, the management for asymptomatic 
patients carrying pathogenic variant is the most challenging since SCD could be 
the first manifestation of disease [15, 16]. The clinical management of most cardiac 
diseases is suboptimal due to lack of comprehensive knowledge of mutations and 
possible mechanism involved. Thus, the mechanism of how mutation leads to modify 
the normal cardiac physiology and engender lethal arrhythmias should be deciphered 
so that the promising prevention and treatment could be established.
The prior cardiovascular research and drug screening have mostly been performed 
in animal models through knock-in/knock-out approaches. Although animal models 
have provided some fundamental information and led to many discoveries in genetic 
cardiac disease, physiological and pharmacological results cannot directly extrapolate 
from animals to humans because of some fundamental differences that exist between 
animal and human cardiac physiology [17]. For example, the resting heart rate of 
human is 75 bpm, while that of rat is 300 bpm, and the animal (mice and rats) can 
tolerate 6–400-fold higher concentration of some drugs compared to human [18]. 
The animal models become even worse when studying human cardiomyopathies due 
to mutations in contractile proteins, which are not highly expressed in mouse or rat. 
Therefore, it is more complicated to extrapolate physiological and pharmacologi-
cal results from animal to human [17, 18]. Furthermore, most of cardiovascular 
drug screening and toxicology studies were performed in non-cardiac cell lines or 
animals, which do not accurately represent human CMs. Thus, considerable amount 
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hiPSC-CM-based modeling of human genetic cardiac diseases. Human-induced pluripotent stem cells (hiPSCs) 
can be differentiated into hiPSC-derived cardiomyocytes (hiPSC-CMs). There are at least three subtypes 
of hiPSC-CMs, namely, ventricular-like, atrial-like, and nodal-like hiPSC-CMs. hiPSC-CMs derived 
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were able to mitigate these abnormalities in hiPSC-CMs.
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testing. However, the human sample exhibits some of the major challenges: there is 
limited supply of human cardiac biopsies, and it involves complex procedures and 
ethical issues. In addition, these cardiac biopsies are typically obtained from the end 
stage of cardiac diseases; hence it is not possible to understand the mechanism of 
cardiac diseases [20, 21]. These obstacles are mostly overcome by the groundbreaking 
discovery of reprogramming adult somatic cells into induced pluripotent stem cells 
(iPSCs) [22, 23] which can be differentiated into cardiomyocytes (CMs) (hiPSC-
CMs) [24–26]. The main advantages of hiPSC-CMs are iPSCs can be generated at any 
period of a patient’s life, they have unlimited supply, and these retain the same genetic 
information as the donor, i.e., hiPSC-CMs are patient specific (Figure 2). These are 
superior features of hiPSC-CMs to the conventional in vitro modeling of cardiac 
diseases. In addition, hiPSC-CMs can be cultured for several months, which enable us 
to study acute and chronic effect of mutation and drugs on CMs. Thus, hiPSC-CMs 
not only provide the platform to investigate the mutation-specific mechanism but also 
assist to anticipate drug response on an individual basis and guide us to personalized 
medicine in future.
2. Channelopathy phenotypes in hiPSC-CMs
Channelopathy cardiac diseases are caused by mutations in cardiac ion channels 
located in the cellular membrane or organelles. Mutations in ion channels result 
in misbalance of fine-tuning ion exchange during excitation-contraction coupling 
(ECC), which could lead to cardiac arrhythmias and SCD in the worst case. The 
main cardiac channelopathies are CPVT, LQTS, BrS, and short QT syndromes 
(SQTS) [27]. These cardiac channelopathies have been extensively studied using 
hiPSC-CMs and described below.
2.1 Catecholaminergic polymorphic ventricular tachycardia (CPVT)
CPVT is an inherited cardiac disease with the prevalence of about 
1:5000/10,000. This disease is characterized by premature ventricular contraction 
and/or polymorphic ventricular tachycardia (VT) induced by adrenergic stimula-
tion in response to emotional stress or physical exercise in structurally normal 
heart. Over 150 mutations in ryanodine receptor type 2 (RYR2 gene) are responsible 
for ~ 55% of CPVT type 1 cases (CPVT1), and mutation in calsequestrin 2 (CASQ2 
gene) CPVT accounts for 3–5% CPVT type 2 (CPVT2) cases [28, 29]. In addi-
tion, mutations in calmodulin (CALM1) genes and in triadin (TRDN) have been 
reported causing CPVT. RYR2, CASQ2, CALM1, and TRDN are involved in ECC, 
and mutation in any of these genes results in elevated intracellular Ca2+, which 
leads to abnormal Ca2+ handling and arrhythmias [28, 29]. In consistency with 
clinical phenotype, many hiPSC-CM model had demonstrated the exacerbation 
of electrophysiological and Ca2+ handling abnormalities upon adrenergic stimula-
tion [26, 30–32]. Furthermore, Zhang and colleagues had modeled hiPSC-CMs 
harboring CPVT1-associated F2483I mutation in RYR2 gene and demonstrated that 
CPVT1 hiPSC-CMs had longer and wandering Ca2+ sparks and smaller sarcoplasmic 
reticulum Ca2+ content [32]. Later on, the same group corrected this mutation using 
clustered regularly interspaced short palindromic repeats/Cas9 (CRISPR/Cas9) 
gene editing technique and showed that this mutation is causative rather than asso-
ciative to the disease [33]. hiPSC-CM model for CPVT has also been used in study-
ing the efficacy of various drugs. Previously we had directly compared the clinical 
results from CPVT1 patients with dantrolene medication, and the clinical response 
of dantrolene was similar as in hiPSC-CMs from the same patients; dantrolene 
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abolished or markedly reduced arrhythmias in patients and their hiPSC-CMs with 
certain mutation in RYR2, while it did not have any clinical effect with hiPSC-
CMs or with other RYR2 mutations [31]. Furthermore, an antiarrhythmic drug, 
flecainide, used to treat CPVT1 patients [34] was able to reduce the Ca2+ irregulari-
ties under adrenergic stimulation in CPVT1 hiPSC-CMs [30, 35]. CPVT2 patients 
harboring homozygous CASQ2-G112 + 5X mutation in CASQ2 gene showed the 
rapid polymorphic VT under exercise stress test [36]. Adult rat ventricular myocytes 
were studied to understand the effect of CASQ2 mutation in ECC, demonstrating 
that mutated CMs exhibited spontaneous extrasystolic Ca2+ elevations and delayed 
afterdepolarization (DADs) upon adrenergic stimulation [36]. Later, hiPSC-CM 
model harboring CASQ2-G112 + 5X mutation emulated these phenotypic features 
of disease, and AAV9-based gene delivery effectively prevents the development of 
adrenergic-induced DADs and triggered arrhythmias in CPVT2 hiPSC-CMs [37].
2.2 LQT type 1 (LQT1)
LQT type 1 (LQT1) is caused by loss-of-function mutation in KCNQ1 gene encod-
ing α subunit of potassium (K+) channel mediating slow delayed rectifier K+ current 
(IKs). LQT1 is responsible for 30–35% of all LQTS cases [38]. LQT1 is characterized by 
prolongation of QT interval in ECG, which could lead to SCD due to VT, typically tor-
sades de pointes [39]. hiPSC-CMs derived from LQT1 patients faithfully recapitulated 
the clinical hallmark by showing prolonged action potential duration (APD) which is 
analogous to QT duration in ECG, and reduced IKs current densities are held respon-
sible for abnormal repolarization [40–42]. ML277, an IKs activator, increased the IKs 
amplitude by enhancing the activation of IKs, thus resulting in shortening of APD 
in LQT1 hiPSC-CMs [40]. In addition, adrenergic stimulation in LQT1 hiPSC-CMs 
induced the early afterdepolarization (EAD) [42], which is similar to arrhythmias 
triggered in LQT1 patients by exercise or emotional stress [39]. Clinically, β-blockers 
were effective in minimizing the risk of cardiac events in LQT1 patients [43]. Similar 
antiarrhythmic effect of β-blockers has been observed in LQT1 hiPSC-CMs [42]. 
Furthermore, hypokalemia is the electrolyte disturbance caused by lower K+ level in 
blood serum, which aggravates the QT prolongation and facilitates the development 
of hypokalemia-induced torsades de pointes in LQT1 patients [39, 44]. We success-
fully developed and mimicked these disease phenotypes in LQT1 hiPSC-CMs carrying 
G589D or IVS7-2A > G mutation in KCNQ1 gene. Additionally, lowering the extracel-
lular K+ concentration prolonged APDs and induced the formation of EADs in LQT1 
hiPSC-CMs [45]. Both G589D- and IVS7-2A > G-specific LQT1 hiPSC-CMs displayed 
longer APD and higher Ca2+ abnormalities in baseline; G589D hiPSC-CMs dem-
onstrated prolonged contraction, while IVS7-2A > G hiPSC-CMs showed impaired 
relaxation [46] observed in our video image-based software analysis [47].
2.3 LQT type 2 (LQT2)
LQT type 2 (LQT2) is an LQTS subtype, which is caused by loss-of-function 
mutations in KCNH2 gene also known as human ether-a-go-go-related gene (hERG) 
encoding K+ channel mediating rapid delayed rectifier K current (IKr). LQT2 is 
responsible for approximately 25–30% of all LQTS cases [38]. Similar to LQT1, LQT2 
patients also exhibit the prolongation of QT interval and torsades de pointes. As in 
LQT1 hiPSC-CM model, LQT2 hiPSC-CMs also recapitulated clinical phenotypes by 
displaying longer APD resulted from reduced IKr current densities and enhanced EAD 
following the adrenergic stimulation [48–50]. Our early study of LQT2 hiPSC-CMs car-
rying R176W mutation in KCNH2 gene demonstrated the reduced IKr current densities, 
prolonged repolarization, and increased arrhythmogenicity although the donor is an 
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testing. However, the human sample exhibits some of the major challenges: there is 
limited supply of human cardiac biopsies, and it involves complex procedures and 
ethical issues. In addition, these cardiac biopsies are typically obtained from the end 
stage of cardiac diseases; hence it is not possible to understand the mechanism of 
cardiac diseases [20, 21]. These obstacles are mostly overcome by the groundbreaking 
discovery of reprogramming adult somatic cells into induced pluripotent stem cells 
(iPSCs) [22, 23] which can be differentiated into cardiomyocytes (CMs) (hiPSC-
CMs) [24–26]. The main advantages of hiPSC-CMs are iPSCs can be generated at any 
period of a patient’s life, they have unlimited supply, and these retain the same genetic 
information as the donor, i.e., hiPSC-CMs are patient specific (Figure 2). These are 
superior features of hiPSC-CMs to the conventional in vitro modeling of cardiac 
diseases. In addition, hiPSC-CMs can be cultured for several months, which enable us 
to study acute and chronic effect of mutation and drugs on CMs. Thus, hiPSC-CMs 
not only provide the platform to investigate the mutation-specific mechanism but also 
assist to anticipate drug response on an individual basis and guide us to personalized 
medicine in future.
2. Channelopathy phenotypes in hiPSC-CMs
Channelopathy cardiac diseases are caused by mutations in cardiac ion channels 
located in the cellular membrane or organelles. Mutations in ion channels result 
in misbalance of fine-tuning ion exchange during excitation-contraction coupling 
(ECC), which could lead to cardiac arrhythmias and SCD in the worst case. The 
main cardiac channelopathies are CPVT, LQTS, BrS, and short QT syndromes 
(SQTS) [27]. These cardiac channelopathies have been extensively studied using 
hiPSC-CMs and described below.
2.1 Catecholaminergic polymorphic ventricular tachycardia (CPVT)
CPVT is an inherited cardiac disease with the prevalence of about 
1:5000/10,000. This disease is characterized by premature ventricular contraction 
and/or polymorphic ventricular tachycardia (VT) induced by adrenergic stimula-
tion in response to emotional stress or physical exercise in structurally normal 
heart. Over 150 mutations in ryanodine receptor type 2 (RYR2 gene) are responsible 
for ~ 55% of CPVT type 1 cases (CPVT1), and mutation in calsequestrin 2 (CASQ2 
gene) CPVT accounts for 3–5% CPVT type 2 (CPVT2) cases [28, 29]. In addi-
tion, mutations in calmodulin (CALM1) genes and in triadin (TRDN) have been 
reported causing CPVT. RYR2, CASQ2, CALM1, and TRDN are involved in ECC, 
and mutation in any of these genes results in elevated intracellular Ca2+, which 
leads to abnormal Ca2+ handling and arrhythmias [28, 29]. In consistency with 
clinical phenotype, many hiPSC-CM model had demonstrated the exacerbation 
of electrophysiological and Ca2+ handling abnormalities upon adrenergic stimula-
tion [26, 30–32]. Furthermore, Zhang and colleagues had modeled hiPSC-CMs 
harboring CPVT1-associated F2483I mutation in RYR2 gene and demonstrated that 
CPVT1 hiPSC-CMs had longer and wandering Ca2+ sparks and smaller sarcoplasmic 
reticulum Ca2+ content [32]. Later on, the same group corrected this mutation using 
clustered regularly interspaced short palindromic repeats/Cas9 (CRISPR/Cas9) 
gene editing technique and showed that this mutation is causative rather than asso-
ciative to the disease [33]. hiPSC-CM model for CPVT has also been used in study-
ing the efficacy of various drugs. Previously we had directly compared the clinical 
results from CPVT1 patients with dantrolene medication, and the clinical response 
of dantrolene was similar as in hiPSC-CMs from the same patients; dantrolene 
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abolished or markedly reduced arrhythmias in patients and their hiPSC-CMs with 
certain mutation in RYR2, while it did not have any clinical effect with hiPSC-
CMs or with other RYR2 mutations [31]. Furthermore, an antiarrhythmic drug, 
flecainide, used to treat CPVT1 patients [34] was able to reduce the Ca2+ irregulari-
ties under adrenergic stimulation in CPVT1 hiPSC-CMs [30, 35]. CPVT2 patients 
harboring homozygous CASQ2-G112 + 5X mutation in CASQ2 gene showed the 
rapid polymorphic VT under exercise stress test [36]. Adult rat ventricular myocytes 
were studied to understand the effect of CASQ2 mutation in ECC, demonstrating 
that mutated CMs exhibited spontaneous extrasystolic Ca2+ elevations and delayed 
afterdepolarization (DADs) upon adrenergic stimulation [36]. Later, hiPSC-CM 
model harboring CASQ2-G112 + 5X mutation emulated these phenotypic features 
of disease, and AAV9-based gene delivery effectively prevents the development of 
adrenergic-induced DADs and triggered arrhythmias in CPVT2 hiPSC-CMs [37].
2.2 LQT type 1 (LQT1)
LQT type 1 (LQT1) is caused by loss-of-function mutation in KCNQ1 gene encod-
ing α subunit of potassium (K+) channel mediating slow delayed rectifier K+ current 
(IKs). LQT1 is responsible for 30–35% of all LQTS cases [38]. LQT1 is characterized by 
prolongation of QT interval in ECG, which could lead to SCD due to VT, typically tor-
sades de pointes [39]. hiPSC-CMs derived from LQT1 patients faithfully recapitulated 
the clinical hallmark by showing prolonged action potential duration (APD) which is 
analogous to QT duration in ECG, and reduced IKs current densities are held respon-
sible for abnormal repolarization [40–42]. ML277, an IKs activator, increased the IKs 
amplitude by enhancing the activation of IKs, thus resulting in shortening of APD 
in LQT1 hiPSC-CMs [40]. In addition, adrenergic stimulation in LQT1 hiPSC-CMs 
induced the early afterdepolarization (EAD) [42], which is similar to arrhythmias 
triggered in LQT1 patients by exercise or emotional stress [39]. Clinically, β-blockers 
were effective in minimizing the risk of cardiac events in LQT1 patients [43]. Similar 
antiarrhythmic effect of β-blockers has been observed in LQT1 hiPSC-CMs [42]. 
Furthermore, hypokalemia is the electrolyte disturbance caused by lower K+ level in 
blood serum, which aggravates the QT prolongation and facilitates the development 
of hypokalemia-induced torsades de pointes in LQT1 patients [39, 44]. We success-
fully developed and mimicked these disease phenotypes in LQT1 hiPSC-CMs carrying 
G589D or IVS7-2A > G mutation in KCNQ1 gene. Additionally, lowering the extracel-
lular K+ concentration prolonged APDs and induced the formation of EADs in LQT1 
hiPSC-CMs [45]. Both G589D- and IVS7-2A > G-specific LQT1 hiPSC-CMs displayed 
longer APD and higher Ca2+ abnormalities in baseline; G589D hiPSC-CMs dem-
onstrated prolonged contraction, while IVS7-2A > G hiPSC-CMs showed impaired 
relaxation [46] observed in our video image-based software analysis [47].
2.3 LQT type 2 (LQT2)
LQT type 2 (LQT2) is an LQTS subtype, which is caused by loss-of-function 
mutations in KCNH2 gene also known as human ether-a-go-go-related gene (hERG) 
encoding K+ channel mediating rapid delayed rectifier K current (IKr). LQT2 is 
responsible for approximately 25–30% of all LQTS cases [38]. Similar to LQT1, LQT2 
patients also exhibit the prolongation of QT interval and torsades de pointes. As in 
LQT1 hiPSC-CM model, LQT2 hiPSC-CMs also recapitulated clinical phenotypes by 
displaying longer APD resulted from reduced IKr current densities and enhanced EAD 
following the adrenergic stimulation [48–50]. Our early study of LQT2 hiPSC-CMs car-
rying R176W mutation in KCNH2 gene demonstrated the reduced IKr current densities, 
prolonged repolarization, and increased arrhythmogenicity although the donor is an 
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asymptomatic carrier [50]. These results are in parallel with clinical findings that LQT2 
patients usually display symptoms when heart rate is slow. In addition, this report illus-
trated that electrophysiological abnormalities can be detected in hiPSC-CMs, although 
iPSCs are derived from asymptomatic carriers of KCNH2 mutations. The application of 
IKr blockers (E4031 and sotalol) further prolonged the APD resulting in EADs, whereas 
Ca2+ channel blocker (nifedipine), IK,ATP channel opener (pinacidil and nicorandil), 
and IKr channel enhancer (PD-118057) reduced the APD and thus mitigated the forma-
tion of EAD in LQT2 hiPSC-CMs [48, 49]. Several novel pharmacological strategies 
including ICA-105574 (potent IKr activator) [51], chaperone modulator N-[N-(N-acetyl-
L-leucyl)-L-leucyl]-L-norleucine (ALLN) [52], LUF7346 (hERG allosteric modulators) 
[53], as well as application of allele-specific RNA interference approach [54] have been 
attempts to rescue the LQT phenotype in LQT2 hiPSC-CMs. Correcting the mutation 
associated with LQT2 not only confirmed that mutation caused IKr reduction and APD 
prolongation but also suggested that trafficking defect as the pathological mechanism is 
responsible for the electrophysiological phenotype in LQT2 [51, 55].
2.4 LQT type 3 (LQT3)
LQT type 3 (LQT3) is caused by gain-of-function mutations in SCN5A encoding 
α subunit of cardiac Na+ channels [56]. The gain-of-function SCN5A mutation results 
in augmented late or persistent Na+ current (INaL), which leads to prolongation of QT 
interval in ECG and proarrhythmia. LQT3 is the third most common LQTS accounting 
for 5–10% of all LQTS cases [56]. LQT3 patients exhibit longer QT duration at slower 
heart rate, thus LQT3 patients are at higher risk for cardiac events during rest or sleep 
[57]. LQT3 patients harboring V1763 M mutation in SCN5A [58] R1644H mutation in 
SCN5A [59] or F1473C mutation in SCN5A and a polymorphism (K897 T) in KCNH2 
[60] had prolonged QT interval, and in vitro models using hiPSC-CMs derived from 
all those LQT3 patients demonstrated prolonged APD resulting in the larger INa,L and 
altered biophysical properties of Na+ channels [58–60]. Mexiletine, a Na+ channel 
inhibitor commonly used in LQT3 therapy, lowered the INa,L and thereby rescued the 
APD prolongation phenotype [58, 59] and suppressed the occurrence of EAD [59] and 
also corrected the altered Na+ channel inactivation [60]. Incorporating the biophysics 
of Na+ channel and pharmacological analysis illustrated that the improper functioning 
of Na+ channel was responsible for LQT3 phenotypes rather than KCNH2 polymor-
phism [60]. In addition to LQT3, mutation in SCN5A gene can cause BrS, and mixed 
phenotypes are often seen, which is also known as the “overlap syndrome.” Loss in 
function of Na+ channel is often seen in BrS. Liang and co-workers had generated hiP-
SCs from two BrS patients, one with double missense mutation (R620H and R811H) 
in SCN5A gene (BrS(p1)) and another with one-base pair deletion mutation in the 
SCN5A gene (BrS(p2)), and showed that BrS hiPSC-CMs derived from both patients 
had reduced Na+ current and increased triggered activity and abnormal Ca2+ handling 
[61]. These phenotypes were alleviated by correcting the mutation by CRISPR/Cas9 in 
hiPSCs derived from BrS (p2) [61]. Importantly, only BrS hiPSC-CMs harboring BrS-
associated SCN5A-1795insD mutation displayed reduced Na+ current and upstroke 
velocity, but not with three sets of hiPSC-CMs derived from BrS patients who tested 
negative for mutations in the known BrS-associated genes suggesting the Na+ channel 
dysfunction may not be prerequisite for BrS [62]. In another study, Na+ current and 
upstroke velocity were reduced, but not the voltage-dependent inactivation in BrS 
hiPSC-CMs carrying the mutations R1638X and W156X [63].
2.5 LQT type 7 (LQT7) or Andersen-Tawil syndrome (ATS)
LQT type 7 (LQT7) or Andersen-Tawil syndrome (ATS) is a rare inherited cardiac 
disease associated with mutation in KCNJ2 gene (ATS type 1) encoding inward 
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rectifying K+ channel (Kir2.1) and accounts for ~70% of all ATS cases. However, the 
genetic cause of the remaining 30% of ATS (ATS type 2) remains unknown. In ATS 
patients, QT interval prolongation is not common, but prominent U wave and QU 
interval in ECG could be hallmarks of ATS, and they experienced cardiac arrhythmias 
including non-sustained VT and torsade de pointes [64]. Kuroda and co-workers 
generated hiPSCs from ATS patients carrying R218W, R67W, and R218Q mutations in 
KCNJ2 gene and showed strong arrhythmic events and higher incidence of irregular 
Ca2+ handling in ATS hiPSC-CMs, but flecainide and KB-R7943 (a reverse-mode  
Na+/Ca2+ exchanger inhibitor) were able to suppress those events [65].
2.6 LQT type 8 (LQT8) or Timothy syndrome (TS)
2.6 LQT type 8 (LQT8) or Timothy syndrome (TS) is a very rare genetic cardiac 
disease which results from mutation in CACNA1C gene encoding Ca2+ channel 
(CaV1.2). LQT8 is the most severe type of LQTS, which is characterized by markedly 
prolonged QT interval, severe ventricular arrhythmia, and multiorgan dysfunction 
[66]. hiPSC-CMs derived from TS patients recapitulated the disease phenotypes, but 
roscovitine rescued those abnormalities such as altered Ca2+ channel inactivation, 
prolonged APD, higher incidences of arrhythmias, and abnormal Ca2+ handling [67].
2.7 Short QT (SQT)
SQT is a rare inherited cardiac disease characterized by QT internal shortening, 
which is in contrast to QT prolongation observed in LQTS. SQT is associated with 
mutations in genes associated with K+ channel or Ca2+ channels [68]. The preva-
lence of SQT is between 0.02–0.1% and 0.05% in adults and children, respectively 
[69]. Recently El-Battrawy and co-workers had generated hiPSCs from SQT type 
1 patients carrying a mutation (N588K) in KCNH2, and hiPSC-CMs mimicked the 
clinical phenotype of SQT by showing a shortened APD as a result of increased 
IKr current densities [70]. In addition, SQT hiPSC-CMs exhibited abnormal Ca2+ 
transients and rhythmic activities, which are enhanced by carbachol, but quinidine 
alleviated those carbachol-induced arrhythmias and prolonged the APD [70].
3. Cardiomyopathy phenotypes in hiPSC-CMs
Cardiomyopathies are diseases of cardiac muscle and associated with structural 
and/or functional abnormalities. The most common genetic cardiomyopathies are 
hypertrophic cardiomyopathy (HCM), dilated cardiomyopathy (DCM), and arrhyth-
mogenic right ventricular cardiomyopathy/dysplasia (ARVC/D). These genetic 
cardiomyopathies have been also extensively studied using hiPSC-CMs [71, 72].
3.1 Hypertrophic cardiomyopathy (HCM)
HCM is one of the most common genetic cardiac diseases with an estimate preva-
lence of 1 in 500. HCM is characterized by unexplained symmetrical or asymmetrical 
left ventricular hypertrophy. Mutations in sarcomeric proteins account for ~60% of 
all HCM cases including mutation in β-myosin heavy chain (MYH7), cardiac myosin-
binding protein C (MYBPC3), cardiac troponin I (cTnI), cardiac troponin T (cTnT), 
and tropomyosin (TPM1) [73]. Hypertrophy of myocytes and disarray of sarcomere 
are the histological hallmarks of HCM seen in cardiac biopsies from HCM patients 
[74], and these histological phenotypes are also observed in hiPSC-CM model of HCM 
[25, 75–77]. In addition, HCM hiPSC-CMs also demonstrated other hallmarks of HCM 
such as nuclear translocation of nuclear factor of activated T cells (NFAT) [75–77], 
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asymptomatic carrier [50]. These results are in parallel with clinical findings that LQT2 
patients usually display symptoms when heart rate is slow. In addition, this report illus-
trated that electrophysiological abnormalities can be detected in hiPSC-CMs, although 
iPSCs are derived from asymptomatic carriers of KCNH2 mutations. The application of 
IKr blockers (E4031 and sotalol) further prolonged the APD resulting in EADs, whereas 
Ca2+ channel blocker (nifedipine), IK,ATP channel opener (pinacidil and nicorandil), 
and IKr channel enhancer (PD-118057) reduced the APD and thus mitigated the forma-
tion of EAD in LQT2 hiPSC-CMs [48, 49]. Several novel pharmacological strategies 
including ICA-105574 (potent IKr activator) [51], chaperone modulator N-[N-(N-acetyl-
L-leucyl)-L-leucyl]-L-norleucine (ALLN) [52], LUF7346 (hERG allosteric modulators) 
[53], as well as application of allele-specific RNA interference approach [54] have been 
attempts to rescue the LQT phenotype in LQT2 hiPSC-CMs. Correcting the mutation 
associated with LQT2 not only confirmed that mutation caused IKr reduction and APD 
prolongation but also suggested that trafficking defect as the pathological mechanism is 
responsible for the electrophysiological phenotype in LQT2 [51, 55].
2.4 LQT type 3 (LQT3)
LQT type 3 (LQT3) is caused by gain-of-function mutations in SCN5A encoding 
α subunit of cardiac Na+ channels [56]. The gain-of-function SCN5A mutation results 
in augmented late or persistent Na+ current (INaL), which leads to prolongation of QT 
interval in ECG and proarrhythmia. LQT3 is the third most common LQTS accounting 
for 5–10% of all LQTS cases [56]. LQT3 patients exhibit longer QT duration at slower 
heart rate, thus LQT3 patients are at higher risk for cardiac events during rest or sleep 
[57]. LQT3 patients harboring V1763 M mutation in SCN5A [58] R1644H mutation in 
SCN5A [59] or F1473C mutation in SCN5A and a polymorphism (K897 T) in KCNH2 
[60] had prolonged QT interval, and in vitro models using hiPSC-CMs derived from 
all those LQT3 patients demonstrated prolonged APD resulting in the larger INa,L and 
altered biophysical properties of Na+ channels [58–60]. Mexiletine, a Na+ channel 
inhibitor commonly used in LQT3 therapy, lowered the INa,L and thereby rescued the 
APD prolongation phenotype [58, 59] and suppressed the occurrence of EAD [59] and 
also corrected the altered Na+ channel inactivation [60]. Incorporating the biophysics 
of Na+ channel and pharmacological analysis illustrated that the improper functioning 
of Na+ channel was responsible for LQT3 phenotypes rather than KCNH2 polymor-
phism [60]. In addition to LQT3, mutation in SCN5A gene can cause BrS, and mixed 
phenotypes are often seen, which is also known as the “overlap syndrome.” Loss in 
function of Na+ channel is often seen in BrS. Liang and co-workers had generated hiP-
SCs from two BrS patients, one with double missense mutation (R620H and R811H) 
in SCN5A gene (BrS(p1)) and another with one-base pair deletion mutation in the 
SCN5A gene (BrS(p2)), and showed that BrS hiPSC-CMs derived from both patients 
had reduced Na+ current and increased triggered activity and abnormal Ca2+ handling 
[61]. These phenotypes were alleviated by correcting the mutation by CRISPR/Cas9 in 
hiPSCs derived from BrS (p2) [61]. Importantly, only BrS hiPSC-CMs harboring BrS-
associated SCN5A-1795insD mutation displayed reduced Na+ current and upstroke 
velocity, but not with three sets of hiPSC-CMs derived from BrS patients who tested 
negative for mutations in the known BrS-associated genes suggesting the Na+ channel 
dysfunction may not be prerequisite for BrS [62]. In another study, Na+ current and 
upstroke velocity were reduced, but not the voltage-dependent inactivation in BrS 
hiPSC-CMs carrying the mutations R1638X and W156X [63].
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rectifying K+ channel (Kir2.1) and accounts for ~70% of all ATS cases. However, the 
genetic cause of the remaining 30% of ATS (ATS type 2) remains unknown. In ATS 
patients, QT interval prolongation is not common, but prominent U wave and QU 
interval in ECG could be hallmarks of ATS, and they experienced cardiac arrhythmias 
including non-sustained VT and torsade de pointes [64]. Kuroda and co-workers 
generated hiPSCs from ATS patients carrying R218W, R67W, and R218Q mutations in 
KCNJ2 gene and showed strong arrhythmic events and higher incidence of irregular 
Ca2+ handling in ATS hiPSC-CMs, but flecainide and KB-R7943 (a reverse-mode  
Na+/Ca2+ exchanger inhibitor) were able to suppress those events [65].
2.6 LQT type 8 (LQT8) or Timothy syndrome (TS)
2.6 LQT type 8 (LQT8) or Timothy syndrome (TS) is a very rare genetic cardiac 
disease which results from mutation in CACNA1C gene encoding Ca2+ channel 
(CaV1.2). LQT8 is the most severe type of LQTS, which is characterized by markedly 
prolonged QT interval, severe ventricular arrhythmia, and multiorgan dysfunction 
[66]. hiPSC-CMs derived from TS patients recapitulated the disease phenotypes, but 
roscovitine rescued those abnormalities such as altered Ca2+ channel inactivation, 
prolonged APD, higher incidences of arrhythmias, and abnormal Ca2+ handling [67].
2.7 Short QT (SQT)
SQT is a rare inherited cardiac disease characterized by QT internal shortening, 
which is in contrast to QT prolongation observed in LQTS. SQT is associated with 
mutations in genes associated with K+ channel or Ca2+ channels [68]. The preva-
lence of SQT is between 0.02–0.1% and 0.05% in adults and children, respectively 
[69]. Recently El-Battrawy and co-workers had generated hiPSCs from SQT type 
1 patients carrying a mutation (N588K) in KCNH2, and hiPSC-CMs mimicked the 
clinical phenotype of SQT by showing a shortened APD as a result of increased 
IKr current densities [70]. In addition, SQT hiPSC-CMs exhibited abnormal Ca2+ 
transients and rhythmic activities, which are enhanced by carbachol, but quinidine 
alleviated those carbachol-induced arrhythmias and prolonged the APD [70].
3. Cardiomyopathy phenotypes in hiPSC-CMs
Cardiomyopathies are diseases of cardiac muscle and associated with structural 
and/or functional abnormalities. The most common genetic cardiomyopathies are 
hypertrophic cardiomyopathy (HCM), dilated cardiomyopathy (DCM), and arrhyth-
mogenic right ventricular cardiomyopathy/dysplasia (ARVC/D). These genetic 
cardiomyopathies have been also extensively studied using hiPSC-CMs [71, 72].
3.1 Hypertrophic cardiomyopathy (HCM)
HCM is one of the most common genetic cardiac diseases with an estimate preva-
lence of 1 in 500. HCM is characterized by unexplained symmetrical or asymmetrical 
left ventricular hypertrophy. Mutations in sarcomeric proteins account for ~60% of 
all HCM cases including mutation in β-myosin heavy chain (MYH7), cardiac myosin-
binding protein C (MYBPC3), cardiac troponin I (cTnI), cardiac troponin T (cTnT), 
and tropomyosin (TPM1) [73]. Hypertrophy of myocytes and disarray of sarcomere 
are the histological hallmarks of HCM seen in cardiac biopsies from HCM patients 
[74], and these histological phenotypes are also observed in hiPSC-CM model of HCM 
[25, 75–77]. In addition, HCM hiPSC-CMs also demonstrated other hallmarks of HCM 
such as nuclear translocation of nuclear factor of activated T cells (NFAT) [75–77], 
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elevation of β-myosin/α-myosin ratio, and calcineurin activation [75]. Furthermore, 
isolated CMs from HCM patients displayed the prolonged APDs, increased Ca2+ 
current densities, reduced transient outward K+ current densities, abnormal Ca2+ 
handling, and increased frequency of arrhythmias [21]. These electrophysiological 
and Ca2+ transient irregularity phenotypes have been faithfully recapitulated in HCM 
hiPSC-CMs [25, 75, 76, 78]. When HCM tissues carrying a mutation in MYBPC3 gene 
were compared with donor heart sample, no specific truncated MyBP-C peptides were 
detected, but the overall level of MyBP-C in myofibrils was significantly reduced [79]. 
Similar haploinsufficiency results were also shown in HCM hiPSC-CMs with muta-
tion in MYBPC3 gene [25, 80], and gene replacement in HCM hiPSC-CMs partially 
improves the haploinsufficiency and reduces cellular hypertrophy [80]. Similar to 
higher myofilament Ca2+ sensitivity observed in isolated cardiac biopsies from HCM 
with E99K mutation in cardiac actin [81], in vitro model of HCM hiPSC-CMs carrying 
E99K mutation in cardiac actin demonstrated significantly stronger contraction and 
increased arrhythmogenic events [82] Furthermore, a study in HCM mice harbor-
ing I79N mutation in cTnT resulted in increased cardiac contractility, altered Ca2+ 
transients, and remodeling of action potential [83]. These phenotypes were faithfully 
recapitulated by HCM hiPSC-CMs carrying the same I79N mutation in cTnT [84]. 
These hypercontractility and increased arrhythmogenicity phenotypes were reversed 
in HCM hiPSC-CMs when the E99K mutation in cardiac actin [82] and I79N mutation 
in cTnT [84] were corrected using CRISPR/Cas9 gene editing technique. Recently, we 
have shown that HCM hiPSC-CMs carrying TPM1-Asp175Asn mutation exhibited VT 
type of arrhythmias [78], and this observation is in line with earlier clinical observa-
tion of HCM patients with TPM1-Asp175Asn mutation being at increased risk of fatal 
arrhythmias [85]. Currently, there is no specific pharmacological therapy for HCM 
patients, and drugs are prescribed mainly based on symptoms and personal history. 
However, drug therapy has also resulted in poor outcomes in HCM patients [12]. We 
reported the similar poor antiarrhythmic efficiency of β-blocker in preventing lethal 
arrhythmias in HCM hiPSC-CMs [78]. In another HCM report, several environmental 
factors were investigated with hiPSC-CMs to study their effect on disease progression 
[77]. They found that endothelin (ET)-1 was able to induce HCM phenotypes such 
as cellular hypertrophy and myofibrillar disarray in hiPSC-CMs, which are inhibited 
by ET receptor type A blocker [77]. HCM patients exhibited defects in mitochondrial 
functions and ultrastructure and abnormal energy metabolism [74]. These structural 
and functional phenotypes were recapitulated in hiPSC-CMs carrying m.2336 T > C 
mutation in mitochondrial genome causing HCM [86]. They reported that HCM 
hiPSC-CMs expressed reduced levels of mitochondrial proteins, ATP/ADP ratio, and 
mitochondrial membrane potential [86].
3.2 Dilated cardiomyopathy (DCM)
DCM is a myocardial disease characterized by ventricular chamber enlargement 
and systolic dysfunction and progressive heart failure without significant change in 
ventricular wall thickness. Mutations in >30 genes encoding proteins of cytoskel-
eton, sarcomere, and nuclear lamina are found in 30–35% of DCM patients [87]. 
DCM patients with mutations in RBM20, encoding RNA binding motif protein 20 
(RBM20), have an early onset of disease phenotype [88]. Isolated CMs from DCM 
patients carrying mutation in RBM20 displayed elongated and thinner sarcomere 
structure [88], and such disorganized sarcomeric structure phenotypes were reca-
pitulated in DCM hiPSC-CMs carrying mutation in RBM20 [89, 90]. RBM20 is the 
main regulator of the heart-specific titin splicing, and N2BA isoform is predomi-
nantly expressed in CMs from DCM patient carrying mutation in the RBM20 gene 
[91]. In vitro model of RBM20 hiPSC-CMs successfully mirrored the altered titin 
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isoform expression (titin isoform switch) [89, 90]. Furthermore, RBM20 hiPSC-CMs 
showed delayed Ca2+ extrusion and reuptake and more Ca2+ being released during 
each ECC, which resulted into deficient muscle contraction, the hallmark of cardiac 
dysfunction of DCM patients [89, 90]. In addition, a three-dimensional engineered 
heart muscle generated from RBM20 hiPSC-CMs showed an impaired force of con-
traction, and passive stress was decreased in response to stepwise increase in strain, 
suggesting higher viscoelasticity caused by mutation in RBM20 [89]. Besides HCM, 
mutation in cTnT also caused DCM and resulted in shifts in Ca2+ sensitivity and force 
of contraction [92]. Sun and co-workers generated iPSCs from DCM patients carry-
ing R173W mutation in cTnT and reported that DCM hiPSC-CMs exhibited altered 
Ca2+ handling, decreased contractility, and abnormal sarcomeric α–actinin distribu-
tion [93]. DCM patients with lamin A/C (LMNA) mutations show a highly variable 
phenotype. Cardiac biopsies from DCM patients harboring LMNA mutations exhibit 
reduced LMNA in nuclei with nuclear membrane damage such as focal disruption 
and nuclear pore clustering [94]. Nonsense mutation (R225X) in exon 4 of the 
LMNA gene causing DCM was associated with accelerated nuclear senescence and 
apoptosis of DCM hiPSC-CMs under electrical stimulation [95]. In another in vitro 
modeling of DCM, harboring A285V mutation in desmin (DES) using hiPSC-CMs 
displayed the pathogenic phenotypes of DCM such as diffuse abnormal DES aggre-
gation, poor co-localization of DES with cTnT, and Z-disk streaming with accumula-
tion of granulofilamentous materials or pleomorphic dense structures adjacent to the 
Z-disk or between the myofibrils [96]. DCM patients harboring R14del mutation in 
phospholamban (PLN) result in ventricular dilation, contractile dysfunction, and 
episodic ventricular arrhythmias [97]. Similarly, hiPSC-CMs carrying R14del muta-
tion in PLN induced the Ca2+ handling abnormalities, irregular electrical activity, 
and abnormal intracellular distribution of PLN in DCM hiPSC-CMs [98]. These PLN 
R14del-associated disease phenotypes were mitigated upon correction of PLN R14del 
mutation by transcription activator-like effector nuclease (TALENs) gene editing 
technique [98]. Furthermore, genetic correction of PLN R14del mutation by TALENs 
improved the force development and restored the contractile function in three-
dimensional human engineered cardiac tissue derived from R14del-iPSCs [99].
3.3 Arrhythmogenic right ventricular cardiomyopathy (ARVC)
ARVC is rare genetic cardiac disease with the prevalence ranging from 1:000 
to 1:5000 worldwide. The histopathological hallmark of ARVC is the substitution 
of the cardiac myocytes with fibro-fatty deposits, particularly within the free 
wall of the right ventricle. The consequent results from the disruption of normal 
myocardial architecture can lead to right ventricular dysfunction, life-threatening 
arrhythmias, and SCD [100]. ARVC is caused by mutations in genes encoding 
desmosomal proteins such as plakoglobin (JUP), desmoplakin (DSP), plakophilin-2 
(PKP2), desmoglein-2 (DSG2), and desmocollin-2 (DSC2) [100]. Similar to immu-
nohistological results from the biopsy sample from ARVC patients [101], ARVC 
hiPSC-CMs harboring a plakophilin 2 (PKP2) gene mutation mimicked the reduced 
PKP2 immunosignal [102, 103]. In addition, clusters of lipid droplets accumulat-
ing within the cytoplasm were identified in ARVC-hiPSC-CMs associated with 
structural distortion of desmosomes [103]. Another study showed that induction of 
adult-like metabolic energetics from an embryonic/glycolytic state and abnormal 
peroxisome proliferator-activated receptor gamma (PPARγ) activation underlie the 
pathogenesis of ARVC [104]. It has been observed that male ARVC patients develop 
earlier and more severe phenotype than female ARVC patients [105]. To understand 
whether sex hormones in serum may contribute to the major arrhythmic cardiovas-
cular events in ARVC, Akdis and co-workers combined a clinical study and in vitro 
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elevation of β-myosin/α-myosin ratio, and calcineurin activation [75]. Furthermore, 
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isoform expression (titin isoform switch) [89, 90]. Furthermore, RBM20 hiPSC-CMs 
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cular events in ARVC, Akdis and co-workers combined a clinical study and in vitro 
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hiPSC-CM model and showed that increased levels of testosterone accelerate ARVC 
pathologies, while premenopausal female estradiol levels slow down exaggerated 
apoptosis and lipid accumulation in ARVC hiPSC-CMs [106].
4. Limitations and future prospective
The reprogramming of somatic cells into pluripotent stems cells and subsequent 
differentiation into specific cell types is a newly emerging technique and is certainly 
not free from limitation.
One of the most questionable issues of hiPSC-CMs is their maturity. Despite 
expressing relevant ion channels [107] and structural genes [25, 26, 75, 76, 89, 108],  
hiPSC-CMs lack t-tubules and exhibit lower expression of Kir2.1 and weaker 
contractility; thus they do not fully resemble adult CMs. In order to improve the 
maturity of hiPSC-CMs and consequently upgrade the functionality of hiPSC-CMs, 
various techniques have been investigated in different groups. Three-dimensional 
construction of engineered heart tissue is a rapidly growing technique for structural 
and functional maturations of hiPSC-CMs [109], which resulted in higher Na+ 
current density and upstroke velocity [110], and enhances the metabolic maturation 
[111] comparable to adult CMs. Furthermore, Shadrin and co-workers introduced 
the “Cardiopatch” platform for three-dimensional culture and maturation of 
hiPSC-CMs; this platform produces robust electromechanical coupling, consistent 
H-zone and I bands, and evidence of t-tubules and M-bands [112].
Another issue of hiPSC-CMs is the purity of differentiated CMs. The CMs 
differentiated from hiPSCs yield in heterogeneous population of CMs. There are 
at least three subtypes of CMs such as ventricular, atrial, and nodal CMs; among 
them the majority (~70%) of CMs are ventricular-like, and only a minority of 
CMs are atrial-like (~20%) and nodal-like (~10%) [40, 58, 93, 107]. Although 
many molecular and functional characteristics are shared among these CMs 
subtypes, they also exhibit their own unique features. For example, ventricular 
CMs have prominent plateau phase (phase 2) in action potential profile, atrial 
CMs exclusively exhibit IKur channels, and nodal CMs lack strong upstroke veloc-
ity [113]. Most of the published methods of differentiation protocol yield in a 
lower amount of atrial-like and nodal-like CMs [40, 58, 93, 107], but sufficient 
numbers of subtype-specific CMs are needed to understand the subtype-related 
disease mechanism and development of specific therapeutic approaches. Atrial 
fibrillation (AF) is one of the most common cardiac arrhythmias; however, current 
antiarrhythmic drugs for treatment of AF are not atrial-specific and could cause 
unacceptable ventricular events [114]. Thus, sufficient supply of atrial CMs is 
crucial for investigating the AF cellular mechanism. hiPSCs have been differenti-
ated into high-purity atrial-specific CMs by using retinoic acid signaling at the 
mesoderm stage of development [115]. These patient-specific atrial CMs allow us 
to investigate in detail mechanisms of AF and to develop atrial-specific therapeutic 
drugs. Furthermore, sinoatrial node (SAN) dysfunction can manifest bradycardia 
and asystolic pauses, but its pathophysiology is not completely understood [116]. 
SAN pacemaker cells from hiPSCs would facilitate the study of the disease mecha-
nism and provide a cell source for developing a biological pacemaker. Protze and 
co-workers had reported the transgene-independent method for the generation 
of pacemaker cells (nodal-like CMs) from human pluripotent stem cells by stage-
specific manipulation of developmental signaling pathways [117]. Besides CMs, 
the heart also consists of many other cell types such as fibroblast, endothelial and 
vascular smooth muscle cells, and also extracellular matrix. Importantly, the origin 
of cardiac diseases may not always exclusively originate from CMs, but might 
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involve non-CMs. Thus, incorporating the fibroblasts [118], endothelial cells [119], 
and vascular smooth muscle cells [120] into CMs from the same hiPSCs could offer 
new insight of disease mechanism.
The establishment of appropriate control is another challenge in disease model-
ing using hiPSC-CMs. It is generally argued/suggested that when comparing the 
results between control and mutated hiPSC-CMs, both should have the same genetic 
background. This objective is achieved in somehow by using healthy family mem-
bers as control [58, 93]. However, only ~50% of genome is shared between siblings, 
and phenotypic difference could result from DNA variants in the rest of genome 
besides disease-associated mutation [121]. Mutated genes can be corrected with the 
help of newly growing gene editing technology such as TALENs [98] and CRISPR/
Cas9 [33, 51, 84], thus establishing the so-called isogenic lines. This isogenic line 
would be the most appropriate control for comparison as it differs only in the pres-
ence and absence of mutation. Therefore, advance genome engineering will not only 
provide more reliable control lines but also guide us to understand how mutation 
modifies the normal functioning of cells. However, for diseased CMs without known 
mutation, healthy family members or otherwise controls are still the best.
5. Conclusion
While animal models fail to recapitulate human cardiac disease phenotype 
properly, hiPSC-CMs have been successful in recapitulating crucial phenotypes of 
many genetic cardiac diseases in terms of morphology, contractility, Ca2+ handling, 
ion channel biophysics, cell signaling, and metabolism. Most strikingly, hiPSC-CMs 
provide the patient-specific platform to study the disease mechanism and drug 
response individually, which the traditional disease modeling technique would never 
offer. In addition, cardiac subtype-specific arrhythmias and drug screening could be 
performed with the help of unlimited supply of hiPSC-CMs; thus chamber-specific 
treatment modalities could be identified. Certainly, by improving the current weak-
nesses of hiPSC-CMs and incorporating with new gene editing techniques, complex 
cardiac disease mechanism could be deciphered, and novel effective treatment 
therapies could be identified to improve the life of cardiac patients.
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Cardiovascular disease in populations with obesity is a major concern because 
of it is epidemic proportion. Obesity leads to the development of cardiomyopathy 
directly via inflammatory mediators and indirectly by obesity-induced hyper-
tension, diabetes, and coronary artery diseases. Metabolic disturbances such as 
increased free fatty acid levels, insulin resistance, elevated levels of adipokines, myo-
cardial remodeling, activation of the sympathetic nervous and renin-angiotensin-
aldosterone systems, and small-vessel disease are the most important mechanisms 
in the development of obesity cardiomyopathy. The myocardial changes related with 
obesity are increasingly recognized, and they are independent of classic risk factors 
as hypertension, coronary artery disease, and obstructive sleep apnea. There is a 
wide range of evidence: the association between heart failure and obesity shown 
in epidemiologic studies; the confirmation of the association of adiposity with left 
ventricular dysfunction, independent of hypertension, coronary artery disease, 
and other heart diseases; and experimental evidence of functional and structural 
changes in the myocardium in response to increased adiposity support the existence 
of a cardiomyopathy related to obesity.
Keywords: heart failure, obesity, adipokines, myocardiopathy
1. Introduction
During the past half-century, the advances in the prevention, diagnosis, and man-
agement of cardiovascular disease (CVD) have been spectacular. The cardiovascular- 
related deaths have declined by about two-thirds in industrialized nations [1].
Heart failure is characterized by an increased rate of cell death, which has been 
attributed to a variety of conditions: oxidative stress; abnormal elevations in circu-
lating neurohormones; toxins, such as alcohol or cancer chemotherapeutic drugs; 
excessive adrenergic activity; inflammation; and infiltrative processes. Apoptosis is a 
highly regulated type of cell death that normally increases with aging. It has been sug-
gested that, over time, the resulting deletion of myocytes leads to heart failure [2, 3].
The metabolic demand is increased in obesity; this is due to different factors 
as increasing blood volume, greater adipose tissue and lean mass, and as such, 
increased preload to the heart. In addition, in obese patients there are vascular 
alterations impacting arterial stiffness, and resistance increases afterload to the 
heart. In adults with obesity, both eccentric and concentric hypertrophies have been 
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1. Introduction
During the past half-century, the advances in the prevention, diagnosis, and man-
agement of cardiovascular disease (CVD) have been spectacular. The cardiovascular- 
related deaths have declined by about two-thirds in industrialized nations [1].
Heart failure is characterized by an increased rate of cell death, which has been 
attributed to a variety of conditions: oxidative stress; abnormal elevations in circu-
lating neurohormones; toxins, such as alcohol or cancer chemotherapeutic drugs; 
excessive adrenergic activity; inflammation; and infiltrative processes. Apoptosis is a 
highly regulated type of cell death that normally increases with aging. It has been sug-
gested that, over time, the resulting deletion of myocytes leads to heart failure [2, 3].
The metabolic demand is increased in obesity; this is due to different factors 
as increasing blood volume, greater adipose tissue and lean mass, and as such, 
increased preload to the heart. In addition, in obese patients there are vascular 
alterations impacting arterial stiffness, and resistance increases afterload to the 
heart. In adults with obesity, both eccentric and concentric hypertrophies have been 
noted and are impacted by the duration and the degree of the obesity [4, 5].
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2. Regional adiposity and cardiovascular risk
While the cardiovascular risk is linked to the adipose tissue quantity, recent data 
indicate that differences in fat tissue quality, which can be examined directly by 
noninvasive computed tomography radiodensity attenuation imaging or by immu-
nohistochemistry, are closely linked to insulin resistance, cardiometabolic risk, 
and all-cause mortality, independent of total fat volume. These data demonstrate, 
independent of body mass index, that abnormalities at the adipose tissue level may 
be key factors that regulate systemic metabolism and drive cardiometabolic disease. 
These qualitative abnormalities in fat are a growing area of research interest that 
have been recently termed sick fat or adiposopathy and may in part explain the 
clinical observation of metabolically healthy obesity. The interindividual variability 
in adipose tissue “quality” may be related, in part, to differences in lifestyle, as 
physical activity has effects on adipose tissue physiology and cardiometabolic risk. 
While animal models of obesity tend to generate fairly uniform phenotypes, the 
degree of adipose tissue dysfunction in obese humans exhibits significant hetero-
geneity with lower degrees of adiposopathy being associated with more favorable 
systemic metabolic profiles and vascular function.
3. Adipokines, myokines, and cardiovascular disease
It is recognized that obesity contributes to cardiovascular and metabolic disor-
ders through alterations in the levels of adipocyte-derived cytokines that are named 
adipokines.
The functions of adipose tissue are as energy storage and as secretory tissue 
producing a variety of bioactive substances, including leptin, tumor necrosis factor 
alpha (TNFα), plasminogen activator inhibitor type 1, and adiponectin [6–9]. These 
bioactive molecules are generally referred to as adipokines, and several are involved 
in the pathophysiology of various obesity-linked disorders.
4. Leptin
Leptin is an adipose tissue-specific-secreted hormone and is highly expressed 
by adipocytes; this adipokine is encoded by the ob gene, which was identified in 
genetically obese ob/ob mice through positional cloning. The circulating leptin 
levels increase in parallel to adipose tissue mass. Leptin exerts important metabolic 
actions by suppressing appetite and increasing energy expenditure. Many lines of 
evidence suggest that hyperleptinemia contributes to cardiovascular complications. 
Leptin has pro-inflammatory actions in many immune cell types including mono-
cytes/macrophage, neutrophils, NK cells, and T cells [10–17].
5. Adiponectin
Adiponectin is abundantly present in human plasma at a range between 3 and 
30 μg/mL. It is an adipokine whose mRNA is largely expressed in adipose tissue. 
Adiponectin multimerizes to form stable higher-order complexes and shares struc-
tural homology with the collectin family of proteins.
Lower plasma levels of adiponectin are implicated in the pathogenesis of 




increase following weight loss [22, 23]. In patients with diabetes mellitus, the levels 
of adiponectin are lower than patients without diabetes matched for age and weight 
[14]. An inverse correlation has been demonstrated between circulating levels of 
adiponectin and those as C-reactive protein and interleukin 6 [24–27].
Adiponectin appears to protect against the development of various vascular 
diseases. In murine experiments, it has been demonstrated that adiponectin has an 
anti-atherogenic function. In apolipoprotein E-deficient mice, the administration 
of an adenovirus-expressing adiponectin reduces atherosclerotic lesion size [28]. 
In apolipoprotein E-deficient mice, the adiponectin deficit leads to an increase 
in vascular lesion area [29]. Adiponectin knockout mice also develop increased 
neointimal thickness and display increased vascular smooth muscle cell prolifera-
tion following acute arterial injury, whereas overexpression of adiponectin inhibits 
neointimal lesion formation in wild-type mice [30].
Experimental studies have found that adiponectin exerts beneficial actions 
on the heart under pathological conditions. Adiponectin-deficient mice develop 
severe cardiac hypertrophy, and there is increased mortality in response to pressure 
overload because of transverse aortic constriction [31, 32].
6. Interleukin 6
Interleukin 6 (IL-6) is known to be secreted by several tissues; it is a pleiotropic 
cytokine with complex roles in metabolic and cardiovascular disease. IL-6 also 
can act in a local fashion. However, adipose tissue is a major source of this protein, 
capable of producing high levels of this protein in the blood. It has been estimated 
that as much as one-third of total circulating IL-6 originates from adipose tissue. 
Therefore, IL-6 can be considered an adipokine with endocrine actions.
IL-6-induced cell signaling is typically classified as either classic or trans-
signaling, and it can lead to different cell responses. In the classic signaling way, the 
target cells are stimulated by IL-6 stimulates via a membrane-bound IL-6 receptor 
(IL6R), which upon ligand binding forms a complex with the signaling receptor 
protein gp130. Essentially all cells exhibit gp130 on the cell surface, whereas few cell 
types express membrane-bound IL6R. While the cells that only express gp130 are not 
responsive to IL-6 alone, they can be stimulated, via trans-signaling, by a complex of 
IL-6 bound to a naturally occurring soluble form of IL6R (sIL6R), markedly expand-
ing the spectrum of IL-6 actions and target cells.
7. Resistin
Resistin is highly expressed by mature adipocytes in rodents. This adipokine is 
a secreted protein that was initially suggested to be a major link between insulin 
resistance and obesity. Circulating resistin levels are increased in diabetic and obese 
mice, and the important role of resistin in metabolic dysfunction associated with 
obesity through pleiotropic effects on insulin sensitivity and glucose metabolism 
has been suggested in several loss- and gain-of-function studies in mice .
8. Myokines
Myokines have been defined as cytokines and proteins produced and released 
by myocytes under the action of contractile activity. They exert an autocrine, 
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paracrine, or endocrine effect. Their receptors were found in the muscle, fat, liver, 
pancreas, bone tissue, heart, brain, and immune cells [33, 34].
Although the endocrine function of adipose tissue has long been recognized, 
most of the factors produced are pro-inflammatory and harmful in the setting of 
obesity-induced metabolic disorders and cardiovascular disease. In this regard, 
adiponectin is relatively unique as an adipokine because it is expressed at highest 
levels in lean, healthy individuals.
Candidate cDNAs that encode secreted proteins and are differentially regulated 
in the muscle of the MyoMouse model are then used to construct adenoviral vectors 
for further testing in animal models of disease. One such factor, follistatin-like 1 
(Fstl1), was identified in this type of screen and shown to have cardiovascular- 
protective properties. Fstl1, also referred to as TSC36, is an extracellular glycopro-
tein that has been grouped into the follistatin family of proteins [35].
The main myokines studied to date are myostatin, decorin, irisin, myonectin, 
interleukin-6 (IL-6), interleukin-8 (IL-8), interleukin-15 (IL-15), follistatin, fibro-
blast growth factor 21 (FGF21), bone morphogenetic protein (BMP), and brain-
derived neurotrophic factor (BDNF). Other possible factors have been detected in 
the skeletal muscle, but their functions, as well as their presence in the circulation, 
are largely unknown: musclin and nonneuronal acetylcholine.
9. Myostatin
Also called growth differentiation factor 8 (GDF-8), it is a member of the 
transforming growth factor-β (TGF-β) family, expressed in developing and adult 
muscular tissue. It is one of the first described myokines.
Its main function is the negative regulation of the muscle mass, which means 
high level of myostatin and less muscle mass. It plays a role in stopping myoblast 
proliferation and suppressing satellite cell activation, inducing muscle atrophy. In 
addition, it influences the differentiation of muscle fibers by types (fast and slow) 
and the arrangement of muscle glucose as well as the muscle-adipose tissue cross-
talking [36–40].
10. Irisin
Discovered in 2012 as a transmembrane protein, FNDC5 has a cleaved soluble 
form, irisin, that it is released into circulation during the proteolytic process after 
acute exercising of skeletal muscles. It increases the energetic and oxidative metab-
olism of the muscle by activating genes related to these processes. It has a high level 
during myogenesis and induces glucose uptake improving glucose homeostasis, 
inhibiting lipid accumulation, and reducing body weight [41, 42]. Irisin has been 
studied especially in relation to obesity but also with myopathies such as muscular 
dystrophy. In these latter studies, injection of irisin induced muscle hypertrophy, 
improving muscle strength and reducing necrosis and development of connective 
tissue in a murine model [42].
11. Myonectin
Myonectin is a protein belonging to the C1q/TNF-related protein (CTRP) 
family, and it is found mainly in the muscle, less in circulation, being especially 




by exercise and nutrients and is supposed to induce nutrient uptake and storage in 
other tissues, such as adipose tissue, causing a flux of glucose or fatty acids [42, 43].
12. Mechanism of myocardiopathy in obesity
Insulin resistance, adiposity, and adipokines have been implicated in the develop-
ment of abnormal myocardial mechanics in adults with obesity and type 2 diabetes. 
Adiposopathy in obese individuals is ultimately the consequence of a dysfunctional 
remodeling of the adipose tissue. Therefore, for understanding how obesity contrib-
utes to cardiovascular disease, it is primordial to know how both quantitative and 
qualitative effects of this adipose tissue remodeling contribute to that.
13. Adipose tissue expansion
In response to an excessive caloric intake, the mechanisms by which adipose 
depots expand represent an important determinant of the risk of cardiovascular 
disease and metabolic dysfunction. This expansion is mediated by two ways: an 
enlargement of adipocyte size (hypertrophy) and/or an increase in adipocyte 
numbers (hyperplasia).
Adipocyte hypertrophy typically leads to lipid-laden, dysfunctional adipocytes 
that undergo cell death and contribute to adipose tissue inflammation, dysfunction, 
and associated pathologies; in contrast it has been classically accepted that hyper-
plasia allows a “healthy” expansion of the adipose tissue, since it is mediated by the 
formation of functional adipocytes from progenitor cells (adipogenesis).
14. Immune cell infiltration
In most cases chronic excessive caloric intake eventually leads to adipocyte 
dysfunction, regardless of the mechanisms of adipose tissue expansion, and this 
is paralleled by qualitative and quantitative changes in the composition of adipose 
tissue at cellular level. Immune cells are of great relevance in this regard. Low-grade 
chronic inflammation is a major hallmark of adipose tissue in obesity, and it is 
now known that almost every immune cell type can be found in the adipose tis-
sue. Total numbers of B cells, T cells, neutrophils, macrophages, and mast cells are 
increased in visceral adipose tissue of obese individuals. In contrast, the number of 
eosinophils and specific subsets of T cells—T-helper type 2 (Th2) cells and regula-
tory T (Treg) cells—are decreased or remained static in the adipose tissue of obese 
individuals [36].
Macrophages are the most abundant immune cell in the adipose tissue of obese 
individuals, and their recruitment and proliferation upon high-calorie feeding is 
generally associated with adipose tissue inflammation and insulin resistance [44–47].
15. Impaired vascular structure and function
Several studies in humans and animal models have shown that obesity induces 
capillary rarefaction in adipose tissue, and this has been associated with metabolic 
dysfunction. It is widely a reduced adipose tissue; capillarization is present in 
obesity, and this reduced blood supply may limit nutrient delivery and contribute to 
adipocyte dysfunction and insulin resistance.
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Evidence of a causal role of adipose tissue vascularization in obesity-associated 
metabolic dysfunction have been shown in recent studies with genetically engi-
neered mice. Experiments demonstrated that an increased VEGF-mediated 
angiogenesis in adipose tissue can attenuate some of the metabolic effects of 
diet-induced obesity, such as insulin resistance and hepatic steatosis in mice overex-
pressing vascular endothelial growth factor A (VEGF-A) in adipocytes. Conversely, 
adipocyte-restricted deletion of VEGF-A results in diminished adipose tissue 
vascularization, which leads to increased adipose tissue inflammation and systemic 
metabolic dysfunction further supporting the noxious effects of reduced adipose 
tissue vascularity in obesity [48–51].
16. Adipose tissue fibrosis
Within the adipose tissue of lean organisms, adipocytes are surrounded by 
extracellular matrix that provides mechanical support and participates in cell 
signaling. There is a general increase in the synthesis of several extracellular matrix 
components with the development of obesity, in particular collagen VI, which leads 
to adipose tissue fibrosis and is associated with impaired metabolic function in 
mice. Adipose tissue fibrosis is increased in both subcutaneous and visceral depots 
in obesity. Obesity-induced adipose tissue fibrosis is due, at least in part, to hypoxia-
induced upregulation of hypoxia-inducible factor 1α (HIF1α). Interestingly, HIF1α 
activation does not contribute to an angiogenic response in this context, but instead 
promotes adipose tissue fibrosis [52].
17. Conclusions
An increasing evidence supports the evolving concept that quality, quantity, and 
location of adipose tissue are critical factors in shaping cardiometabolic pheno-
types in obese individuals. The specific pathogenic mechanisms and their relative 
contributions remain incompletely understood. Adipose tissue communicates with 
remote organs, including the heart and vasculature, through the release of various 
adipokines. While some adipokines have been highly studied and have shown to 
be causally linked to various disease processes, new adipokine candidates continue 
to be discovered and elucidated. In murine models and many human individuals, 
obesity leads to adipose tissue dysfunction; this dysfunction is termed adiposopa-
thy, particularly in visceral fat depots, which is mediated by dysfunctional tissue 
remodeling that involves adipocyte hypertrophy, increased fibrosis exacerbated 
inflammation, and impaired vascular function and structure. This ultimately cre-
ates a chronic, low-grade systemic inflammatory reaction mediated by an imbalance 
in adipokine levels which contributes to the initiation and progression of metabolic 
and cardiovascular complications. As our understanding of adipokines and obesity-
induced adiposopathy increases, the major challenge will reside in translating this 
information into new prognostic and therapeutic approaches to limit cardiovascular 
risk in obese individuals. Considering that a third of the world’s population is cur-
rently overweight or obese and this proportion is expected to increase in the coming 
decades, studies of adipokine biology should provide a better understanding of the 
pathogenesis of cardiovascular disease.
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Roles of Trans and ω Fatty Acids in 
Health; Special References to Their 
Differences between Japanese and 
American Old Men
Akikazu Takada, Fumiko Shimizu and Shinji Koba
Abstract
Omega and trans-fatty acids play important roles in atherogenesis of vascular 
system. In this review, we discuss such roles in health; there are much differences 
in coronary heart disease (CHD) rates between the US and Japan. Fatty acids 
profiles in the plasma are related to risks of CHD. There have been few studies that 
compared plasma levels of fatty acids, including trans-fatty acids, in people in 
Japan and the US. Plasma levels of long-chain omega-3 fatty acids (docosahexae-
noic acid [DHA] and eicosapentaenoic acid [EPA]) were higher in Japanese men, 
and omega-6 fatty acids (e.g., arachidonic acid [AA]) were lower compared with 
American men. American people had higher plasma levels of the major industri-
ally produced trans-fatty acids (IP-TFAs; elaidic and inoelaidic acids), and levels 
of the potentially cardioprotective, primarily ruminant-derived trans-fatty acid, 
palmitoelaidic acid (POA) were higher in Japanese men. Plasma levels of saturated 
or monounsaturated fatty acids were also higher in American men. Only intakes of 
preference drinks have significant correlation with plasma levels of palmitoelaidic 
acid and linoelaidic acid. The higher levels of DHA and EPA, along with the lower 
levels of the IP-TFAs, are consistent with the markedly lower risk for coronary heart 
disease in Japan vs. the US.
Keywords: trans-fatty acids, omega fatty acids, lipid, DHA, EPA,  
arachidonic acid, palmitoelaidic acid, elaidic acid, linoelaidic acid, food, protein, 
carbohydrate, preference drink, coffee, tea, cholesterol, GRP120, insulin, GLP-1
1. Introduction
Coronary heart disease (CHD) is the leading cause of death worldwide, 
and certain dietary fatty acids (FAs) are known to play an important role in 
CHD risk [1]. It has been reported that higher intakes of industrially produced 
trans-fatty acids (IP-TFA) [2] and of saturated fatty acids (SFAs) are associ-
ated with increased risk for CHD [3, 4] and that higher intakes of both the 
omega-6 (n-6) polyunsaturated fatty acids (PUFAs) and the omega-3 PUFAs 
are  associated with lower risk of CHD [5, 6]. Intakes of the PUFAs (especially 
the omega-3 class) and IP-TFAs are considered to be biomarkers strongly 
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linked to risks. Because risk for CHD is much lower in Japan than in the US [7], 
we tried to compare the FA profiles in Japanese and American men over the 
age of 50.
1.1 Configurations of trans-fatty acids and their origins
Trans-fatty acids have at least one double bond in the trans configuration and 
formed during partial hydrogenation of vegetable oils. This process is used for the 
conversion of vegetable oils to semisolid fats used for margarines.
Most of trans-fatty acids isomers are monosaturated with carbon number 18 
(trans type octadecenoic acid (t-C18:1)). Trans type octadecenoic acids contained 
in foods are classified 13 isomers depending upon the location of the double bond 
(Figure 1). These trans isomers are produced industrially or naturally. The largest 
amounts of industrially produced trans-fatty acids are elaidic acids (t 9-C18:1) and 
those of naturally produced forms are vaccenic acid (t11-C18:1) [8].
In the cis forms of fatty acids, hydrogen atoms are present on the same side of 
the bond, which causes a bend in the fatty acid chain, whereas the trans form has 
hydrogen atoms in the opposite sides of the chain, which straightens the fatty acid 
chain (upper figure). There are many isomers in carbon 18 fatty acids. Elaidic acid 
has the double bond at the ninth carbon atom (t9-18:1). Oleic acid has the double 
bond at the same location (c9-18:1). Partially hydrogenated oils contain mixture 
of isomers in which the trans form may be detected anywhere between the 4th 
and 14th carbon. Smaller amounts of isomers with a second trans double bond 
(trans,trans-18:2) are also present.
Figure 1. 
The configuration of cis and trans forms of the double bond.
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1.2 Molecular mechanisms of trans-fatty acids
Fatty acids modulate cell functions. They change membrane fluidity and 
responses of membrane receptors. Fatty acids not only bind to membrane receptors 
but also bind to and modulate nuclear receptors that regulate gene transcription, 
peroxisome-proliferator-activated receptors, liver X receptor, and sterol regula-
tory element-binding protein 1 [9] (Figure 2). Fatty acids modulate metabolic and 
inflammatory responses of the endoplasmic reticulum [10].
Trans-fatty acids change the secretion, lipid composition, and the size of 
apoB100 produced by hepatic cells [11, 12]. In hepatocytes, trans-fatty acids 
increase the accumulation and secretion of free cholesterol and cholesterol esters 
[11]. Trans-fatty acids increase plasma activity of cholesteryl ester transfer protein 
[13], which may result in decreases in plasma levels of high density lipoprotein 
(HDL) and increase in the levels of low density lipoprotein (LDL) and very low 
density lipoprotein (VLDL).
Trans-fatty acids modulate monocyte and macrophage functions resulting in 
increase in the production of tissue necrosis factor (TNF)-α and interleukin-6 [14]. 
Endothelial dysfunctions are caused by trans-fatty acids, and arterial dilatation is 
impaired due to nitric oxide [15].
Fatty acid metabolism of adipocytes was affected by trans-fatty acids, causing 
reduced triglyceride uptake, reduced esterification of cholesterol, and increased pro-
duction of free fatty acids [16]. In animal studies, the gene expression was changed 
by the consumption of trans-fatty acids in adipocytes. These gene products are 
peroxisome-proliferator-activated receptor-γ, resistin, and lipoprotein lipase [17].
Trans-fatty acids may affect plasma lipid levels due to changes in hepatocytes 
of the production, secretion, and catabolism of lipoproteins and plasma levels of 
Figure 2. 
Effects of trans-fatty acids.
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cholesteryl ester transfer protein (CETP) (upper left panel). In adipocytes, trans-
fatty acids change fatty acid metabolism and, possibly, inflammatory responses. 
When trans fats are taken, nitric acid-dependent endothelial dysfunction is 
observed and circulating adhesion molecules increase. Trans fat modulates mono-
cyte and macrophage function (lower left panel). Membrane receptors may affect 
subcellular mechanisms. These receptors localize with and are influenced by spe-
cific membrane phospholipids (upper right panel) such as endothelia nitric oxide 
synthetase or toll-like receptors. Trans-fatty acids may bind to nuclear receptors-
regulating gene transcription such as liver X receptor (lower left panel).
1.3 Effects on cardiovascular diseases
Trans-fatty acids may increase the risks of coronary heart disease (CHD). In a 
meta-analysis of four prospective cohort studies, a 2% increase in energy intake 
from trans-fatty acids was shown to be associated with a 23% increase in the 
incidence of CHD [18–21].
There are many papers showing increased risks of CHD in patients with 
high fatty acids levels [22–25]. These data are obtained using cohorts of Western 
populations.
Koba et al. [26] recently reported using Japanese adult males that total trans-
fatty acids levels were similar between acute coronary syndrome (ACS) and control 
subjects. Palmitelaidic acid levels were lower in ACS patients and were significantly 
directly associated with HDL cholesterol (HDL-C) and n-3 polyunsaturated FA 
(n-3 PUFA). Linoleic trans isomers (total C18:2 TFA) and primary industrially pro-
duced TFA (IP-TFAs) were significantly higher in ACS patients. Total trans-C18:1 
isomers were comparable between ACS and control.
1.4 Intakes of trans-fatty acids in people of US and Japan
Allison et al. [27] used food intake data from1989 to 1991 Continuing Survey of 
Food Intakes by Individuals (CSFII) and the trans-fatty acid contents of specific 
foods, which were calculated from a data base of the US Department of Agriculture. 
These data show the mean levels of trans-fatty acids intakes of US population.
The average percentage of energy ingested as trans-fatty acids was 2.6%, and 
the average percentage of total fat ingested as trans-fatty acids was 7.4%. Across all 
age and gender groups examined, estimates ranged from 2.6 to 2.8% and 7.1 to 7.9%, 
respectively [27].
In Japan, mean total fat and trans-fatty acid intake was 56.9 g/day (27.7% total 
energy) and 1.7 g/day (0.8% total energy), respectively, for women and 66.8 g/day 
(25.5% total energy) and 1.7 g/day (0.7% total energy) for men [28].
Recent studies indicate that the average trans-fatty acids intake was estimated to 
be 0.92–0.96 g/day, which was 0.44–0.47% of total daily energy intakes [29].
These data indicate that Japanese take far less amounts of trans-fatty acids 
compared with American.
1.5 Omega fatty acids
Intakes of long-chain ω-3 fatty acids (eicosapentaenoic acid (EPA), docosa 
pentaenoic acid (DPA), and docosahexanoic acid (DHA)) found in fish, and fish 
oils has been shown to be related to the low incidence of coronary heart disease in 
the Inuit people of Greenland [30].
We do not review roles of such fatty acids in health and disease in details.
Figure 3 summarizes roles of EPA in causing various dysfunctions of the body.
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Arachidonic acid (n-6 polyunsaturated fatty acid “PUFA”) is converted to PGH2 
(prostaglandin H2, which is converted to prostaglandin E2, inflammatory mediator) 
or to TXA2 (thromboxane A2), causing thrombosis. AA is also converted to LTA4 
(leukotriene A2), then to leukotriene B4, inflammatory mediator [31].
Cells produce TNF-α or interleukin (IL)-1β, which case cell damages.
Figure 3. 
Roles of EPA in the prevention of cell damage, inflammation, or thrombosis.
Figure 4. 
Function of G-protein-coupled receptor 120 as a receptor of DHA and EPA.
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Figure 3 summarizes roles of EPA in causing various dysfunctions of the body.
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Arachidonic acid (n-6 polyunsaturated fatty acid “PUFA”) is converted to PGH2 
(prostaglandin H2, which is converted to prostaglandin E2, inflammatory mediator) 
or to TXA2 (thromboxane A2), causing thrombosis. AA is also converted to LTA4 
(leukotriene A2), then to leukotriene B4, inflammatory mediator [31].
Cells produce TNF-α or interleukin (IL)-1β, which case cell damages.
Figure 3. 
Roles of EPA in the prevention of cell damage, inflammation, or thrombosis.
Figure 4. 
Function of G-protein-coupled receptor 120 as a receptor of DHA and EPA.
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EPA inhibits such processes, preventing cell damages, inflammation, and 
thrombosis. DHA may work in the similar ways as EPA.
1.6 ω fatty acid receptor
GPR120 is proposed to function as an ω-3 FA receptor/sensor in pro-inflamma-
tory macrophages and mature adipocytes. By signaling through GPR120, DHA and 
EPA mediate potent anti-inflammatory effects to inhibit both TLR (toll-like recep-
tor) and TNF-α inflammatory signaling pathways [32].
DHA and EPA stimulate GRP 120 and cause a decrease of glucose uptake by 
adipocytes, inhibit inflammation by macrophages, secrete glucagon-like peptide 1 
(GLP-1), and increase insulin secretion by pancreas (Figure 4).
These data suggest that DHA and EPA may be effective for prevention and treat-
ment of cardiovascular disease and diabetes mellitus.
2.  Differences of plasma levels of fatty acids between Japanese and 
American old men
2.1 Materials and methods
2.1.1 Participants
In Japan, we recruited 44 male volunteers older than 50. They were friends and 
family members of the research team for this study [33, 34]. Exclusion criteria 
included the use of medications to treat diabetes, hyperlipidemia, hypertension, 
and/or cardiovascular disease (CVD). Smokers were also excluded. The 76 US men 
were participants in the Chicago Area Sleep Study, a prospective cohort study to 
examine risk factors for the development of sleep disorders [35]. This cohort excluded 
men with known sleep disturbances but did not exclude for the chronic conditions 
excluded in the Japanese cohort. We collected blood samples after an overnight fast, 
and plasma was isolated for fatty acid analysis. We obtained an informed consent 
prior to conducting the protocol which had been approved by the Ethical Committee 
of Showa Women’s University and Saiseikai Shibuya Satellite Clinic. The Chicago Area 
Sleep Study was approved by the Northwestern University Institutional Review Board.
2.2 Analyses of plasma samples
Fatty acids levels were measured in plasma obtained from ethylenediamine 
tetraacetic acid anticoagulated blood samples. Samples were frozen at −80°C until 
analyzed at Omegaquant, LLC (Sioux Falls, SD, USA). After thawing, an aliquot of 
plasma was combined (1.40 parts) with the methylating mixture (boron trifluoride 
in methanol [14%], toluene, and methanol [35/30/35, vv]), shaken at 100°C for 
45 min. After cooling, 40 parts of both hexane and distilled water were added. 
After briefly vortexing, the samples were spun to separate layers, and an aliquot 
of the hexane layer that contained the fatty acid methyl esters was analyzed by gas 
chromatography as previously described.
2.3 Statistical analysis
Student’s t test was used for the comparison of two groups, and p < 0.05 was 
considered as significant difference. Results are expressed as mean ± SD. Spearman’s 
correlation tests were used to examine statistical significance.
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3. Results
The ages of the two cohorts was reasonably similar (Japan, 61 ± 10 and US, 
57 ± 5 years), as were the body mass indexes (24.9 ± 3.7 vs. 25.1 ± 3.4 kg/m2) (Figure 5).
Of the fatty acids that constituted at least 1% of the total in either cohorts, those that 
are significantly higher in Japanese men than US men were as follows: palmitic, palmi-
toleic, arachidic, EPA, and DHA. Those that were lower in the Japanese men were as 
follows: linoleic acid (LA), dihomo-gamma linolenic acid (DGLA), and AA (Table 1).
Figure 5. 
Profiles of plasma levels of fatty acids of Japanese and American old men.
Japanese (n = 44) American (n = 76)
Age 62.4 ± 9.6 57.5 ± 4.3
Height (m) 1.68 ± 0.07 1.70 ± 0.1
Weight (kg) 68.8 ± 10.9 74.4 ± 12.1
Body mass index (BMI) 24.3 ± 3.2 25.3 ± 3.4
Total cholesterol (mg/dL) 209.9 ± 32.3 185 ± 33.5
Triglyceride (mg/dL) 126.4 ± 81.3 118.0 ± 62.8
HDL-C (mg/dL) 60.9 ± 16.6 54.0 ± 15.7
LDL-C (mg/dL) 123.8 ± 30.2 107.0 ± 29.6
Fasting blood glucose (mg/dL) 91.7 ± 16.3 97 ± 22.3
Table 1. 
Backgrounds of various parameters of healthy old men in Japan and US.
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Figure 6 compares plasma levels of palmitoelaidic, elaidic, and linoelaidic acids.
IP-TFAs (elaidic and mainly industrially produced linoelaidic), 
although of low abundance in both cohorts, were considerably higher in the 
US than in Japan. Palmitoleic was slightly but significantly higher in Japan 
(Figure 7).
Plasma levels of DHA and EPA are higher in Japanese than American old men; 
on the other hand, plasma levels of arachidonic acid and dihomoγlinoleinic acid are 
higher in American than Japanese old men.
Figure 7. 
Comparison of plasma levels of C20–22 fatty acids between Japanese and American old men.
Figure 6. 
Plasma levels of trans-fatty acids in Japanese and American old men.
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Table 2 summarizes plasma levels of important fatty acids between Japanese and 
American men.
4. Food intakes and plasma levels of fatty acids
Participants were given self-administered diet history questionnaires and 
described answers on each item by recollection of diets they took (7 days dietary 
recall). We used a brief-type self-administered diet history questionnaire 
(BDHQ ) by using which the Japanese Ministry of Health, Labour and Welfare 
reports National Nutrition Surveys. From these questionnaires, we calculated the 
intakes of energy and varieties of foods such as proteins, carbohydrates, lipids 
vitamins, etc.
4.1 Results
Table 3 shows that only preference drinks such as tea and coffee had significant 
correlations with plasma levels of palmitoelaidic acid and linoelaidic acid.
Plasma fatty acids (% of total) Japanese (n = 44) US (n = 76) ss
Myristic 0.7 ± 0.2 0.85 ± 0.34 **
Palmitic 22.3 ± 1.3 21.23 ± 2.13 *
Palmitoelaidic (trans) 0.2 ± 0.1 0.14 ± 0.07 **
Palmitoleic 1.9 ± 0.6 1.45 ± 0.80 **
Stearic 7.0 ± 0.7 7.24 ± 0.83
Elaidic (trans) 0.1 ± 0.01 0.61 ± 0.34 **
Oleic 20.0 ± 2.6 19.96 ± 3.34
Linoelaidic (trans) 0.2 ± 0.1 0.35 ± 0.12 **
Linoleic (LA) 26.3 ± 4.0 32.83 ± 5.24 **
Arachidic 0.13 ± 0.04 0.13 ± 0.04
Gamma linolenic 0.3 ± 0.1 0.53 ± 0.27 **
Eicosenoic 0.2 ± 0.04 0.15 ± 0.05
Alpha-linolenic 0.7 ± 0.2 0.72 ± 0.32
Eicosadienoic 0.2 ± 0.03 0.29 ± 0.07 **
Behenic 0.15 ± 0.02 0.20 ± 0.10 **
Dihomo-gamma linolenic (DGLA) 1.0 ± 0.2 1.56 ± 0.37 **
Arachidonic (AA) 6.0 ± 1.1 7.38 ± 2.18 **
Eicosapentaenoic (EPA) 2.5 ± 1.3 0.77 ± 0.60 **
Lignoceric 0.22 ± 0.10 0.18 ± 0.07 *
Nervonic 0.33 ± 0.18 0.26 ± 0.10 *
Docosatetraenoic 0.12 ± 0.04 0.26 ± 0.11 **
Docosapentaenoic (n6) 0.14 ± 0.04 0.18 ± 0.08 **
Docosapentaenoic (n3) 0.68 ± 0.26 0.59 ± 0.14 *
Docosahexaenoic (DHA) 5.0 ± 1.5 2.14 ± 0.85 **
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Palmitelaidic Elaidic Linoelaidic
Energy 0.319 −0.135 0.181
Protein 0.239 0.031 0.034
Animal protein 0.233 0.135 0.034
Vegetable protein 0.193 −0.081 0.152
Lipid 0.187 0.120 0.034
Animal lipid 0.188 0.154 0.094
Vegetable lipid 0.167 0.027 −0.066
Carbohydrate 0.188 −0.197 0.138
Na 0.128 0.033 −0.073
K 0.223 −0.015 0.137
Ca 0.099 0.263 −0.021
Mg 0.283 −0.003 0.143
Phosphorus 0.230 0.088 0.020
Iron 0.193 −0.120 0.112
Zinc 0.109 0.081 0.072
Copper 0.211 −0.066 0.163
Mn 0.422 −0.059 0.113
Retinol 0.307 −0.195 0.054
β-Carotene −0.001 −0.049 −0.005
Vit D 0.295 −0.001 −0.066
Tocopherol 0.167 −0.049 −0.004
Vit K 0.098 0.014 0.083
Vit B1 0.095 0.119 0.098
Vit B2 0.246 0.169 0.135
Niacine 0.320 −0.012 0.081
Vit B6 0.239 −0.036 0.129
Vit B12 0.353 −0.090 0.049
Folic acid 0.333 −0.120 0.080
Pantothenic acid 0.299 0.120 0.083
Vit C 0.214 −0.040 0.034
Saturated fatty acids 0.209 0.144 0.112
Monovalent fatty acids 0.156 0.126 −0.004
Multivalent fatty acids 0.179 0.024 −0.062
Cholesterol 0.221 −0.025 0.125
Soluble dietary fiber 0.133 −0.080 0.155
Insoluble dietary fiber 0.125 −0.047 0.076
Total dietary fiber 0.082 0.027 0.089
Salt 0.128 0.033 −0.073





Correlations between foods intake and plasma levels of fatty acids.
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5. Discussion
Fatty acids are major components of blood vessels. So their changes exert 
tremendous impact to pathophysiology of cardiovascular system.
Epidemiological studies repeatedly showed that Japanese people had lower 
incidence of CVD, compared with American people [7]. As discussed below, kinds 
of intaken foods, life-styles, and genetics may contribute to such differences.
We thought the measurements of fatty acids composition in plasma may help to 
elucidate such differences between Japanese and American people.
We compared plasma levels of fatty acids between Japanese and American men 
over 50 years of age. We found, not surprisingly, that levels of EPA and DHA are 
higher in Japanese than American and that levels of arachidonic acid are lower 
in Japanese. Although both Japanese and American take meat, egg, and fish, fish 
has far more omega-3 fatty acids compared to eggs. When we eat larger amounts 
of omega-3 fatty acids such as DHA and EPA, omega-3 fatty acids are known to 
replace omega-6 fatty acids in cell membrane [36]. The omega-3 fatty acids are 
found predominantly in oily fish, whereas arachidonic acid (the major long chain 
omega-6 fatty acid) is contained in meats and eggs and can be synthesized (albeit 
very slowly) [37]. The differences between Japanese and US men in regard to the 
consumption of these types of foods can help explain these differences in blood 
levels [38]. The other major finding of this study was the lower levels of IP-TFA such 
as linoelaidic acid in Japanese vs. the US men.
Currently, CHD death rates in Japan are 3× lower for women and 4× lower 
for men (ages 35–74) compared with the US. Among 30 countries for which the 
American Heart Association provided CHD death rates in its 2017 Statistical 
Update [7], Japan had the second and third lowest rates (men and women, 
respectively) compared with the US. Sekikawa et al. [39] showed in 2014 that 
the calcification of the coronary artery was twice in American compared with 
Japanese men, but the calcification of Hawaiian Japanese was similar to that of 
people on the US mainland.
These results do not necessarily prove differences of CVD incidences between 
Japanese and American are due to foods and lifestyle. Since Japanese immigrants 
to the US have increased CHD mortality [40], although still lower US Whites, it 
appears that some genetic variabilities between American and Japanese must be 
responsible for this difference. However, the possibility that differences in dietary 
fatty acid patterns may contribute to this phenomenon is the subject of this report.
We found that the levels of the long-chain omega-3 fatty acids such as EPA and 
DHA were 2–3× higher in Japan vs. the US. The relationship of fish and dietary 
omega-3 fatty acids and cardiovascular disease (CVD) has been investigated in 
numerous studies and comprehensive reviews and recommendations exist. Still 
controversies exist. A recent meta-analysis of randomized trials with omega-3 fatty 
acids [41] did not find a statistically significant reduction in CVD mortality, but in 
these researches, some important factors were said to be ignored [42–44]. Other 
systematic reviews have reported mortality benefits for omega-3 fatty acids [45, 
46], and omega-3 biomarker levels have been strongly associated with risk for fatal 
CHD in still other meta-analyses [47, 48]. Hence, higher omega-3 levels could at 
least partly explain the lower CHD risk in Japan.
We also found that IP-trans-fatty acid such as linoelaidic acid was lower in Japan 
than US. The reported intake of IP-TFA is 75% lower in Japan than in the US, again 
supporting the observed differences in biomarker levels. Circulating 18:2 trans-fatty 
acids was shown to be most adversely associated with total mortality, mainly due to 
the increased risk of CVD [23]. It was also positively associated with total mortality 
and CHD.
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Japanese and American are due to foods and lifestyle. Since Japanese immigrants 
to the US have increased CHD mortality [40], although still lower US Whites, it 
appears that some genetic variabilities between American and Japanese must be 
responsible for this difference. However, the possibility that differences in dietary 
fatty acid patterns may contribute to this phenomenon is the subject of this report.
We found that the levels of the long-chain omega-3 fatty acids such as EPA and 
DHA were 2–3× higher in Japan vs. the US. The relationship of fish and dietary 
omega-3 fatty acids and cardiovascular disease (CVD) has been investigated in 
numerous studies and comprehensive reviews and recommendations exist. Still 
controversies exist. A recent meta-analysis of randomized trials with omega-3 fatty 
acids [41] did not find a statistically significant reduction in CVD mortality, but in 
these researches, some important factors were said to be ignored [42–44]. Other 
systematic reviews have reported mortality benefits for omega-3 fatty acids [45, 
46], and omega-3 biomarker levels have been strongly associated with risk for fatal 
CHD in still other meta-analyses [47, 48]. Hence, higher omega-3 levels could at 
least partly explain the lower CHD risk in Japan.
We also found that IP-trans-fatty acid such as linoelaidic acid was lower in Japan 
than US. The reported intake of IP-TFA is 75% lower in Japan than in the US, again 
supporting the observed differences in biomarker levels. Circulating 18:2 trans-fatty 
acids was shown to be most adversely associated with total mortality, mainly due to 
the increased risk of CVD [23]. It was also positively associated with total mortality 
and CHD.
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It may be surprising that TFA is not necessarily adverse for health. Some are 
beneficial for health. In a recent study from Germany, total trans-fatty acids in 
erythrocyte membranes were shown to be inversely associated with mortality, but 
this was mainly driven by the naturally occurring 16:1 trans (trans-palmitoleic acid) 
[49]. As to relationship between IP-TFA or SFA intakes and CHD mortality, exces-
sive intakes of both had a greater impact on risk for CHD in the US compared with 
Japan, whereas insufficient intakes of omega-6 PUFAs had about the same impact 
on risk in both countries [50].
Our results also indicate that plasma levels of SFAs are higher in American 
than in Japanese. Saturated fatty acids are considered to be one of the dietary 
risk factors of CVD, primarily because these fats raise LDL-cholesterol levels. 
Many health and government organizations have recommended the reduction 
of intakes of SFA s to lower the incidence of CVD. Although this difference in 
SFA plasma levels may also be one of the reasons that Americans have a higher 
mortality rate for CVD than Japanese, plasma saturated (and monounsaturated) 
fatty acids are claimed to be relatively poor markers of dietary SFA (saturated 
fatty acid) intake [51].
Plasma fatty acid profiles in older men from Japan and US differed in many 
ways that are consistent with the lower rate of CHD in the former country. Efforts 
to lower TFA levels and increase EPA + DHA levels may help lower risk for CHD 
in the US, and current trends in Japan toward a more western diet [52] should be 
discouraged.
As to relationship between TFA or SFA intakes and CHD mortality, excessive 
intakes of both had a greater impact on risk for CHD in the US compared with 
Japan, whereas insufficient intakes of omega-6 PUFAs had about the same impact 
on risk in both countries [50]. As stated above, naturally occurring trans fats are 
consumed in smaller amounts (about 0.5% of total energy intake) in meats and 
dairy products from cows, sheep, and other ruminants; these trans fats are pro-
duced by the action of bacteria in the ruminant stomach [22]. Since trans-fatty 
acids are not used in foods in Japan, all the trans-fatty acids must come from meat 
or dairy products. We found that there was no relationship between various foods 
intake and plasma levels of trans-fatty acids in Japanese old men. Only intakes of 
preference drinks such as tea and coffee had significant relationship with plasma 
levels of palmitoelaidic acid and linoelaidic acid. These results seem to indicate that 
plasma levels of trans-fatty acids are not derived from foods but derived by intesti-
nal microbes.
Human gut microbes are important in neural, endocrine, and immune com-
munication with the host [53]. Communication is considered to be bidirectional. 
Mediators of microbiota-gut-brain communication affected by microbial 
metabolism include short-chain fatty acids, neurotransmitters such as serotonin, 
γ-aminobutyric acid (GABA), hormones such as cortisol, and immune system 
mediators such as quinolinic acid [51].
In conclusion, some of trans-fatty acids may be produced by hydrogenation of 
fatty acids by gut microbes.
6. Conclusion
We here report our results of comparison of plasma levels of fatty acids between 
healthy old men in Japan and the US.
The higher levels of DHA and EPA, along with the lower levels of the IP-TFAs, 
are consistent with the markedly lower risk for coronary heart disease in Japan vs. 
the US.
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